gene_symbol,nM_value,measurement_type,database,treatment
BCL2,4.4,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL, US Patent",ABT-199
BCL2A1,1000.0,ic50,Curated from the literature by BindingDB,ABT-199
BCL2L1,106.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",ABT-199
MCL1,2500.0,ic50,"Curated from the literature by BindingDB, ChEMBL",ABT-199
BCL2,10.0,ic50,"ChEMBL, US Patent",ABT-263
BCL2L1,8.2,ic50,"ChEMBL, US Patent",ABT-263
MCL1,20000.0,ic50,ChEMBL,ABT-263
BCL2,7.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",ABT-737
BCL2L1,6.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",ABT-737
MCL1,1000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",ABT-737
ABCC4,133000.0,ic50,ChEMBL,Acetaminophen
PTGS1,200000.0,ic50,ChEMBL,Acetaminophen
PTGS2,141000.0,ic50,ChEMBL,Acetaminophen
ABCC4,133000.0,ic50,ChEMBL,Acetazolamide
CA1,900.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Acetazolamide
CA12,60.5,ic50,ChEMBL,Acetazolamide
CA14,136.0,ic50,ChEMBL,Acetazolamide
CA2,68.3,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Acetazolamide
CA4,70.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Acetazolamide
CA5A,69.0,ic50,ChEMBL,Acetazolamide
CA7,1438.5,ic50,ChEMBL,Acetazolamide
CA9,213.45,ic50,ChEMBL,Acetazolamide
ABCC4,133000.0,ic50,ChEMBL,Acyclovir
ABCC4,133000.0,ic50,ChEMBL,Acipimox
CHRM1,0.14,ic50,ChEMBL,Aclidinium
CHRM2,0.17,ic50,ChEMBL,Aclidinium
CHRM3,2.285,ic50,"ChEMBL, US Patent",Aclidinium
CHRM5,0.158,ic50,ChEMBL,Aclidinium
ABCC4,133000.0,ic50,ChEMBL,Adapalene
RARA,22.0,ec50,ChEMBL,Adapalene
RARB,2.0,ec50,ChEMBL,Adapalene
RARG,3.1,ec50,ChEMBL,Adapalene
ABCC4,133000.0,ic50,ChEMBL,Adefovir dipivoxil
ABCC4,133000.0,ic50,ChEMBL,Adrucil
CYP19A1,630.0,ic50,ChEMBL,Adrucil
EGFR,320.0,ic50,Curated from the literature by BindingDB,Adrucil
ABCC4,133000.0,ic50,ChEMBL,Agomelatine
HTR2C,4.52,ic50,US Patent,Agomelatine
MTNR1A,1.56,"ec50, ic50","ChEMBL, US Patent",Agomelatine
MTNR1B,0.21,"ec50, ic50","ChEMBL, US Patent",Agomelatine
ABCC4,133000.0,ic50,ChEMBL,Albendazole
ACHE,18.0,ic50,ChEMBL,Uroxatral
ADRA1A,23.0,ic50,ChEMBL,Uroxatral
CACNA1C,199526.0,ic50,ChEMBL,Uroxatral
KCND3,1000000.0,ic50,ChEMBL,Uroxatral
SCN5A,892209.5,ic50,ChEMBL,Uroxatral
REN,0.7,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Aliskiren
HTR1B,12.0,ic50,Guide to Pharmacology,Almotriptan
HTR1D,13.0,ic50,Guide to Pharmacology,Almotriptan
DPP4,4.5,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Alogliptin
HNF4A,39841.0,ic50,PubChem,Alverine
CACNA1C,2511886.0,ic50,ChEMBL,Ambrisentan
EDNRA,21.7,ic50,"Guide to Pharmacology, ChEMBL",Ambrisentan
EDNRB,1190.0,ic50,"Guide to Pharmacology, ChEMBL",Ambrisentan
KCND3,251189.0,ic50,ChEMBL,Ambrisentan
SCN5A,1129462.5,ic50,ChEMBL,Ambrisentan
ABCC4,133000.0,ic50,ChEMBL,Amfebutamone
CHRNA1,7900.0,ic50,ChEMBL,Amfebutamone
CHRNA7,28950.0,ic50,ChEMBL,Amfebutamone
CHRNB2,1000.0,ic50,ChEMBL,Amfebutamone
CHRNB4,15.0,ic50,ChEMBL,Amfebutamone
SLC6A2,1600.0,ic50,ChEMBL,Amfebutamone
SLC6A3,660.0,ic50,"Guide to Pharmacology, ChEMBL",Amfebutamone
SLC6A4,47000.0,ic50,ChEMBL,Amfebutamone
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,Amfebutamone
ABL1,1000.0,ic50,ChEMBL,AMG-458
AKT1,10000.0,ic50,ChEMBL,AMG-458
AKT2,25000.0,ic50,ChEMBL,AMG-458
AURKA,1000.0,ic50,ChEMBL,AMG-458
AURKB,1000.0,ic50,ChEMBL,AMG-458
BTK,1000.0,ic50,ChEMBL,AMG-458
CSF1R,238.0,ic50,ChEMBL,AMG-458
FGFR1,25000.0,ic50,ChEMBL,AMG-458
IGF1R,1000.0,ic50,ChEMBL,AMG-458
INSR,1000.0,ic50,ChEMBL,AMG-458
ITK,62.0,ic50,ChEMBL,AMG-458
JAK2,25000.0,ic50,ChEMBL,AMG-458
JAK3,1000.0,ic50,ChEMBL,AMG-458
KIT,10000.0,ic50,ChEMBL,AMG-458
LCK,865.0,ic50,ChEMBL,AMG-458
MAPK14,100000.0,ic50,ChEMBL,AMG-458
MAPK3,100000.0,ic50,ChEMBL,AMG-458
MET,60.0,ic50,ChEMBL,AMG-458
PIM1,25000.0,ic50,ChEMBL,AMG-458
RET,25000.0,ic50,ChEMBL,AMG-458
RPS6KB1,25000.0,ic50,ChEMBL,AMG-458
SRC,1000.0,ic50,ChEMBL,AMG-458
TEK,1000.0,ic50,ChEMBL,AMG-458
AURKA,5.0,ic50,"Guide to Pharmacology, ChEMBL",AMG-900
AURKB,4.0,ic50,"Guide to Pharmacology, ChEMBL",AMG-900
ABCC4,132000.0,ic50,ChEMBL,Theophylline
ADORA2A,28200.0,ec50,ChEMBL,Theophylline
KCNK2,486000.0,ec50,Curated from the literature by BindingDB,Theophylline
PDE1B,338000.0,ic50,ChEMBL,Theophylline
PDE3A,300000.0,ic50,ChEMBL,Theophylline
PDE4A,386000.0,ic50,Curated from the literature by BindingDB,Theophylline
PDE4B,140500.0,ic50,ChEMBL,Theophylline
PIK3CG,2904000.0,ic50,ChEMBL,Theophylline
ABCC4,133000.0,ic50,ChEMBL,Amiodarone
CACNA1C,1085.0,ic50,ChEMBL,Amiodarone
SQLE,12000.0,ic50,ChEMBL,Amiodarone
ABCC4,133000.0,ic50,ChEMBL,Amisulpride
DRD2,3.02,ic50,"ChEMBL, US Patent",Amisulpride
ABCC4,133000.0,ic50,ChEMBL,Amprenavir
ABCG2,181000.0,ic50,ChEMBL,Amprenavir
P2RY12,1050.0,ec50,ChEMBL,Anagrelide
PDE3A,80.0,ic50,ChEMBL,Anagrelide
ABCC4,133000.0,ic50,ChEMBL,Anastrozole
CYP19A1,11.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Anastrozole
TAAR1,19936.5,"ec50, ic50",PubChem,Antazoline
ALK,0.62,ic50,ChEMBL,AP26113
IGF1R,3.2,ic50,ChEMBL,AP26113
INSR,100.0,ic50,ChEMBL,AP26113
ROS1,1.9,ic50,ChEMBL,AP26113
KDR,1.0,ic50,"Guide to Pharmacology, ChEMBL",Apatinib
KIT,429.0,ic50,Guide to Pharmacology,Apatinib
RET,13.0,ic50,Guide to Pharmacology,Apatinib
F10,210.0,ic50,ChEMBL,Apixaban
PDE4A,14.0,ic50,Guide to Pharmacology,Apremilast
PDE4B,28.5,ic50,"ChEMBL, US Patent",Apremilast
PDE4D,41.5,ic50,"Guide to Pharmacology, ChEMBL",Apremilast
ABCC4,133000.0,ic50,ChEMBL,Ipratropium
CHRM1,2.65,ic50,ChEMBL,Ipratropium
CHRM2,2.24,ic50,ChEMBL,Ipratropium
CHRM3,2.07,ic50,ChEMBL,Ipratropium
CHRM1,0.1,ic50,ChEMBL,Tiotropium
CHRM2,0.2,ic50,ChEMBL,Tiotropium
CHRM3,0.4,ic50,ChEMBL,Tiotropium
HDAC6,15.0,ic50,ChEMBL,Ruxolitinib
JAK2,3.1,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Ruxolitinib
JAK3,300.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ruxolitinib
CACNA1C,1584893.0,ic50,ChEMBL,Darunavir
KCND3,100000.0,ic50,ChEMBL,Darunavir
SCN5A,69905.5,ic50,ChEMBL,Darunavir
ABCC4,133000.0,ic50,ChEMBL,Paroxetine
CACNA1C,3900.0,ic50,ChEMBL,Paroxetine
MPO,20.0,ic50,ChEMBL,Paroxetine
PRKCA,220000.0,ic50,ChEMBL,Paroxetine
SLC6A2,317.5,ic50,ChEMBL,Paroxetine
SLC6A4,0.56,ic50,ChEMBL,Paroxetine
TACR1,900.0,ic50,ChEMBL,Paroxetine
ABCC4,133000.0,ic50,ChEMBL,Pramipexole
CFTR,50000.0,ec50,PubChem,Pramipexole
DRD1,10000.0,ec50,ChEMBL,Pramipexole
DRD2,27.0,"ec50, ic50",ChEMBL,Pramipexole
DRD3,2.8,ec50,ChEMBL,Pramipexole
DRD4,15.0,ec50,ChEMBL,Pramipexole
HRH2,166.0,ec50,ChEMBL,Pramipexole
ABCC4,133000.0,ic50,ChEMBL,Sparfloxacin
CACNA1C,88800.0,ic50,ChEMBL,Sparfloxacin
SLC6A2,5500.0,ic50,ChEMBL,Milnacipran
SLC6A3,10000.0,ic50,ChEMBL,Milnacipran
SLC6A4,100.0,ic50,ChEMBL,Milnacipran
CHRM1,832.0,ec50,ChEMBL,Pilocarpine
CHRM2,63000.0,ec50,ChEMBL,Pilocarpine
SLC5A1,684.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Canagliflozin
SLC5A2,4.4,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Canagliflozin
SLC5A1,7943.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Empagliflozin
SLC5A2,3.1,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Empagliflozin
ABCG2,25900.0,ic50,ChEMBL,Novobiocin
HSP90AB1,700000.0,ec50,ChEMBL,Novobiocin
TOP2A,454000.0,ic50,ChEMBL,Novobiocin
ABCC4,133000.0,ic50,ChEMBL,Zalcitabine
CXCR4,88.0,ec50,ChEMBL,Zalcitabine
ABCC4,133000.0,ic50,ChEMBL,Didanosine
CACNA1C,5305.0,ic50,ChEMBL,Solifenacin
CHRM1,63.5,ic50,"Guide to Pharmacology, ChEMBL",Solifenacin
CHRM2,573.7,ic50,"Guide to Pharmacology, ChEMBL",Solifenacin
CHRM3,77.4,"ec50, ic50","Guide to Pharmacology, ChEMBL",Solifenacin
KCND3,50119.0,ic50,ChEMBL,Solifenacin
SCN5A,6310.0,ic50,ChEMBL,Solifenacin
ABCC4,133000.0,ic50,ChEMBL,Decitabine
DNMT1,30.0,ic50,ChEMBL,Decitabine
ABCC4,133000.0,ic50,ChEMBL,Topiramate
CA1,250.0,ic50,ChEMBL,Topiramate
CA2,170.0,ic50,"ChEMBL, US Patent",Topiramate
CA4,54.0,ic50,ChEMBL,Topiramate
ABCC4,88500.0,ic50,ChEMBL,Atorvastatin
ABCG2,4300.0,ic50,ChEMBL,Atorvastatin
HDAC1,11383.5,ic50,"ChEMBL, US Patent",Atorvastatin
HDAC2,22547.0,ic50,"ChEMBL, US Patent",Atorvastatin
HDAC6,14308.5,ic50,"ChEMBL, US Patent",Atorvastatin
HMGCR,9.8,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Atorvastatin
CHRM1,10000.0,"ec50, ic50",ChEMBL,Carbachol
CHRM2,795.0,"ec50, ic50",ChEMBL,Carbachol
CHRM3,880.0,"ec50, ic50",ChEMBL,Carbachol
CHRM5,9900.0,"ec50, ic50",ChEMBL,Carbachol
DAO,106000.0,ic50,US Patent,Esomeprazole
ATG4B,7140.0,ic50,PubChem,Cetylpyridinium
ABCC4,133000.0,ic50,ChEMBL,Bromfenac
PTGS1,8.479999542236328,ic50,Guide to Pharmacology,Bromfenac
MTOR,1.99,ic50,US Patent,BGT226
PIK3CA,4.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",BGT226
PIK3CD,38.0,ic50,ChEMBL,BGT226
PIK3CG,38.0,ic50,"Guide to Pharmacology, ChEMBL",BGT226
ABCC4,133000.0,ic50,ChEMBL,Raltitrexed
RFC1,6.3,ic50,ChEMBL,Raltitrexed
TYMS,603.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Raltitrexed
F3,1750000.0,ic50,ChEMBL,Divalproex
HDAC1,400000.0,ic50,"Guide to Pharmacology, ChEMBL",Divalproex
HDAC2,102740.0,ic50,ChEMBL,Divalproex
HDAC3,161000.0,ic50,ChEMBL,Divalproex
HDAC6,1000000.0,ic50,ChEMBL,Divalproex
HDAC8,143650.0,ic50,ChEMBL,Divalproex
PDE3A,8.0,ic50,ChEMBL,Levosimendan
ABCC4,133000.0,ic50,ChEMBL,Atomoxetine
SLC6A2,4.05,ic50,ChEMBL,Atomoxetine
SLC6A3,3050.0,ic50,ChEMBL,Atomoxetine
SLC6A4,180.0,ic50,ChEMBL,Atomoxetine
ABCC4,133000.0,ic50,ChEMBL,Tolvaptan
AVPR1A,470.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tolvaptan
AVPR2,3.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tolvaptan
ACVR1B,1000.0,ic50,ChEMBL,GW788388
TGFBR1,3649.0,ic50,ChEMBL,GW788388
ABCC4,133000.0,ic50,ChEMBL,Moclobemide
MAOA,86200.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Moclobemide
MAOB,550000.0,ic50,ChEMBL,Moclobemide
HTR4,15.6,ec50,ChEMBL,Prucalopride
ABCC4,133000.0,ic50,ChEMBL,Domperidone
DRD2,3.4,ic50,US Patent,Domperidone
HRH1,39.89999961853027,ic50,"Guide to Pharmacology, ChEMBL",Tripelennamine
CACNA1B,2430.0,ic50,ChEMBL,Lomerizine
GSK3B,10000.0,ic50,ChEMBL,Chlorhexidine
HNF4A,22448.5,ic50,PubChem,Chlorhexidine
MMP2,7630.0,ic50,ChEMBL,Chlorhexidine
AVPR1A,3.0,ic50,ChEMBL,Conivaptan
AVPR2,11.0,ic50,ChEMBL,Conivaptan
PDE5A,12.39,ic50,"ChEMBL, US Patent",Avanafil
ABCC4,133000.0,ic50,ChEMBL,Orlistat
DAGLA,60.0,ic50,"Guide to Pharmacology, ChEMBL",Orlistat
DAGLB,100.0,ic50,"Guide to Pharmacology, ChEMBL",Orlistat
FAAH,50005.0,ic50,ChEMBL,Orlistat
PNLIP,80.7,ic50,"Guide to Pharmacology, ChEMBL",Orlistat
PSMB1,100000.0,ic50,ChEMBL,Orlistat
PSMB2,100000.0,ic50,ChEMBL,Orlistat
PSMB5,100000.0,ic50,ChEMBL,Orlistat
SCN5A,7000.0,ic50,ChEMBL,Ranolazine
AKR1B1,100000.0,ic50,ChEMBL,Diclofenac
AKR1C3,2600.0,ic50,ChEMBL,Diclofenac
CA1,100000.0,ic50,Curated from the literature by BindingDB,Diclofenac
CA2,100000.0,ic50,Curated from the literature by BindingDB,Diclofenac
CA9,100000.0,ic50,Curated from the literature by BindingDB,Diclofenac
CXCL8,8.0,ic50,ChEMBL,Diclofenac
PTGS1,12.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Diclofenac
PTGS2,39.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Diclofenac
TRPA1,63096.0,ec50,ChEMBL,Diclofenac
TTR,71871.0,ic50,"ChEMBL, US Patent",Diclofenac
UGT1A1,155000.0,ic50,Curated from the literature by BindingDB,Diclofenac
ABCC4,133000.0,ic50,ChEMBL,Moxifloxacin
CACNA1C,173000.0,ic50,ChEMBL,Moxifloxacin
SCN5A,145500.0,ic50,ChEMBL,Moxifloxacin
CDK2,170.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Flavopiridol
CDK4,132.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Flavopiridol
CDK6,80.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Flavopiridol
CDK7,312.0,ic50,ChEMBL,Flavopiridol
CDK9,15.0,ic50,"ChEMBL, US Patent",Flavopiridol
EGFR,21000.0,ic50,ChEMBL,Flavopiridol
GSK3A,770.0,ic50,ChEMBL,Flavopiridol
GSK3B,837.5,ic50,ChEMBL,Flavopiridol
ITK,14850.0,ic50,ChEMBL,Flavopiridol
LCK,11000.0,ic50,ChEMBL,Flavopiridol
MAPK3,16000.0,ic50,ChEMBL,Flavopiridol
PRKCA,2800.0,ic50,ChEMBL,Flavopiridol
PRKCE,480.0,ic50,ChEMBL,Flavopiridol
SRC,34000.0,ic50,ChEMBL,Flavopiridol
ABCG2,50.0,ic50,ChEMBL,Fostamatinib
SYK,17.0,ic50,ChEMBL,Fostamatinib
ABCC4,16500.0,ic50,ChEMBL,Nisoldipine
CACNA1C,3.0,ic50,ChEMBL,Nisoldipine
SCN1A,26000.0,ic50,ChEMBL,Nisoldipine
ABCC4,133000.0,ic50,ChEMBL,Nimodipine
ABCG2,13700.0,ic50,ChEMBL,Nimodipine
CACNA1C,110.0,ic50,ChEMBL,Nimodipine
NR3C2,160.0,ic50,Guide to Pharmacology,Nimodipine
PDE1C,1243.0,ic50,ChEMBL,Nimodipine
PDE4D,7150.0,ic50,ChEMBL,Nimodipine
ABCC4,133000.0,ic50,ChEMBL,Risperidone
ADRA1A,10.5,ic50,ChEMBL,Risperidone
CACNA1C,79600.0,ic50,ChEMBL,Risperidone
CHRM3,55000.0,ic50,ChEMBL,Risperidone
DRD2,8.75,ic50,"ChEMBL, US Patent",Risperidone
HRH1,454.0,ic50,ChEMBL,Risperidone
HTR1A,55000.0,ec50,"ChEMBL, US Patent",Risperidone
HTR2A,2.695,ic50,"ChEMBL, US Patent",Risperidone
HTR2C,4.4,ic50,ChEMBL,Risperidone
SCN5A,102000.0,ic50,ChEMBL,Risperidone
CYP51A1,50.0,ic50,ChEMBL,Econazole
IDO1,4600.0,ic50,ChEMBL,Econazole
HNF4A,12706.0,ic50,PubChem,Mosapride
ABCC4,133000.0,ic50,ChEMBL,Metoclopramide
ACHE,20000.0,ic50,ChEMBL,Metoclopramide
DRD2,175.0,ic50,US Patent,Metoclopramide
ESR2,50000.0,ic50,PubChem,Metoclopramide
HTR4,794.0,ec50,ChEMBL,Metoclopramide
MPO,2675.0,ic50,ChEMBL,Metoclopramide
PGD,3270000.0,ic50,Curated from the literature by BindingDB,Metoclopramide
ABCC4,133000.0,ic50,ChEMBL,Tolterodine
CACNA1C,25119.0,ic50,ChEMBL,Tolterodine
KCND3,12589.0,ic50,ChEMBL,Tolterodine
SCN5A,18966.5,ic50,ChEMBL,Tolterodine
MAP2K1,19.0,ic50,"Guide to Pharmacology, US Patent",Refametinib
MAP2K2,47.0,ic50,"Guide to Pharmacology, US Patent",Refametinib
CASR,65.5,ec50,"Guide to Pharmacology, ChEMBL",Cinacalcet
ABCC4,133000.0,ic50,ChEMBL,Fluconazole
CYP11B1,30000.0,ic50,ChEMBL,Fluconazole
CYP11B2,13000.0,ic50,ChEMBL,Fluconazole
CYP17A1,200000.0,ic50,ChEMBL,Fluconazole
CYP19A1,22000.0,ic50,ChEMBL,Fluconazole
CYP51A1,137.0,ic50,ChEMBL,Fluconazole
HDAC1,40000.0,ic50,ChEMBL,Fluconazole
ABCC4,133000.0,ic50,ChEMBL,Flutamide
AR,1000.0,ic50,ChEMBL,Flutamide
ABCG2,1400.0,ic50,ChEMBL,Vismodegib
SMO,16.0,"ec50, ic50",ChEMBL,Vismodegib
MDH2,43600.0,ic50,ChEMBL,L-Thyroxine
NR1H4,7860.0,ic50,ChEMBL,L-Thyroxine
PPARG,12000.0,ec50,ChEMBL,L-Thyroxine
RXRA,15400.0,ec50,ChEMBL,L-Thyroxine
TTR,2200.0,ic50,"ChEMBL, US Patent",L-Thyroxine
UGT1A1,5250.0,ic50,ChEMBL,L-Thyroxine
AURKB,110.0,ic50,US Patent,R406
FLT3,10.0,ec50,ChEMBL,R406
JAK2,6.0,"ec50, ic50",ChEMBL,R406
KDR,23.0,"ec50, ic50","ChEMBL, US Patent",R406
LYN,732.0,ic50,ChEMBL,R406
RET,20.5,"ec50, ic50","Guide to Pharmacology, ChEMBL",R406
SYK,60.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",R406
ZAP70,42.0,ic50,ChEMBL,R406
ABCC4,133000.0,ic50,ChEMBL,Ciclopirox
PARP1,160.0,ic50,Guide to Pharmacology,Ciclopirox
FGFR2,7.5,ic50,US Patent,Lenvatinib
FLT1,22.0,ic50,"ChEMBL, US Patent",Lenvatinib
FLT4,5.199999809265137,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Lenvatinib
KDR,4.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Lenvatinib
PDGFRB,39.0,ic50,ChEMBL,Lenvatinib
RET,21.25,ic50,"ChEMBL, US Patent",Lenvatinib
CSF1R,110.0,ic50,Guide to Pharmacology,Cediranib
FGFR1,26.0,ic50,ChEMBL,Cediranib
FLT1,5.0,ic50,"Guide to Pharmacology, ChEMBL",Cediranib
FLT3,1000.0,ic50,Guide to Pharmacology,Cediranib
FLT4,3.0,ic50,"Guide to Pharmacology, ChEMBL",Cediranib
KDR,1.0,ic50,"Guide to Pharmacology, ChEMBL",Cediranib
KIT,3.0,ic50,Guide to Pharmacology,Cediranib
PDGFRB,5.0,ic50,"Guide to Pharmacology, ChEMBL",Cediranib
ACE,29.3,ic50,ChEMBL,Moexipril
ABCC4,133000.0,ic50,ChEMBL,Naproxen
AKR1C3,330.0,ic50,"ChEMBL, US Patent",Naproxen
CASP3,55000.0,ic50,Curated from the literature by BindingDB,Naproxen
PTGS1,8650.0,ic50,"Guide to Pharmacology, ChEMBL",Naproxen
PTGS2,11235.0,ic50,"Guide to Pharmacology, ChEMBL",Naproxen
HDAC1,13.5,ic50,"ChEMBL, US Patent",Bendamustine
HDAC2,9.5,ic50,"ChEMBL, US Patent",Bendamustine
HDAC3,17.5,ic50,"ChEMBL, US Patent",Bendamustine
HDAC6,8.0,ic50,"ChEMBL, US Patent",Bendamustine
HDAC8,107.0,ic50,US Patent,Bendamustine
ABCC4,4600.0,ic50,ChEMBL,Gefitinib
ABCG2,800.0,"ec50, ic50",ChEMBL,Gefitinib
BRAF,30000.0,ic50,US Patent,Gefitinib
EGFR,17.0,"ec50, ic50","WIPO, Curated from the literature by BindingDB, ChEMBL, US Patent",Gefitinib
ERBB2,343.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Gefitinib
JAK3,1000.0,ic50,ChEMBL,Gefitinib
KDR,10400.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Gefitinib
PTK6,980.0,ic50,"ChEMBL, US Patent",Gefitinib
ABCC4,133000.0,ic50,ChEMBL,Lapatinib
ABCG2,3200.0,"ec50, ic50",ChEMBL,Lapatinib
ABL1,23000.0,ic50,ChEMBL,Lapatinib
CACNA1C,8922097.0,ic50,ChEMBL,Lapatinib
CDK2,15500.0,ic50,ChEMBL,Lapatinib
EGFR,16.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Lapatinib
ERBB2,13.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Lapatinib
HDAC1,10000.0,ic50,ChEMBL,Lapatinib
HDAC3,10000.0,ic50,ChEMBL,Lapatinib
HDAC6,10000.0,ic50,ChEMBL,Lapatinib
HDAC8,10000.0,ic50,ChEMBL,Lapatinib
IGF1R,20000.0,ic50,ChEMBL,Lapatinib
INSR,17000.0,ic50,ChEMBL,Lapatinib
KDR,105000.0,ic50,ChEMBL,Lapatinib
KIT,200000.0,ic50,ChEMBL,Lapatinib
PDGFRB,104250.0,ic50,ChEMBL,Lapatinib
PLK1,100000.0,ic50,ChEMBL,Lapatinib
SCN5A,3162278.0,ic50,ChEMBL,Lapatinib
ABCC1,3749.0,ec50,PubChem,L-Adrenaline
ADRA1A,400.0,ec50,ChEMBL,L-Adrenaline
ADRA1B,75.0,ec50,ChEMBL,L-Adrenaline
ADRA2A,30.0,"ec50, ic50",ChEMBL,L-Adrenaline
ADRB1,290.0,ec50,ChEMBL,L-Adrenaline
ADRB2,1380.0,ec50,PubChem,L-Adrenaline
ADRB3,40.0,ec50,ChEMBL,L-Adrenaline
CTSL,59642.0,ic50,PubChem,L-Adrenaline
ABCC4,133000.0,ic50,ChEMBL,Iloperidone
DRD2,110.0,ic50,ChEMBL,Iloperidone
SIGMAR1,64.0,ic50,ChEMBL,Iloperidone
PDE10A,73000.0,ic50,Curated from the literature by BindingDB,Cilomilast
PDE1B,87000.0,ic50,Curated from the literature by BindingDB,Cilomilast
PDE3B,87000.0,ic50,Curated from the literature by BindingDB,Cilomilast
PDE4B,25.0,ic50,Curated from the literature by BindingDB,Cilomilast
PDE4D,11.0,ic50,Curated from the literature by BindingDB,Cilomilast
PDE5A,53000.0,ic50,Curated from the literature by BindingDB,Cilomilast
OPRD1,139.5,"ec50, ic50",ChEMBL,Loperamide
OPRM1,1.5,ic50,ChEMBL,Loperamide
SCN1A,270.0,ic50,ChEMBL,Loperamide
SCN5A,239.0,ic50,ChEMBL,Loperamide
TPH1,417.0,ic50,"Guide to Pharmacology, US Patent",Telotristat
ABCC4,1900.0,ic50,ChEMBL,Febuxostat
ABCG2,27.0,ic50,ChEMBL,Febuxostat
XDH,7.0,ic50,"Guide to Pharmacology, ChEMBL",Febuxostat
ABCC4,53900.0,ic50,ChEMBL,Repaglinide
ABCC8,106.0,ic50,"Guide to Pharmacology, ChEMBL",Repaglinide
AR,219.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Enzalutamide
NR3C1,19500.0,ic50,ChEMBL,Enzalutamide
OPRD1,92461.0,ec50,PubChem,Benzethonium
ABCC4,133000.0,ic50,ChEMBL,Sulfacetamide
ACHE,360.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Pyridostigmine
BCHE,1000.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Pyridostigmine
ABCC4,133000.0,ic50,ChEMBL,Fesoterodine
BRD4,64.5,ic50,"Guide to Pharmacology, ChEMBL",CPI-203
AXL,1.1,ic50,"Guide to Pharmacology, ChEMBL",BMS-777607
BTK,2000.0,ic50,ChEMBL,BMS-777607
EGFR,6750.0,ic50,ChEMBL,BMS-777607
FLT3,18.0,ic50,ChEMBL,BMS-777607
INSR,7250.0,ic50,ChEMBL,BMS-777607
JAK2,2000.0,ic50,ChEMBL,BMS-777607
KDR,159.5,ic50,ChEMBL,BMS-777607
KIT,144.0,ic50,ChEMBL,BMS-777607
LCK,120.0,ic50,ChEMBL,BMS-777607
MET,3.900000095367432,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",BMS-777607
RET,594.0,ic50,ChEMBL,BMS-777607
TEK,500.0,ic50,ChEMBL,BMS-777607
ABCC4,133000.0,ic50,ChEMBL,Cimetidine
ATP4A,50410.0,ic50,ChEMBL,Cimetidine
HRH2,500.0,ic50,ChEMBL,Cimetidine
ABCC4,88000.0,ic50,ChEMBL,Nicardipine
ABCG2,4800.0,ic50,ChEMBL,Nicardipine
ADRA2A,10000.0,ic50,ChEMBL,Nicardipine
CACNA1C,9600.0,ic50,ChEMBL,Nicardipine
ABCC4,133000.0,ic50,ChEMBL,Felodipine
SCN1A,37000.0,ic50,ChEMBL,Felodipine
PRKACG,4580.0,ic50,ChEMBL,Fasudil
PRKCE,3000.0,ic50,ChEMBL,Fasudil
ROCK1,660.0,ic50,ChEMBL,Fasudil
ROCK2,400.0,ic50,"PubChem, ChEMBL",Fasudil
ADRA1A,555.0,ic50,ChEMBL,Naftopidil
ADRA1B,634.0,ic50,ChEMBL,Naftopidil
ADRA1D,55.2,ic50,ChEMBL,Naftopidil
EGFR,25000000.0,ic50,ChEMBL,Phloretin
ESR1,300.0,ic50,ChEMBL,Phloretin
SLC5A1,12400.0,ic50,ChEMBL,Phloretin
SLC5A2,18300.0,ic50,ChEMBL,Phloretin
TOP2A,167000.0,ic50,ChEMBL,Phloretin
ABCC4,133000.0,ic50,ChEMBL,Furosemide
ABCG2,3200.0,ic50,ChEMBL,Furosemide
CA1,80.0,ic50,US Patent,Furosemide
G6PD,315000.0,ic50,Curated from the literature by BindingDB,Furosemide
HSD11B1,3760.0,ic50,ChEMBL,Furosemide
PGD,125000.0,ic50,Curated from the literature by BindingDB,Furosemide
ABL1,1000.0,ic50,ChEMBL,Crizotinib
AKT2,10000.0,ic50,ChEMBL,Crizotinib
ALK,59.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Crizotinib
AXL,197.0,ic50,ChEMBL,Crizotinib
BTK,10000.0,ic50,ChEMBL,Crizotinib
CDK7,10000.0,ic50,ChEMBL,Crizotinib
CSF1R,10000.0,ic50,ChEMBL,Crizotinib
EGFR,6750.0,ic50,ChEMBL,Crizotinib
EPHA2,1000.0,ic50,ChEMBL,Crizotinib
ERBB2,1000.0,ic50,ChEMBL,Crizotinib
FGFR1,1000.0,ic50,ChEMBL,Crizotinib
FGFR3,10000.0,ic50,ChEMBL,Crizotinib
FLT1,1000.0,ic50,ChEMBL,Crizotinib
FLT3,1000.0,ic50,ChEMBL,Crizotinib
IGF1R,1000.0,ic50,ChEMBL,Crizotinib
INSR,650.0,ic50,ChEMBL,Crizotinib
JAK2,27.0,ic50,ChEMBL,Crizotinib
JAK3,1360.0,ic50,ChEMBL,Crizotinib
KDR,5500.0,ic50,ChEMBL,Crizotinib
LCK,2741.0,ic50,ChEMBL,Crizotinib
MET,2.9,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Crizotinib
NTRK1,9.3,ic50,"ChEMBL, US Patent",Crizotinib
NTRK2,200.5,ic50,ChEMBL,Crizotinib
PDGFRB,5500.0,ic50,ChEMBL,Crizotinib
RET,10000.0,ic50,ChEMBL,Crizotinib
ROS1,23.65,ic50,ChEMBL,Crizotinib
RPS6KB1,10000.0,ic50,ChEMBL,Crizotinib
SRC,5500.0,ic50,ChEMBL,Crizotinib
TEK,226.5,ic50,ChEMBL,Crizotinib
ABCC4,133000.0,ic50,ChEMBL,Duloxetine
CACNA1C,25119.0,ic50,ChEMBL,Duloxetine
DAO,5469.0,ic50,US Patent,Duloxetine
KCND3,100000.0,ic50,ChEMBL,Duloxetine
SCN5A,11896.0,ic50,ChEMBL,Duloxetine
SLC6A2,6.95,ic50,ChEMBL,Duloxetine
SLC6A3,870.0,ic50,ChEMBL,Duloxetine
SLC6A4,6.0,ic50,ChEMBL,Duloxetine
EGFR,1600.0,ic50,ChEMBL,BMS-536924
ERBB2,17100.0,ic50,ChEMBL,BMS-536924
IGF1R,100.0,ic50,"Curated from the literature by BindingDB, ChEMBL",BMS-536924
INSR,73.0,ic50,ChEMBL,BMS-536924
KDR,1400.0,ic50,ChEMBL,BMS-536924
LCK,341.0,ic50,ChEMBL,BMS-536924
MAP2K1,182.0,ic50,ChEMBL,BMS-536924
MET,4870.0,ic50,ChEMBL,BMS-536924
ACHE,2476100.0,ic50,ChEMBL,Hesperetin
DPP4,280.0,ic50,ChEMBL,Hesperetin
GSK3B,26900.0,ic50,ChEMBL,Hesperetin
MAPK14,54600.0,ic50,Curated from the literature by BindingDB,Hesperetin
ABCC4,20800.0,ic50,ChEMBL,Quercetin
ABCG2,3589.0,"ec50, ic50",ChEMBL,Quercetin
ACHE,72830.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
AKR1B1,2875.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
AKT1,5390.0,ic50,ChEMBL,Quercetin
ALK,3320.0,ic50,ChEMBL,Quercetin
ALOX5,3670.0,"ec50, ic50",ChEMBL,Quercetin
AURKB,2435.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
AVPR2,15200.0,ic50,ChEMBL,Quercetin
AXL,960.0,ic50,ChEMBL,Quercetin
BCHE,420760.0,ic50,ChEMBL,Quercetin
CALM1,12970.0,ic50,ChEMBL,Quercetin
CAMK2B,3000.0,ic50,ChEMBL,Quercetin
CDK2,40000.0,ic50,ChEMBL,Quercetin
CDK4,61000.0,ic50,ChEMBL,Quercetin
CDK6,25000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
CTSL,59642.0,ic50,PubChem,Quercetin
CYP19A1,6006.0,ic50,ChEMBL,Quercetin
DPP4,66460.0,ic50,ChEMBL,Quercetin
EGFR,14900.0,ic50,ChEMBL,Quercetin
F2,15750.0,ic50,ChEMBL,Quercetin
FLT3,590.0,ic50,ChEMBL,Quercetin
G6PD,31020.0,ic50,ChEMBL,Quercetin
GSK3B,6030.0,"ec50, ic50","PubChem, ChEMBL",Quercetin
HTR1A,100000.0,ec50,ChEMBL,Quercetin
IGF1R,300.0,ic50,ChEMBL,Quercetin
KDR,1660.0,ic50,ChEMBL,Quercetin
LCK,72500.0,ic50,ChEMBL,Quercetin
MAOA,2800.0,ic50,ChEMBL,Quercetin
MAOB,64330.0,ic50,ChEMBL,Quercetin
MAPK14,3450.0,ic50,Curated from the literature by BindingDB,Quercetin
MET,580.0,ic50,ChEMBL,Quercetin
MGAM,10800.0,ic50,ChEMBL,Quercetin
MMP2,6680.0,ic50,ChEMBL,Quercetin
MPO,1210.0,ic50,ChEMBL,Quercetin
OXTR,29913.0,ec50,PubChem,Quercetin
PIK3CG,8795.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
PIK3R1,3800.0,ic50,ChEMBL,Quercetin
PIM1,1096.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
PLK1,34875.0,ic50,ChEMBL,Quercetin
PPARG,26000.0,ic50,ChEMBL,Quercetin
PRSS1,19000.0,ic50,ChEMBL,Quercetin
PSMB5,2750.0,ic50,ChEMBL,Quercetin
PTGS2,28600.0,ic50,ChEMBL,Quercetin
PTPN1,32120.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Quercetin
RET,78100.0,ic50,ChEMBL,Quercetin
SRC,15000.0,ic50,ChEMBL,Quercetin
SYK,27500.0,"ec50, ic50",ChEMBL,Quercetin
TOP2A,22800.0,ic50,ChEMBL,Quercetin
TYR,44380.0,ic50,ChEMBL,Quercetin
XDH,3250.0,ic50,"ChEMBL, US Patent",Quercetin
ABCC1,3000.0,ic50,ChEMBL,Diosmetin
AURKB,3860.0,ic50,Curated from the literature by BindingDB,Diosmetin
MAPK14,23200.0,ic50,Curated from the literature by BindingDB,Diosmetin
ABCC1,1.9,ic50,ChEMBL,Mitoxantrone
ABCG2,904.0,ic50,ChEMBL,Mitoxantrone
APEX1,2000.0,ic50,ChEMBL,Mitoxantrone
BTK,1000.0,ic50,ChEMBL,Mitoxantrone
CACNA1C,22500.0,ic50,ChEMBL,Mitoxantrone
CFTR,50000.0,ec50,PubChem,Mitoxantrone
PIM1,51.0,ic50,ChEMBL,Mitoxantrone
TOP2A,5300.0,ic50,"Guide to Pharmacology, ChEMBL",Mitoxantrone
APH1A,2.75,ic50,ChEMBL,YO-01027
FGFR1,1.15,ic50,ChEMBL,AZD4547
FGFR2,2.85,ic50,"Guide to Pharmacology, ChEMBL",AZD4547
FGFR3,5.0,ic50,"Guide to Pharmacology, ChEMBL",AZD4547
FGFR4,165.0,ic50,"Guide to Pharmacology, ChEMBL",AZD4547
IGF1R,581.0,ic50,Guide to Pharmacology,AZD4547
KDR,28.5,ic50,"Guide to Pharmacology, ChEMBL",AZD4547
ABCC4,34100.0,ic50,ChEMBL,Losartan
ABCG2,35000.0,ic50,ChEMBL,Losartan
ACE,19.0,ic50,ChEMBL,Losartan
AGTR1,39.5,ic50,ChEMBL,Losartan
MME,10000.0,ic50,ChEMBL,Losartan
PDE3A,13000.0,ic50,ChEMBL,Losartan
PDE4B,26000.0,ic50,ChEMBL,Losartan
TBXA2R,20000.0,ic50,ChEMBL,Losartan
ADRB1,37.0,ic50,ChEMBL,Betaxolol
ADRB2,657.0,ic50,ChEMBL,Betaxolol
ABL1,160.0,ic50,"Curated from the literature by BindingDB, ChEMBL",VX-680
AURKA,21.5,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",VX-680
AURKB,30.0,ic50,"Curated from the literature by BindingDB, ChEMBL",VX-680
CDK2,10000.0,ic50,Curated from the literature by BindingDB,VX-680
FLT3,30.0,ic50,ChEMBL,VX-680
IGF1R,2750.0,ic50,ChEMBL,VX-680
PLK1,10000.0,ic50,Curated from the literature by BindingDB,VX-680
RIPK1,208.0,ic50,ChEMBL,VX-680
HTR1A,200.0,ec50,ChEMBL,Vortioxetine
HTR1B,120.0,ec50,ChEMBL,Vortioxetine
HTR3A,12.0,"ec50, ic50",ChEMBL,Vortioxetine
PTGS1,5.195,ic50,ChEMBL,Vortioxetine
PTGS2,3.105,ic50,ChEMBL,Vortioxetine
SLC6A4,5.4,ic50,ChEMBL,Vortioxetine
ABCC4,23400.0,ic50,ChEMBL,Sildenafil
CACNA1C,100000.0,ic50,ChEMBL,Sildenafil
KCND3,501187.0,ic50,ChEMBL,Sildenafil
PDE10A,6100.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Sildenafil
PDE1B,400.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Sildenafil
PDE3A,20300.0,ic50,ChEMBL,Sildenafil
PDE3B,15000.0,ic50,Curated from the literature by BindingDB,Sildenafil
PDE4A,5000.0,ic50,ChEMBL,Sildenafil
PDE4B,10000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Sildenafil
PDE4D,17000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Sildenafil
PDE5A,4.9,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL, US Patent",Sildenafil
SCN5A,880056.0,ic50,ChEMBL,Sildenafil
ABCG2,70.0,ic50,ChEMBL,Tivozanib
EGFR,123.64,ic50,Curated from the literature by BindingDB,Tivozanib
FLT1,6.26,ic50,"Guide to Pharmacology, ChEMBL",Tivozanib
FLT4,1.67,ic50,"Guide to Pharmacology, ChEMBL",Tivozanib
KDR,2.25,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Tivozanib
PDGFRB,42.39,ic50,Curated from the literature by BindingDB,Tivozanib
ABCC4,133000.0,ic50,ChEMBL,Imatinib
ABCG2,3545.0,ic50,ChEMBL,Imatinib
ABL1,309.5,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Imatinib
ALK,65000.0,ic50,ChEMBL,Imatinib
AURKA,30000.0,ic50,Curated from the literature by BindingDB,Imatinib
AURKB,30000.0,ic50,Curated from the literature by BindingDB,Imatinib
BRAF,100000.0,ic50,ChEMBL,Imatinib
CDK2,55000.0,ic50,ChEMBL,Imatinib
CSF1R,960.0,ic50,ChEMBL,Imatinib
DDR1,337.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Imatinib
EGFR,50000.055,ic50,ChEMBL,Imatinib
ERBB2,0.06,ic50,ChEMBL,Imatinib
FLT3,15065.5,ic50,ChEMBL,Imatinib
HDAC1,100000.0,ic50,ChEMBL,Imatinib
HDAC6,100000.0,ic50,ChEMBL,Imatinib
KDR,25800.0,ic50,ChEMBL,Imatinib
KIT,160.5,"ec50, ic50","ChEMBL, US Patent",Imatinib
LCK,160.0,ic50,ChEMBL,Imatinib
LYN,220.0,ic50,ChEMBL,Imatinib
MAPK14,70000.0,ic50,ChEMBL,Imatinib
PDGFRB,313.0,ic50,ChEMBL,Imatinib
PRKCA,100000.0,ic50,ChEMBL,Imatinib
SRC,100000.0,ic50,ChEMBL,Imatinib
SYK,5000.0,ic50,ChEMBL,Imatinib
ABCG2,2500.0,ic50,ChEMBL,Nilotinib
ABL1,30.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Nilotinib
CACNA1C,199526.0,ic50,ChEMBL,Nilotinib
CSF1R,677.0,ic50,ChEMBL,Nilotinib
DDR1,43.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Nilotinib
EPHA2,33.0,ic50,Curated from the literature by BindingDB,Nilotinib
FLT3,9548.0,ic50,ChEMBL,Nilotinib
KCND3,3162278.0,ic50,ChEMBL,Nilotinib
KIT,158.0,ic50,ChEMBL,Nilotinib
LCK,108.1,ic50,ChEMBL,Nilotinib
LYN,1281.0,ic50,ChEMBL,Nilotinib
MAPK14,4600.0,ec50,ChEMBL,Nilotinib
PDGFRB,60.0,ic50,ChEMBL,Nilotinib
RAF1,1100.0,ic50,ChEMBL,Nilotinib
SCN5A,3005936.0,ic50,ChEMBL,Nilotinib
SRC,1300.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Nilotinib
ALK,290.0,ic50,ChEMBL,BI 2536
BRD4,167.0,ic50,ChEMBL,BI 2536
PLK1,6.199999999999999,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",BI 2536
ADRA2A,21.0,"ec50, ic50",ChEMBL,Clonidine
ADRA2B,670.5,ec50,ChEMBL,Clonidine
ADRA2C,56.5,ec50,ChEMBL,Clonidine
NISCH,366.2,ic50,ChEMBL,Clonidine
SLC6A2,20000.0,ic50,ChEMBL,Clonidine
ABCC4,133000.0,ic50,ChEMBL,Haloperidol
ADRA1A,20.0,ic50,ChEMBL,Haloperidol
CACNA1C,1500.0,ic50,ChEMBL,Haloperidol
CHRM1,5500.0,ic50,ChEMBL,Haloperidol
DRD2,4.0,ic50,ChEMBL,Haloperidol
DRD3,1.875,ic50,ChEMBL,Haloperidol
DRD4,6.0,"ec50, ic50",ChEMBL,Haloperidol
HTR1A,1500.0,ic50,ChEMBL,Haloperidol
HTR1B,10000.0,ic50,ChEMBL,Haloperidol
HTR2A,288.0,ic50,ChEMBL,Haloperidol
HTR2C,10000.0,ic50,ChEMBL,Haloperidol
KCNK2,5500.0,ic50,ChEMBL,Haloperidol
OPRM1,10000.0,ec50,ChEMBL,Haloperidol
SCN1A,1200.0,ic50,ChEMBL,Haloperidol
SIGMAR1,8.0,ic50,ChEMBL,Haloperidol
ABCC4,133000.0,ic50,ChEMBL,Leflunomide
DHODH,10000.0,ic50,ChEMBL,Leflunomide
F10,4610.0,ic50,ChEMBL,Gabexate
F2,687.0,ic50,ChEMBL,Gabexate
HPN,383.0,ic50,ChEMBL,Gabexate
PLG,1550.0,ic50,ChEMBL,Gabexate
ABCC4,133000.0,ic50,ChEMBL,Valsartan
AGTR1,2.7,ic50,"Guide to Pharmacology, ChEMBL",Valsartan
AGTR1,11.0,ic50,ChEMBL,Candesartan
S1PR1,840.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Fingolimod
ABCC4,133000.0,ic50,ChEMBL,Glipizide
TACR1,1.2000000476837158,ic50,Guide to Pharmacology,Fosaprepitant
ALK,3180.0,ic50,ChEMBL,Foretinib
AXL,14.0,ic50,ChEMBL,Foretinib
EGFR,3010.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Foretinib
EPHA2,1.9,ic50,Curated from the literature by BindingDB,Foretinib
FLT1,6.8,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Foretinib
FLT3,5.4,ic50,"Curated from the literature by BindingDB, ChEMBL",Foretinib
FLT4,2.799999976158142,ic50,"Guide to Pharmacology, ChEMBL",Foretinib
KDR,4.8,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Foretinib
KIT,6.7,ic50,"Curated from the literature by BindingDB, ChEMBL",Foretinib
MET,2.1,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Foretinib
NTRK1,3.0,ic50,ChEMBL,Foretinib
PDGFRB,9.6,ic50,ChEMBL,Foretinib
ROS1,10.0,ic50,ChEMBL,Foretinib
TEK,1.1,ic50,ChEMBL,Foretinib
ABCC4,133000.0,ic50,ChEMBL,Posaconazole
ABCG2,6000.0,ic50,ChEMBL,Posaconazole
CYP11B1,310.0,ic50,ChEMBL,Posaconazole
CYP11B2,21.0,ic50,ChEMBL,Posaconazole
CYP17A1,921.0,ic50,ChEMBL,Posaconazole
CYP19A1,8400.0,ic50,ChEMBL,Posaconazole
BRD4,570.0,ic50,"ChEMBL, US Patent",TG101348
FLT3,20.0,ic50,ChEMBL,TG101348
JAK2,3.03,ic50,"Guide to Pharmacology, ChEMBL, US Patent",TG101348
JAK3,1000.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",TG101348
RET,32.5,ic50,ChEMBL,TG101348
F2,2.6,ic50,ChEMBL,Dabigatran etexilate
ABCC4,133000.0,ic50,ChEMBL,Sotalol
ADRB1,8900.0,ic50,ChEMBL,Sotalol
CACNA1C,608150.0,ic50,ChEMBL,Sotalol
ABCC4,133000.0,ic50,ChEMBL,Fluoxetine
ACHE,5065.0,ic50,ChEMBL,Fluoxetine
HTR2A,710.0,ic50,ChEMBL,Fluoxetine
HTR2C,160.0,ic50,ChEMBL,Fluoxetine
KCNK2,16500.0,ic50,ChEMBL,Fluoxetine
SIGMAR1,851.0,ic50,ChEMBL,Fluoxetine
SLC6A2,2000.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB, US Patent",Fluoxetine
SLC6A3,14200.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB, US Patent",Fluoxetine
SLC6A4,9.4,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB, US Patent",Fluoxetine
ABCC4,133000.0,ic50,ChEMBL,Celecoxib
ALOX5,8435.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Celecoxib
CA1,50000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Celecoxib
CA2,21.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Celecoxib
CA4,290.0,ic50,ChEMBL,Celecoxib
CA9,16.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Celecoxib
HDAC1,1411.0,ic50,ChEMBL,Celecoxib
HDAC6,643.0,ic50,ChEMBL,Celecoxib
MAPK14,810.0,ic50,ChEMBL,Celecoxib
PDE5A,37000.0,ic50,"ChEMBL, US Patent",Celecoxib
PTGS1,14200.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Celecoxib
PTGS2,110.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Celecoxib
TRPV1,10000.0,ic50,ChEMBL,Celecoxib
ABCG2,3100.0,ic50,ChEMBL,Sorafenib
ABL1,80.0,ic50,ChEMBL,Sorafenib
AKT1,10000.0,ic50,ChEMBL,Sorafenib
AURKA,3800.0,ic50,ChEMBL,Sorafenib
AURKB,1800.0,ic50,ChEMBL,Sorafenib
BRAF,39.5,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Sorafenib
CDK2,150000.0,ic50,Curated from the literature by BindingDB,Sorafenib
CDK4,3000.0,ic50,ChEMBL,Sorafenib
CDK6,130.0,ic50,ChEMBL,Sorafenib
CSF1R,58.0,ic50,ChEMBL,Sorafenib
CYP19A1,58.0,ic50,Curated from the literature by BindingDB,Sorafenib
EGFR,58.0,ic50,"ChEMBL, US Patent",Sorafenib
ERBB2,130.0,ic50,"ChEMBL, US Patent",Sorafenib
FGFR1,580.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Sorafenib
FGFR2,10.0,ic50,US Patent,Sorafenib
FLT1,31.0,ic50,"ChEMBL, US Patent",Sorafenib
FLT3,33.0,ic50,"Guide to Pharmacology, ChEMBL",Sorafenib
FLT4,20.0,ic50,"ChEMBL, US Patent",Sorafenib
GSK3B,8300.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Sorafenib
KDR,34.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Sorafenib
KIT,68.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Sorafenib
LCK,60.0,ic50,ChEMBL,Sorafenib
MAP2K1,3300.0,ic50,ChEMBL,Sorafenib
MAPK1,110.0,ic50,ChEMBL,Sorafenib
MAPK14,84.4,ic50,ChEMBL,Sorafenib
MAPK3,18.0,ic50,ChEMBL,Sorafenib
MET,5750.0,ic50,ChEMBL,Sorafenib
PDGFRB,57.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Sorafenib
PLK1,10000.0,ic50,ChEMBL,Sorafenib
RAF1,7.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Sorafenib
RET,10.5,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Sorafenib
RIPK1,1500.0,ic50,ChEMBL,Sorafenib
TEK,0.83,ic50,ChEMBL,Sorafenib
ABCC4,49500.0,ic50,ChEMBL,Pioglitazone
MAOB,298.0,ic50,ChEMBL,Pioglitazone
PPARA,6700.0,ec50,ChEMBL,Pioglitazone
PPARG,787.5,"ec50, ic50","ChEMBL, US Patent",Pioglitazone
PTPN1,220000.0,ic50,ChEMBL,Pioglitazone
CDK2,273.0,ic50,"ChEMBL, US Patent",LY2835219
CDK4,2.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",LY2835219
CDK6,7.8,ic50,"Guide to Pharmacology, ChEMBL, US Patent",LY2835219
CDK7,483.5,ic50,"ChEMBL, US Patent",LY2835219
CDK9,45.75,ic50,"ChEMBL, US Patent",LY2835219
GSK3B,64.0,ic50,ChEMBL,LY2835219
PIM1,3.92,ic50,US Patent,LY2835219
ABCC4,133000.0,ic50,ChEMBL,Rasagiline
ACHE,50009.5,ic50,ChEMBL,Rasagiline
BCHE,52380.0,ic50,ChEMBL,Rasagiline
MAOA,1020.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Rasagiline
MAOB,25.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Rasagiline
ABCC4,133000.0,ic50,ChEMBL,Dronedarone
KCNA5,2370.0,ic50,"Guide to Pharmacology, ChEMBL",Dronedarone
HTR1D,1.6,ec50,ChEMBL,Naratriptan
ABCC4,133000.0,ic50,ChEMBL,Sumatriptan
HTR1A,501.0,"ec50, ic50",ChEMBL,Sumatriptan
HTR1B,21.5,"ec50, ic50",ChEMBL,Sumatriptan
HTR1D,14.0,"ec50, ic50",ChEMBL,Sumatriptan
HTR1F,1000.0,"ec50, ic50",ChEMBL,Sumatriptan
HTR2A,8971.64,ic50,ChEMBL,Sumatriptan
HTR2C,7921.5,ic50,ChEMBL,Sumatriptan
HTR3A,9.3,ic50,ChEMBL,Sumatriptan
PRKCA,7.0,ic50,Guide to Pharmacology,Go 6983
PRKCB,7.0,ic50,Guide to Pharmacology,Go 6983
ESR1,50000.0,ic50,PubChem,Nabumetone
ABCC4,133000.0,ic50,ChEMBL,Ondansetron
HTR3A,0.09,ic50,ChEMBL,Ondansetron
CACNA1C,1584893.0,ic50,ChEMBL,Darifenacin
CHRM3,32.0,ec50,ChEMBL,Darifenacin
KCND3,12589.0,ic50,ChEMBL,Darifenacin
SCN5A,1585.0,ic50,ChEMBL,Darifenacin
TGFBR1,88.0,ic50,ChEMBL,SB525334
ABCC1,8000.0,ic50,ChEMBL,Daunorubicin
HDAC1,47.0,ic50,ChEMBL,Daunorubicin
HDAC6,20.0,ic50,ChEMBL,Daunorubicin
HDAC8,220.0,ic50,ChEMBL,Daunorubicin
HSP90AA1,14721.85,ic50,PubChem,Daunorubicin
MMP2,1900.0,ic50,ChEMBL,Daunorubicin
TTR,100000.0,ic50,ChEMBL,Daunorubicin
SLC6A4,1.1200000047683716,ic50,Guide to Pharmacology,Dapoxetine
ACHE,3120.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Rivastigmine
BCHE,375.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Rivastigmine
MAOB,100000.0,ic50,ChEMBL,Rivastigmine
SLC6A4,1000.0,ic50,ChEMBL,Rivastigmine
ADRA1A,56.0,ec50,ChEMBL,Phenylephrine
ADRA1B,3.3800000000000003,ec50,ChEMBL,Phenylephrine
ADRB1,6000.0,ec50,ChEMBL,Phenylephrine
ABCG2,170.0,"ec50, ic50",ChEMBL,Erlotinib
BRAF,60.0,ic50,ChEMBL,Erlotinib
CDK2,1140.0,ic50,ChEMBL,Erlotinib
EGFR,37.0,ic50,"WIPO, Curated from the literature by BindingDB, Guide to Pharmacology, ChEMBL, US Patent",Erlotinib
ERBB2,389.5,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Erlotinib
FLT1,250.0,ic50,ChEMBL,Erlotinib
IGF1R,20000.0,ic50,ChEMBL,Erlotinib
INSR,21250.0,ic50,ChEMBL,Erlotinib
JAK2,20000.0,ic50,ChEMBL,Erlotinib
KDR,820.0,ic50,"ChEMBL, US Patent",Erlotinib
MET,12500.0,ic50,ChEMBL,Erlotinib
PDGFRB,21100.0,ic50,ChEMBL,Erlotinib
PTGS2,10000.0,ic50,ChEMBL,Erlotinib
CHEK1,6.945,"ec50, ic50","Guide to Pharmacology, ChEMBL",AZD7762
CHEK2,10.0,ic50,"Guide to Pharmacology, ChEMBL",AZD7762
ABCC4,133000.0,ic50,ChEMBL,Quinapril
ACE,8.3,ic50,ChEMBL,Quinapril
ABCC4,133000.0,ic50,ChEMBL,Enalapril
ACE,1200.0,ic50,"Guide to Pharmacology, ChEMBL",Enalapril
MAOA,45000.0,ic50,ChEMBL,Safinamide
MAOB,23.07,"ec50, ic50","Guide to Pharmacology, ChEMBL",Safinamide
JAK2,1.8,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CEP-33779
JAK3,150.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CEP-33779
ABCC4,133000.0,ic50,ChEMBL,Clopidogrel
P2RY12,2400.0,ic50,ChEMBL,Clopidogrel
ACHE,2110000.0,ic50,ChEMBL,Gallamine
CHRM1,171890.03999999998,ec50,ChEMBL,Gallamine
CHRM2,776.0,ic50,ChEMBL,Gallamine
CHRNA1,1000.0,ic50,Guide to Pharmacology,Gallamine
ACVR1B,138.5,ic50,"Guide to Pharmacology, ChEMBL",LY2157299
KDR,442.0,ic50,ChEMBL,LY2157299
MAPK14,490.0,ic50,ChEMBL,LY2157299
TGFBR1,109.5,ic50,"Guide to Pharmacology, ChEMBL",LY2157299
TGFBR2,754.0,ic50,"Guide to Pharmacology, ChEMBL",LY2157299
ABCC4,21000.0,ic50,ChEMBL,Rosiglitazone
MAOB,832.0,ic50,ChEMBL,Rosiglitazone
PPARA,3390.0,ec50,ChEMBL,Rosiglitazone
PPARG,107.5,"ec50, ic50","ChEMBL, US Patent",Rosiglitazone
PTPN1,400000.0,ic50,ChEMBL,Rosiglitazone
ABCC4,133000.0,ic50,ChEMBL,Oxybutynin
AKT1,7.25,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",MK-2206
AKT2,12.0,ic50,"Guide to Pharmacology, ChEMBL",MK-2206
AKT3,65.0,ic50,"Guide to Pharmacology, ChEMBL",MK-2206
KDR,10.0,ic50,"Curated from the literature by BindingDB, ChEMBL",MGCD-265
MET,29.0,ic50,"Curated from the literature by BindingDB, ChEMBL",MGCD-265
ABCC4,133000.0,ic50,ChEMBL,Ziprasidone
ADRA1A,11.0,ic50,ChEMBL,Ziprasidone
DRD2,5.0,ic50,ChEMBL,Ziprasidone
HTR2A,0.42,ic50,ChEMBL,Ziprasidone
ABCC4,133000.0,ic50,ChEMBL,Dexlansoprazole
HTR1A,41.0,"ec50, ic50",ChEMBL,Buspirone
HTR1B,26000.0,ic50,ChEMBL,Buspirone
SIGMAR1,149.5,ic50,ChEMBL,Buspirone
ABCC1,70000.0,ic50,ChEMBL,Vincristine
ABCC4,133000.0,ic50,ChEMBL,Vincristine
HDAC1,52.5,"ec50, ic50","Guide to Pharmacology, ChEMBL",Givinostat
HDAC2,293.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Givinostat
HDAC3,78.5,"ec50, ic50","Guide to Pharmacology, ChEMBL",Givinostat
HDAC6,35.5,"ec50, ic50","Guide to Pharmacology, ChEMBL",Givinostat
HDAC8,837.0,ic50,ChEMBL,Givinostat
ABCC4,133000.0,ic50,ChEMBL,Quinine
CFTR,50000.0,ec50,PubChem,Quinine
KCNK2,3850.0,ic50,Curated from the literature by BindingDB,Quinine
SCN1A,4400.0,ic50,ChEMBL,Quinine
EDNRA,0.5,ic50,"Guide to Pharmacology, ChEMBL",Macitentan
EDNRB,391.0,ic50,"Guide to Pharmacology, ChEMBL",Macitentan
CDK2,47.0,ic50,"Curated from the literature by BindingDB, ChEMBL",SNS-032
CDK4,497.0,ic50,ChEMBL,SNS-032
CDK7,62.0,ic50,ChEMBL,SNS-032
CDK9,40.0,ic50,ChEMBL,SNS-032
BRAF,100.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Vemurafenib
CHRM1,1195.0,ec50,US Patent,Vemurafenib
CHRM2,1600.0,ec50,US Patent,Vemurafenib
CHRM3,4000.0,ec50,US Patent,Vemurafenib
CSF1R,1000.0,ic50,US Patent,Vemurafenib
DDR1,1000.0,ic50,US Patent,Vemurafenib
EGFR,5024.0,ic50,"ChEMBL, US Patent",Vemurafenib
KDR,360.0,ic50,ChEMBL,Vemurafenib
RAF1,135.0,ic50,"ChEMBL, US Patent",Vemurafenib
AURKA,145.0,ic50,Guide to Pharmacology,PF-562271
FLT3,97.0,ic50,Guide to Pharmacology,PF-562271
ADRA2A,3.55,"ec50, ic50",ChEMBL,Brimonidine
ADRA2C,6.45,ec50,ChEMBL,Brimonidine
ALOX5,10000.0,ic50,ChEMBL,Idebenone
CHEK1,0.31,ic50,ChEMBL,CHIR-124
MTOR,0.34,ic50,ChEMBL,GSK2126458
PIK3CA,0.63,ic50,ChEMBL,GSK2126458
PIK3CD,0.78,ic50,ChEMBL,GSK2126458
PIK3CG,0.605,ic50,ChEMBL,GSK2126458
PIK3R1,0.019,ic50,ChEMBL,GSK2126458
PIM1,10000.0,ic50,ChEMBL,GSK2126458
ABCC4,8100.0,ic50,ChEMBL,Pazopanib
ABL1,620.0,ic50,Curated from the literature by BindingDB,Pazopanib
ACHE,930.0,ic50,ChEMBL,Pazopanib
CSF1R,146.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
FGFR1,140.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
FGFR2,140.0,ic50,ChEMBL,Pazopanib
FLT1,10.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
FLT4,47.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
KDR,30.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Pazopanib
KIT,96.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
PDGFRB,84.0,ic50,"Guide to Pharmacology, ChEMBL",Pazopanib
RIPK1,873.0,ic50,ChEMBL,Pazopanib
BRAF,2.100000023841858,"ec50, ic50","Guide to Pharmacology, ChEMBL",Dabrafenib
RAF1,150.0,ic50,ChEMBL,Dabrafenib
RIPK1,53200.0,ic50,ChEMBL,Dabrafenib
TGFBR1,3700.0,ic50,ChEMBL,Dabrafenib
ALOX5,1250.0,ic50,ChEMBL,Embelin
ABCC4,16700.0,ic50,ChEMBL,Tolcapone
COMT,64.0,ic50,ChEMBL,Tolcapone
TTR,16600.0,ic50,ChEMBL,Tolcapone
KCND3,5011872.0,ic50,ChEMBL,Desvenlafaxine
SCN5A,257877.0,ic50,ChEMBL,Desvenlafaxine
SLC6A2,538.0,ic50,ChEMBL,Desvenlafaxine
SLC6A4,53.0,ic50,ChEMBL,Desvenlafaxine
ABCC4,133000.0,ic50,ChEMBL,Timolol
CTSL,10000.0,ic50,ChEMBL,Camostat
F2,16190.0,ic50,ChEMBL,Camostat
HPN,29.0,ic50,ChEMBL,Camostat
PRSS1,4.6,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Camostat
SCN1A,2900.0,ic50,ChEMBL,Oxybuprocaine
ABCC4,22000.0,ic50,ChEMBL,Bosentan
EDNRA,45.0,ic50,ChEMBL,Bosentan
EDNRB,202.0,ic50,ChEMBL,Bosentan
ESR1,1.8,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Raloxifene
ESR2,15.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Raloxifene
MAOA,200000.0,ic50,ChEMBL,Raloxifene
MAOB,200000.0,ic50,ChEMBL,Raloxifene
NR1H4,11560.0,ic50,ChEMBL,Raloxifene
PGR,100.0,ic50,ChEMBL,Raloxifene
CFTR,50000.0,ec50,PubChem,Topotecan
TOP2A,605.0,ic50,ChEMBL,Topotecan
ABCC4,133000.0,ic50,ChEMBL,Tizanidine
ABCC4,133000.0,ic50,ChEMBL,Loxapine
CHRM1,5500.0,ic50,ChEMBL,Loxapine
DRD2,54.0,ic50,ChEMBL,Loxapine
DRD3,22.0,ic50,ChEMBL,Loxapine
DRD4,14.0,ic50,ChEMBL,Loxapine
KCNK2,19850.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB",Loxapine
ROCK1,14.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",GSK429286A
ROCK2,5031.5,ic50,ChEMBL,GSK429286A
RPS6KA1,780.0,ic50,Guide to Pharmacology,GSK429286A
ABCC4,97000.0,ic50,ChEMBL,Nelfinavir
ABCG2,12500.0,ic50,ChEMBL,Nelfinavir
KCND3,5011872.0,ic50,ChEMBL,Nelfinavir
SCN5A,290310.0,ic50,ChEMBL,Nelfinavir
SCN5A,174750.0,ic50,Guide to Pharmacology,Ropivacaine
ABCC4,133000.0,ic50,ChEMBL,Venlafaxine
SLC6A2,581.0,ic50,"Guide to Pharmacology, ChEMBL",Venlafaxine
SLC6A3,8670.0,ic50,ChEMBL,Venlafaxine
SLC6A4,35.0,ic50,"Guide to Pharmacology, ChEMBL",Venlafaxine
ABCG2,59000.0,ic50,ChEMBL,Cobicistat
ABCC4,133000.0,ic50,ChEMBL,Cyclophosphamide
MAP2K1,1.0,ic50,"ChEMBL, US Patent",Trametinib
MAP2K2,1.8,ic50,"Guide to Pharmacology, ChEMBL",Trametinib
ESR1,23.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Bazedoxifene
ESR2,85.0,ic50,"Guide to Pharmacology, ChEMBL",Bazedoxifene
ADRA1A,1.1,ic50,ChEMBL,Phentolamine
ADRA1B,10.9,ic50,ChEMBL,Phentolamine
ADRA1D,12.75,ic50,ChEMBL,Phentolamine
ESR2,50000.0,ic50,PubChem,Phentolamine
HRH1,316227.77,ic50,ChEMBL,Phentolamine
HTR1A,34775.0,ic50,PubChem,Phentolamine
SCN1A,8400.0,ic50,ChEMBL,Phentolamine
SIGMAR1,550.0,ic50,ChEMBL,Phentolamine
ABCC4,133000.0,ic50,ChEMBL,Levetiracetam
CACNA1C,133519.0,ic50,ChEMBL,Vardenafil
CFTR,25070.0,"ec50, ic50",PubChem,Vardenafil
HNF4A,25077.0,ic50,PubChem,Vardenafil
KCND3,79433.0,ic50,ChEMBL,Vardenafil
PDE10A,835.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Vardenafil
PDE1B,300.0,ic50,Curated from the literature by BindingDB,Vardenafil
PDE3A,500.0,ic50,ChEMBL,Vardenafil
PDE3B,580.0,ic50,Curated from the literature by BindingDB,Vardenafil
PDE4B,2150.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Vardenafil
PDE4D,3900.0,ic50,Curated from the literature by BindingDB,Vardenafil
PDE5A,0.7,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Vardenafil
SCN5A,1355706.0,ic50,ChEMBL,Vardenafil
ABCC4,133000.0,ic50,ChEMBL,Meloxicam
G6PD,67000.0,ic50,Curated from the literature by BindingDB,Meloxicam
PGD,33500.0,ic50,Curated from the literature by BindingDB,Meloxicam
PTGS1,16700.0,ic50,"Guide to Pharmacology, ChEMBL",Meloxicam
PTGS2,490.0,ic50,"Guide to Pharmacology, ChEMBL",Meloxicam
ABCC1,8500.0,ic50,ChEMBL,Etravirine
ABCG2,6000.0,ic50,ChEMBL,Etravirine
KCND3,3162278.0,ic50,ChEMBL,Etravirine
SCN5A,2241129.5,ic50,ChEMBL,Etravirine
CACNA1C,73450.0,ic50,ChEMBL,Phenytoin
SCN1A,18500.0,ic50,ChEMBL,Phenytoin
SCN5A,74500.0,ic50,ChEMBL,Phenytoin
CA1,3040.0,ic50,ChEMBL,Sulfasalazine
CA2,4490.0,ic50,ChEMBL,Sulfasalazine
AR,50000.0,ic50,ChEMBL,Liothyronine
F2,3.7,ec50,ChEMBL,Liothyronine
MCL1,14687.40483,ic50,PubChem,Liothyronine
PPARG,5800.0,ec50,ChEMBL,Liothyronine
ABCC4,100600.0,ic50,ChEMBL,Erythromycin
CYP51A1,200000.0,ic50,ChEMBL,Erythromycin
TTR,3500.0,ic50,ChEMBL,Triclabendazole
DRD1,1630.0,ic50,ChEMBL,Rotundine
DRD2,450.0,ic50,ChEMBL,Rotundine
F3,23.0,ic50,ChEMBL,Rotundine
ABCC4,133000.0,ic50,ChEMBL,Voriconazole
CACNA1C,414200.0,ic50,ChEMBL,Voriconazole
CYP46A1,5023.5,ic50,ChEMBL,Voriconazole
ABCC4,133000.0,ic50,ChEMBL,Linezolid
CACNA1C,105400.0,ic50,ChEMBL,Linezolid
MAOA,35000.0,ic50,"Guide to Pharmacology, ChEMBL",Linezolid
MAOB,2100.0,ic50,"Guide to Pharmacology, ChEMBL",Linezolid
PTGS1,8190.0,ic50,ChEMBL,Linezolid
CFTR,49.0,ec50,ChEMBL,Ivacaftor
ABCC4,36000.0,ic50,ChEMBL,Telmisartan
ABCG2,16900.0,ic50,ChEMBL,Telmisartan
AGTR1,1.0,ic50,ChEMBL,Telmisartan
PPARA,10000.0,"ec50, ic50",ChEMBL,Telmisartan
PPARG,4300.0,"ec50, ic50",ChEMBL,Telmisartan
PTGS2,7530.0,ic50,ChEMBL,Mesalamine
ABCC4,57500.0,ic50,ChEMBL,Nalidixic acid
TOP2B,223000.0,ic50,ChEMBL,Nalidixic acid
CASP3,19700.0,ic50,PubChem,Ipriflavone
MIF,255000.0,ic50,ChEMBL,Ipriflavone
ABCG2,104.0,ec50,ChEMBL,OSI-906
EGFR,11250.0,ic50,ChEMBL,OSI-906
ERBB2,10000.0,ic50,ChEMBL,OSI-906
IGF1R,18.0,ic50,"Guide to Pharmacology, ChEMBL",OSI-906
INSR,54.5,ic50,"Guide to Pharmacology, ChEMBL",OSI-906
MET,12500.0,ic50,ChEMBL,OSI-906
ABCC4,133000.0,ic50,ChEMBL,Aripiprazole
ADRA1A,170.0,ic50,ChEMBL,Aripiprazole
CHRM3,100000.0,ic50,ChEMBL,Aripiprazole
DRD2,17.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Aripiprazole
DRD3,19.5,ec50,ChEMBL,Aripiprazole
HRH1,420.0,ic50,ChEMBL,Aripiprazole
HTR1A,367.5,ec50,"ChEMBL, US Patent",Aripiprazole
HTR2A,2790.0,ic50,"ChEMBL, US Patent",Aripiprazole
HTR2C,1380.0,ic50,ChEMBL,Aripiprazole
ABCC1,12300.0,ic50,ChEMBL,Indomethacin
ABCC4,5800.0,ic50,ChEMBL,Indomethacin
AKR1B1,6000.0,ic50,ChEMBL,Indomethacin
AKR1C3,4100.0,ic50,ChEMBL,Indomethacin
ALOX5,7000.0,ic50,ChEMBL,Indomethacin
AR,0.14,ec50,ChEMBL,Indomethacin
CXCL8,50.0,ic50,ChEMBL,Indomethacin
EGFR,10000.0,ic50,ChEMBL,Indomethacin
PPARG,50000.0,ec50,ChEMBL,Indomethacin
PTGDR2,389.0,ec50,ChEMBL,Indomethacin
PTGS1,130.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Indomethacin
PTGS2,825.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Indomethacin
TBXAS1,50050.0,ic50,ChEMBL,Indomethacin
BTK,5830.0,ic50,ChEMBL,PD168393
EGFR,2.35,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",PD168393
ERBB2,24.0,ic50,"Curated from the literature by BindingDB, ChEMBL",PD168393
ITK,30000.0,ic50,ChEMBL,PD168393
JAK3,6570.0,ic50,ChEMBL,PD168393
SRC,27000.0,ic50,ChEMBL,PD168393
ABCC4,133000.0,ic50,ChEMBL,Flumazenil
GSK3B,31.0,ic50,ChEMBL,AZD1080
PARP1,1.75,"ec50, ic50",ChEMBL,BMN 673
PARP2,0.8,ic50,ChEMBL,BMN 673
CHEK1,5.0,ic50,ChEMBL,PF-477736
CSF1R,10.0,ic50,ChEMBL,PF-477736
PPARA,46580.0,ec50,"Curated from the literature by BindingDB, ChEMBL",Bezafibrate
PPARG,65180.0,ec50,ChEMBL,Bezafibrate
ABCC4,133000.0,ic50,ChEMBL,Fenofibrate
ABCG2,5100.0,ic50,ChEMBL,Fenofibrate
PPARA,30000.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Fenofibrate
PPARG,5000.0,"ec50, ic50",ChEMBL,Fenofibrate
ALOX5,50.0,ic50,ChEMBL,SB202190
BRD4,2950.0,ic50,ChEMBL,SB202190
JAK2,100000.0,ic50,ChEMBL,SB202190
JAK3,100000.0,ic50,ChEMBL,SB202190
MAPK11,66.55,ic50,ChEMBL,SB202190
MAPK14,26.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",SB202190
TYR,30.0,ic50,ChEMBL,SB202190
AURKA,10000.0,ic50,ChEMBL,Quizartinib
CDK2,20000.0,ic50,ChEMBL,Quizartinib
FLT1,10000.0,ic50,ChEMBL,Quizartinib
FLT3,12.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Quizartinib
FLT4,4900.0,ic50,ChEMBL,Quizartinib
KDR,5215.0,ic50,ChEMBL,Quizartinib
LCK,57.8,ic50,US Patent,Quizartinib
PDGFRB,37.8,ic50,US Patent,Quizartinib
RET,13.8,ic50,US Patent,Quizartinib
ABCC4,133000.0,ic50,ChEMBL,Dofetilide
CACNA1C,109244.5,ic50,ChEMBL,Dofetilide
SCN5A,316228.0,ic50,ChEMBL,Dofetilide
PPARA,52500.0,ec50,"Curated from the literature by BindingDB, ChEMBL",Clofibric acid
PPARG,304500.0,ec50,ChEMBL,Clofibric acid
ABCC4,133000.0,ic50,ChEMBL,Chlorpropamide
CYP51A1,200000.0,ic50,ChEMBL,Chlorpropamide
ABCC4,64000.0,ic50,ChEMBL,Glimepiride
AKR1C3,850.0,ic50,ChEMBL,Glimepiride
ABCC4,133000.0,ic50,ChEMBL,Gliclazide
AKR1C3,19620.0,ic50,ChEMBL,Gliclazide
EPHA2,13.0,ic50,Curated from the literature by BindingDB,Golvatinib
KDR,16.0,ic50,"Guide to Pharmacology, ChEMBL",Golvatinib
MET,14.0,ic50,"Guide to Pharmacology, ChEMBL",Golvatinib
MAP2K1,7.0,ic50,US Patent,AZD8330
EGFR,5.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Icotinib
ABCC4,133000.0,ic50,ChEMBL,Zolmitriptan
HTR1B,11.1,"ec50, ic50",ChEMBL,Zolmitriptan
HTR1D,2.8,ic50,ChEMBL,Zolmitriptan
ABL1,41000.0,ic50,ChEMBL,BIRB 796
ACVR1B,44000.0,ic50,ChEMBL,BIRB 796
AKT1,30000.0,ic50,ChEMBL,BIRB 796
AKT2,30000.0,ic50,ChEMBL,BIRB 796
AKT3,30000.0,ic50,ChEMBL,BIRB 796
ALK,30000.0,ic50,ChEMBL,BIRB 796
AURKA,30000.0,ic50,ChEMBL,BIRB 796
AXL,30000.0,ic50,ChEMBL,BIRB 796
BRAF,83.4,ic50,ChEMBL,BIRB 796
BTK,30000.0,ic50,ChEMBL,BIRB 796
CAMK2B,40000.0,ic50,ChEMBL,BIRB 796
CAMK2D,30000.0,ic50,ChEMBL,BIRB 796
CDK2,30000.0,ic50,ChEMBL,BIRB 796
CHEK1,30000.0,ic50,ChEMBL,BIRB 796
CHEK2,19000.0,ic50,ChEMBL,BIRB 796
CSF1R,30000.0,ic50,ChEMBL,BIRB 796
DDR1,1000.0,ic50,ChEMBL,BIRB 796
EGFR,11900.0,ic50,ChEMBL,BIRB 796
EPHA2,160.0,ic50,ChEMBL,BIRB 796
ERBB2,20000.0,ic50,ChEMBL,BIRB 796
FGFR1,15000.0,ic50,ChEMBL,BIRB 796
FGFR2,24000.0,ic50,ChEMBL,BIRB 796
FGFR3,30000.0,ic50,ChEMBL,BIRB 796
FGFR4,7000.0,ic50,ChEMBL,BIRB 796
FLT1,625.0,ic50,ChEMBL,BIRB 796
FLT3,30000.0,ic50,ChEMBL,BIRB 796
FLT4,270.0,ic50,ChEMBL,BIRB 796
FRK,1000.0,ic50,ChEMBL,BIRB 796
GSK3B,37000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",BIRB 796
HCK,1894.0,ic50,"ChEMBL, US Patent",BIRB 796
HSPB1,58.0,ic50,ChEMBL,BIRB 796
IGF1R,30000.0,ic50,ChEMBL,BIRB 796
IKBKB,25000.0,ic50,ChEMBL,BIRB 796
INSR,30000.0,ic50,ChEMBL,BIRB 796
JAK2,30000.0,ic50,ChEMBL,BIRB 796
JAK3,30000.0,ic50,ChEMBL,BIRB 796
KDR,340.0,ic50,ChEMBL,BIRB 796
KIT,1000.0,ic50,ChEMBL,BIRB 796
LCK,20000.0,ic50,ChEMBL,BIRB 796
LYN,960.0,ic50,ChEMBL,BIRB 796
MAPK1,9200.0,ic50,ChEMBL,BIRB 796
MAPK11,503.5,ic50,"Guide to Pharmacology, ChEMBL",BIRB 796
MAPK13,500.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",BIRB 796
MAPK14,12.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",BIRB 796
MAPK3,25000.0,ic50,ChEMBL,BIRB 796
MAPKAPK5,30000.0,ic50,ChEMBL,BIRB 796
MET,30000.0,ic50,ChEMBL,BIRB 796
NTRK1,580.0,ic50,ChEMBL,BIRB 796
NTRK2,525.0,ic50,ChEMBL,BIRB 796
NTRK3,1000.0,ic50,ChEMBL,BIRB 796
PDGFRB,6200.0,ic50,ChEMBL,BIRB 796
PIM1,30000.0,ic50,ChEMBL,BIRB 796
PLK1,30000.0,ic50,ChEMBL,BIRB 796
PRKCA,30000.0,ic50,ChEMBL,BIRB 796
PRKCB,23450.0,ic50,ChEMBL,BIRB 796
PRKX,30000.0,ic50,ChEMBL,BIRB 796
PTK6,30000.0,ic50,ChEMBL,BIRB 796
RAF1,1400.0,ic50,ChEMBL,BIRB 796
RET,515.0,ic50,ChEMBL,BIRB 796
ROCK1,30000.0,ic50,ChEMBL,BIRB 796
ROCK2,30000.0,ic50,ChEMBL,BIRB 796
ROS1,30000.0,ic50,ChEMBL,BIRB 796
RPS6KA1,30000.0,ic50,ChEMBL,BIRB 796
RPS6KB1,30000.0,ic50,ChEMBL,BIRB 796
SGK1,30000.0,ic50,ChEMBL,BIRB 796
SRC,18447.0,ic50,"ChEMBL, US Patent",BIRB 796
SYK,25000.0,ic50,ChEMBL,BIRB 796
TEK,1000.0,ic50,ChEMBL,BIRB 796
ZAP70,25000.0,ic50,ChEMBL,BIRB 796
ABCC4,133000.0,ic50,ChEMBL,Ornidazole
GSK3B,5.0,ic50,ChEMBL,AZD2858
MTOR,2.8,ic50,"Guide to Pharmacology, ChEMBL, US Patent",AZD2014
PIK3R1,3800.0,ic50,ChEMBL,AZD2014
ABCC4,133000.0,ic50,ChEMBL,Ramelteon
CDK2,10180.0,ic50,Curated from the literature by BindingDB,GF109203X
CDK4,990.0,ic50,Curated from the literature by BindingDB,GF109203X
GSK3B,190.5,ic50,ChEMBL,GF109203X
PIM1,88.5,ic50,"Curated from the literature by BindingDB, ChEMBL",GF109203X
PRKCA,2.3,ic50,"Curated from the literature by BindingDB, ChEMBL",GF109203X
PRKCB,1.6,ic50,Curated from the literature by BindingDB,GF109203X
PRKCE,6.6,ic50,"Curated from the literature by BindingDB, ChEMBL",GF109203X
PRKCI,3463.0,ic50,ChEMBL,GF109203X
BRAF,17.0,ic50,"ChEMBL, US Patent",PD0325901
MAP2K1,10.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",PD0325901
MAP2K2,110.0,ic50,ChEMBL,PD0325901
MAPK1,10000.0,ic50,ChEMBL,PD0325901
ABL1,1250.0,ic50,ChEMBL,LDK378
ALK,9.65,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",LDK378
BTK,3360.0,ic50,ChEMBL,LDK378
EGFR,2500.0,"ec50, ic50",ChEMBL,LDK378
FLT3,73.0,ic50,"Guide to Pharmacology, ChEMBL",LDK378
IGF1R,209.0,ic50,"Guide to Pharmacology, ChEMBL",LDK378
INSR,93.0,ic50,"Guide to Pharmacology, ChEMBL",LDK378
JAK2,2160.0,ic50,ChEMBL,LDK378
JAK3,7920.0,ic50,ChEMBL,LDK378
KIT,2855.0,ic50,ChEMBL,LDK378
LCK,672.0,ic50,ChEMBL,LDK378
MET,1169.5,ic50,ChEMBL,LDK378
NTRK1,2727.0,ic50,ChEMBL,LDK378
NTRK2,1829.0,ic50,ChEMBL,LDK378
RET,1352.0,ic50,ChEMBL,LDK378
ROCK2,1270.0,ic50,ChEMBL,LDK378
ROS1,3.1,ic50,ChEMBL,LDK378
SYK,3050.0,ic50,ChEMBL,LDK378
ZAP70,9700.0,ic50,ChEMBL,LDK378
GSK3B,300000.0,ec50,PubChem,Irsogladine
ABCC4,133000.0,ic50,ChEMBL,Levosulpiride
DRD2,1e-08,ic50,ChEMBL,Levosulpiride
MPO,7680.0,ic50,ChEMBL,Levosulpiride
ABCC4,133000.0,ic50,ChEMBL,Lenalidomide
BRD4,5190.0,ic50,ChEMBL,Lenalidomide
ABL1,10000.0,ic50,ChEMBL,NVP-AEW541
AKT1,10000.0,ic50,ChEMBL,NVP-AEW541
ALK,5500.0,ic50,ChEMBL,NVP-AEW541
AURKA,10000.0,ic50,ChEMBL,NVP-AEW541
AXL,10000.0,ic50,ChEMBL,NVP-AEW541
BTK,7600.0,ic50,ChEMBL,NVP-AEW541
CDK2,10000.0,ic50,ChEMBL,NVP-AEW541
CDK4,10000.0,ic50,ChEMBL,NVP-AEW541
EGFR,7600.0,ic50,ChEMBL,NVP-AEW541
ERBB2,10000.0,ic50,ChEMBL,NVP-AEW541
FGFR1,4300.0,ic50,ChEMBL,NVP-AEW541
FGFR2,2700.0,ic50,ChEMBL,NVP-AEW541
FGFR3,10000.0,ic50,ChEMBL,NVP-AEW541
FGFR4,5000.0,ic50,ChEMBL,NVP-AEW541
FLT3,1400.0,ic50,ChEMBL,NVP-AEW541
GSK3B,10000.0,ic50,ChEMBL,NVP-AEW541
IGF1R,61.0,ic50,ChEMBL,NVP-AEW541
INSR,946.0,ic50,ChEMBL,NVP-AEW541
JAK2,10000.0,ic50,ChEMBL,NVP-AEW541
JAK3,10000.0,ic50,ChEMBL,NVP-AEW541
KDR,7100.0,ic50,ChEMBL,NVP-AEW541
KIT,6300.0,ic50,ChEMBL,NVP-AEW541
LCK,5600.0,ic50,ChEMBL,NVP-AEW541
LYN,1400.0,ic50,ChEMBL,NVP-AEW541
MAPK1,10000.0,ic50,ChEMBL,NVP-AEW541
MAPK14,10000.0,ic50,ChEMBL,NVP-AEW541
MAPKAPK5,10000.0,ic50,ChEMBL,NVP-AEW541
MET,10000.0,ic50,ChEMBL,NVP-AEW541
PIK3CA,9050.0,ic50,ChEMBL,NVP-AEW541
PIK3CD,9100.0,ic50,ChEMBL,NVP-AEW541
PIK3CG,3200.0,ic50,ChEMBL,NVP-AEW541
PLK1,10000.0,ic50,ChEMBL,NVP-AEW541
RET,3300.0,ic50,ChEMBL,NVP-AEW541
SRC,4000.0,ic50,ChEMBL,NVP-AEW541
SYK,10000.0,ic50,ChEMBL,NVP-AEW541
ZAP70,10000.0,ic50,ChEMBL,NVP-AEW541
PDE4A,7900.0,ic50,Curated from the literature by BindingDB,GSK256066
PDE4B,0.00794,ic50,ChEMBL,GSK256066
ABCC4,133000.0,ic50,ChEMBL,Gemfibrozil
PPARA,59000.0,ec50,"Guide to Pharmacology, ChEMBL",Gemfibrozil
PPARG,108100.0,ec50,ChEMBL,Gemfibrozil
TTR,180000.0,ic50,ChEMBL,Gemfibrozil
PSMA3,15.0,ic50,ChEMBL,MLN2238
PSMA4,15.0,ic50,ChEMBL,MLN2238
PSMA5,15.0,ic50,ChEMBL,MLN2238
PSMA6,15.0,ic50,ChEMBL,MLN2238
PSMB1,31.0,ic50,ChEMBL,MLN2238
PSMB2,3500.0,ic50,ChEMBL,MLN2238
PSMB5,4.2,ic50,ChEMBL,MLN2238
PSMB7,30000.0,ic50,ChEMBL,MLN2238
PSMB8,2.9,ic50,ChEMBL,MLN2238
PSMA6,7.47,ic50,US Patent,MLN9708
PSMB1,10.82,ic50,ChEMBL,MLN9708
PSMB2,7954.0,ic50,ChEMBL,MLN9708
PSMB5,8.4,ic50,ChEMBL,MLN9708
ABCC4,133000.0,ic50,ChEMBL,Nimesulide
CYP19A1,27000.0,ic50,ChEMBL,Nimesulide
MPO,2100.0,ic50,ChEMBL,Nimesulide
PTGS1,19700.0,ic50,"Guide to Pharmacology, ChEMBL",Nimesulide
PTGS2,1680.0,ic50,"Guide to Pharmacology, ChEMBL",Nimesulide
CHUK,250.0,ic50,ChEMBL,IMD 0354
KIF11,5.0,ic50,ChEMBL,Ispinesib
FNTA,503.95,ic50,ChEMBL,Tipifarnib
CA2,1000.0,ic50,Curated from the literature by BindingDB,Letrozole
CYP11B1,2620.0,ic50,ChEMBL,Letrozole
CYP11B2,1420.0,ic50,ChEMBL,Letrozole
CYP19A1,4.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Letrozole
ESR1,10000.0,ic50,ChEMBL,Letrozole
ABCC4,36500.0,ic50,ChEMBL,Deferasirox
CACNA1C,1000000.0,ic50,ChEMBL,Deferasirox
KCND3,50119.0,ic50,ChEMBL,Deferasirox
SCN5A,290310.0,ic50,ChEMBL,Deferasirox
APH1A,30.0,ic50,ChEMBL,MK-0752
AVPR2,6000.0,ic50,ChEMBL,Itraconazole
CYP51A1,3600.0,ic50,ChEMBL,Itraconazole
ABCC4,133000.0,ic50,ChEMBL,Melatonin
MPO,3000.0,ic50,ChEMBL,Melatonin
MTNR1A,0.565,"ec50, ic50",ChEMBL,Melatonin
MTNR1B,0.48,"ec50, ic50",ChEMBL,Melatonin
AURKB,643.0,ic50,ChEMBL,Pexidartinib
CSF1R,13.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Pexidartinib
EGFR,10000.0,ic50,ChEMBL,Pexidartinib
FLT1,880.0,ic50,Guide to Pharmacology,Pexidartinib
FLT3,11.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Pexidartinib
KDR,970.0,ic50,"Guide to Pharmacology, ChEMBL",Pexidartinib
KIT,27.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Pexidartinib
LCK,860.0,ic50,Guide to Pharmacology,Pexidartinib
MET,3300.0,ic50,ChEMBL,Pexidartinib
NTRK3,890.0,ic50,Guide to Pharmacology,Pexidartinib
PDGFRB,36.0,ic50,ChEMBL,Pexidartinib
ADRA1A,1.85,ic50,ChEMBL,Silodosin
ADRA1B,328.5,ic50,ChEMBL,Silodosin
ADRA1D,16.65,ic50,ChEMBL,Silodosin
CACNA1C,794328.0,ic50,ChEMBL,Silodosin
KCND3,316228.0,ic50,ChEMBL,Silodosin
SCN5A,63096.0,ic50,ChEMBL,Silodosin
ABCC4,133000.0,ic50,ChEMBL,Lidocaine
KCNA5,2188000.0,ic50,ChEMBL,Lidocaine
KCNK2,193500.0,ic50,ChEMBL,Lidocaine
SCN1A,240000.0,ic50,ChEMBL,Lidocaine
SCN4A,2000.0,ic50,ChEMBL,Lidocaine
SCN5A,79000.0,ic50,ChEMBL,Lidocaine
ABCC4,47000.0,ic50,ChEMBL,Lopinavir
ABCG2,7600.0,ic50,ChEMBL,Lopinavir
ABCC4,133000.0,ic50,ChEMBL,Lumiracoxib
PTGS1,7.0,ic50,ChEMBL,Lumiracoxib
PTGS2,130.0,ic50,ChEMBL,Lumiracoxib
HDAC1,113000.0,ic50,ChEMBL,Phenylbutyrate
HDAC2,65000.0,ic50,ChEMBL,Phenylbutyrate
HDAC3,260000.0,ic50,ChEMBL,Phenylbutyrate
HDAC6,240000.0,ic50,ChEMBL,Phenylbutyrate
HDAC8,93000.0,ic50,ChEMBL,Phenylbutyrate
ABCC4,133000.0,ic50,ChEMBL,Salmeterol
ADRB1,372.0,"ec50, ic50",ChEMBL,Salmeterol
ADRB2,0.251189,"ec50, ic50",ChEMBL,Salmeterol
ADRB3,1129.5,ec50,ChEMBL,Salmeterol
ABCC4,133000.0,ic50,ChEMBL,Racecadotril
ABCC4,133000.0,ic50,ChEMBL,Tenoxicam
CSF1R,15.0,ic50,Guide to Pharmacology,OSI-930
FLT1,8.0,ic50,Guide to Pharmacology,OSI-930
KDR,9.0,ic50,"Guide to Pharmacology, ChEMBL",OSI-930
KIT,29.0,ic50,ChEMBL,OSI-930
LCK,22.0,ic50,ChEMBL,OSI-930
RAF1,41.0,ic50,"Guide to Pharmacology, ChEMBL",OSI-930
CAMK2D,10000.0,ic50,ChEMBL,Enzastaurin
PRKCA,419.5,ic50,"Guide to Pharmacology, ChEMBL",Enzastaurin
PRKCB,30.0,ic50,"Guide to Pharmacology, ChEMBL",Enzastaurin
PRKCE,110.0,ic50,ChEMBL,Enzastaurin
SRC,100000.0,ic50,ChEMBL,Enzastaurin
ABCC4,133000.0,ic50,ChEMBL,Ketanserin
HTR1B,8250.0,ic50,ChEMBL,Ketanserin
HTR1D,265.0,ic50,ChEMBL,Ketanserin
HTR2A,11.0,ic50,ChEMBL,Ketanserin
SIGMAR1,1.0,ic50,ChEMBL,Ketanserin
SLC18A2,180.0,ic50,ChEMBL,Ketanserin
CHRM1,295.0,ic50,ChEMBL,Linagliptin
DPP4,1.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Linagliptin
HDAC1,14.0,ic50,"Guide to Pharmacology, ChEMBL",PCI-24781
HDAC2,63.0,ic50,ChEMBL,PCI-24781
HDAC3,78.09999990463257,ic50,"Guide to Pharmacology, ChEMBL",PCI-24781
HDAC6,12.0,ic50,ChEMBL,PCI-24781
HDAC8,370.0,ic50,ChEMBL,PCI-24781
ABCC4,133000.0,ic50,ChEMBL,Zileuton
ALOX5,900.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Zileuton
PTGS1,10000.0,ic50,ChEMBL,Zileuton
PTGS2,10000.0,ic50,ChEMBL,Zileuton
PIK3CA,1602.0,ic50,"Guide to Pharmacology, ChEMBL",IPI-145
PIK3CD,2.5,ic50,"Guide to Pharmacology, ChEMBL",IPI-145
PIK3CG,12.0,ic50,"Guide to Pharmacology, ChEMBL",IPI-145
PIK3R1,8.0,ic50,ChEMBL,IPI-145
MTOR,1000.0,ic50,ChEMBL,CAL-101
PIK3C3,4417.0,ic50,ChEMBL,CAL-101
PIK3CA,737.0,ic50,"Guide to Pharmacology, ChEMBL",CAL-101
PIK3CD,3.6,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",CAL-101
PIK3CG,104.0,ic50,"Guide to Pharmacology, ChEMBL",CAL-101
PIK3R1,293.0,ic50,ChEMBL,CAL-101
AKR1B1,180000.0,ic50,ChEMBL,Ketoprofen
CA1,1066500.0,ic50,Curated from the literature by BindingDB,Ketoprofen
CA2,1400000.0,ic50,Curated from the literature by BindingDB,Ketoprofen
CASP3,50000.0,ic50,Curated from the literature by BindingDB,Ketoprofen
EGFR,10000.0,ic50,ChEMBL,Ketoprofen
PTGS1,330.0,ic50,"Guide to Pharmacology, ChEMBL",Ketoprofen
PTGS2,690.0,ic50,"Guide to Pharmacology, ChEMBL",Ketoprofen
ABCC4,133000.0,ic50,ChEMBL,Valdecoxib
CA1,54000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Valdecoxib
CA2,43.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Valdecoxib
CA4,340.0,ic50,ChEMBL,Valdecoxib
CA9,27.0,ic50,Curated from the literature by BindingDB,Valdecoxib
PTGS1,100000.0,ic50,ChEMBL,Valdecoxib
PTGS2,111.5,ic50,"Guide to Pharmacology, ChEMBL",Valdecoxib
ABCC4,133000.0,ic50,ChEMBL,Vorinostat
ABL1,100000.0,ic50,ChEMBL,Vorinostat
BRD4,391.5,ic50,ChEMBL,Vorinostat
CFTR,25775.0,"ec50, ic50",PubChem,Vorinostat
DNMT1,10000.0,ic50,ChEMBL,Vorinostat
EGFR,456.0,ic50,ChEMBL,Vorinostat
FLT3,10000.0,ic50,ChEMBL,Vorinostat
HDAC1,110.5,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL, US Patent",Vorinostat
HDAC2,120.25,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Vorinostat
HDAC3,55.5,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Vorinostat
HDAC6,34.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL, US Patent",Vorinostat
HDAC8,980.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Vorinostat
HMGCR,10000.0,ic50,"ChEMBL, US Patent",Vorinostat
HSP90AA1,250500.0,ic50,ChEMBL,Vorinostat
JAK2,10000.0,ic50,ChEMBL,Vorinostat
KDR,10000.0,ic50,ChEMBL,Vorinostat
MAOA,100000.0,ic50,ChEMBL,Vorinostat
MAOB,100000.0,ic50,ChEMBL,Vorinostat
PIK3R1,10000.0,ic50,ChEMBL,Vorinostat
PSMB5,25000.0,ic50,ChEMBL,Vorinostat
ABCC4,133000.0,ic50,ChEMBL,Aspirin
CA1,2710000.0,ic50,ChEMBL,Aspirin
CA2,1160000.0,ic50,ChEMBL,Aspirin
EGFR,10000.0,ic50,ChEMBL,Aspirin
MPO,200000.0,ic50,ChEMBL,Aspirin
PTGS1,560100.0,ic50,"Guide to Pharmacology, ChEMBL",Aspirin
PTGS2,62500.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Aspirin
ABCC4,133000.0,ic50,ChEMBL,Nitazoxanide
AKR1B1,8220.0,ic50,ChEMBL,Nitazoxanide
TGFBR1,108.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",SB431542
TGFBR2,66.0,ic50,ChEMBL,SB431542
ABCC4,34000.0,ic50,ChEMBL,Ritonavir
ABCG2,19500.0,ic50,ChEMBL,Ritonavir
UGT1A1,1700.0,ic50,"Guide to Pharmacology, ChEMBL",Ritonavir
PARP1,6.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Olaparib
PARP2,1.7,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Olaparib
PARP3,229.5,ic50,"ChEMBL, US Patent",Olaparib
IDO1,6100.0,ic50,ChEMBL,Sertaconazole
ABCC4,133000.0,ic50,ChEMBL,Piroxicam
PTGS1,127650.0,ic50,"Guide to Pharmacology, ChEMBL",Piroxicam
PTGS2,160400.0,ic50,"Guide to Pharmacology, ChEMBL",Piroxicam
ALK,177.0,"ec50, ic50",ChEMBL,AZD9291
EGFR,39.0,"ec50, ic50","WIPO, Guide to Pharmacology, ChEMBL, US Patent",AZD9291
ERBB2,29.5,"ec50, ic50","ChEMBL, US Patent",AZD9291
HDAC1,1000.0,ic50,ChEMBL,AZD9291
IGF1R,2900000.0,ic50,ChEMBL,AZD9291
INSR,912.0,ic50,ChEMBL,AZD9291
MET,1000.0,ic50,ChEMBL,AZD9291
FLT3,22.0,ic50,ChEMBL,Pacritinib
JAK2,23.0,ic50,ChEMBL,Pacritinib
JAK3,520.0,ic50,ChEMBL,Pacritinib
PARP1,130059.5,ic50,"Curated from the literature by BindingDB, ChEMBL",Nicotinamide
ABCC4,133000.0,ic50,ChEMBL,Pyrazinamide
ABCC4,133000.0,ic50,ChEMBL,Bortezomib
CFTR,50000.0,ec50,PubChem,Bortezomib
CMA1,1190.0,ic50,ChEMBL,Bortezomib
CTSB,30000.0,ic50,ChEMBL,Bortezomib
HDAC1,620.0,ic50,ChEMBL,Bortezomib
HDAC2,800.0,ic50,ChEMBL,Bortezomib
HDAC3,1180.0,ic50,ChEMBL,Bortezomib
HDAC6,69440.0,ic50,ChEMBL,Bortezomib
HDAC8,72.0,ic50,ChEMBL,Bortezomib
PSMA3,8.855,ic50,ChEMBL,Bortezomib
PSMA4,8.855,ic50,ChEMBL,Bortezomib
PSMA5,8.855,ic50,ChEMBL,Bortezomib
PSMA6,9.92,ic50,"ChEMBL, US Patent",Bortezomib
PSMB1,96.5,ic50,ChEMBL,Bortezomib
PSMB2,1500.0,ic50,ChEMBL,Bortezomib
PSMB5,6.2,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Bortezomib
PSMB7,1060.0,ic50,ChEMBL,Bortezomib
PSMB8,4.0,ic50,ChEMBL,Bortezomib
DPP4,62.0,ic50,ChEMBL,Vidarabine
GSK3B,300000.0,ec50,PubChem,Vidarabine
ABL1,86.1,ic50,"ChEMBL, US Patent",Ibrutinib
BTK,1.2,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
CDK2,25000.0,ic50,ChEMBL,Ibrutinib
CSF1R,3272.5,ic50,ChEMBL,Ibrutinib
EGFR,11.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
EPHA2,1000.0,ic50,ChEMBL,Ibrutinib
ERBB2,9.4,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
FGFR2,280.0,ic50,US Patent,Ibrutinib
FLT3,231.0,ic50,"ChEMBL, US Patent",Ibrutinib
FRK,54.1,ic50,ChEMBL,Ibrutinib
HCK,15.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
ITK,11.7,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
JAK2,5500.0,ic50,ChEMBL,Ibrutinib
JAK3,32.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
LCK,2.425,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
LYN,110.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
MAP2K2,10000.0,ic50,ChEMBL,Ibrutinib
PDGFRB,1000.0,ic50,ChEMBL,Ibrutinib
PTK6,3.3,ic50,"ChEMBL, US Patent",Ibrutinib
RET,21.1,ic50,ChEMBL,Ibrutinib
RPS6KA1,10000.0,ic50,ChEMBL,Ibrutinib
SRC,40.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ibrutinib
SYK,10000.0,ic50,"ChEMBL, US Patent",Ibrutinib
ABCG2,3000.0,ic50,ChEMBL,Regorafenib
BRAF,28.0,ic50,"Guide to Pharmacology, ChEMBL",Regorafenib
FGFR1,101.75,ic50,ChEMBL,Regorafenib
FGFR2,7.5,ic50,US Patent,Regorafenib
FLT1,11.5,ic50,"ChEMBL, US Patent",Regorafenib
FLT3,82.0,ic50,ChEMBL,Regorafenib
FLT4,10.0,ic50,"ChEMBL, US Patent",Regorafenib
KDR,5.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Regorafenib
KIT,61.5,ic50,ChEMBL,Regorafenib
PDGFRB,1.5,ic50,ChEMBL,Regorafenib
RAF1,2.0,ic50,ChEMBL,Regorafenib
RET,12.0,ic50,"ChEMBL, US Patent",Regorafenib
TEK,156.25,ic50,ChEMBL,Regorafenib
CDK2,1800.0,ic50,ChEMBL,CX-4945
FLT3,45.0,ic50,ChEMBL,CX-4945
GSK3B,2403.5,ic50,ChEMBL,CX-4945
PIM1,132.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",CX-4945
AKT1,2.2,ic50,ChEMBL,RKI-1447
AURKA,1.0,ic50,ChEMBL,RKI-1447
GSK3B,7.8,ic50,ChEMBL,RKI-1447
IKBKE,1.0,ic50,ChEMBL,RKI-1447
JAK2,1.0,ic50,ChEMBL,RKI-1447
ROCK1,9.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",RKI-1447
ROCK2,6.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",RKI-1447
RPS6KA1,1.0,ic50,ChEMBL,RKI-1447
RPS6KB1,1.0,ic50,ChEMBL,RKI-1447
SGK1,5.0,ic50,ChEMBL,RKI-1447
CACNA1B,10000.0,ic50,ChEMBL,Cyclobenzaprine
RET,300.0,ic50,US Patent,Cyclobenzaprine
SCN1A,1400.0,ic50,ChEMBL,Dibucaine
ADRA1A,63.0,ec50,ChEMBL,Naphazoline
ADRA1B,5012.0,ec50,ChEMBL,Naphazoline
ADRA1D,5012.0,ec50,ChEMBL,Naphazoline
ADRA2C,55.0,ec50,ChEMBL,Naphazoline
TAAR1,647.09,"ec50, ic50",PubChem,Naphazoline
HRH1,3.900000047683716,ic50,"Guide to Pharmacology, ChEMBL",Rupatadine
PTAFR,3700.0,ic50,ChEMBL,Rupatadine
ABCC4,133000.0,ic50,ChEMBL,Reserpine
ABCG2,12600.0,ic50,ChEMBL,Reserpine
CFTR,50000.0,ec50,PubChem,Reserpine
SCN1A,1600.0,ic50,ChEMBL,Reserpine
SLC18A2,13.2,ic50,ChEMBL,Reserpine
AXL,7.0,ic50,ChEMBL,Cabozantinib
EGFR,225.0,ic50,ChEMBL,Cabozantinib
FGFR1,11.0,ic50,ChEMBL,Cabozantinib
FLT1,12.0,ic50,"ChEMBL, US Patent",Cabozantinib
FLT3,25.0,ic50,"ChEMBL, US Patent",Cabozantinib
FLT4,28.0,ic50,"ChEMBL, US Patent",Cabozantinib
IGF1R,10000.0,ic50,ChEMBL,Cabozantinib
KDR,4.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Cabozantinib
KIT,4.6,ic50,ChEMBL,Cabozantinib
MET,14.45,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Cabozantinib
NTRK1,72.0,ic50,ChEMBL,Cabozantinib
RET,41.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Cabozantinib
SRC,178.0,ic50,ChEMBL,Cabozantinib
TEK,14.3,ic50,ChEMBL,Cabozantinib
EGLN1,583.0,"ec50, ic50","ChEMBL, US Patent",FG-4592
OGFOD1,1000.0,ic50,ChEMBL,FG-4592
ABCG2,200.0,ic50,ChEMBL,Vandetanib
ABL1,86.0,ic50,ChEMBL,Vandetanib
CSF1R,1600.0,ic50,ChEMBL,Vandetanib
EGFR,369.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Vandetanib
FGFR1,3600.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Vandetanib
FLT1,95.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Vandetanib
FLT4,110.0,ic50,ChEMBL,Vandetanib
HDAC1,10000.0,ic50,ChEMBL,Vandetanib
IGF1R,10000.0,ic50,ChEMBL,Vandetanib
KDR,42.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Vandetanib
KIT,181.5,ic50,ChEMBL,Vandetanib
PDGFRB,477.0,ic50,ChEMBL,Vandetanib
RET,102.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Vandetanib
SRC,44.0,ic50,ChEMBL,Vandetanib
TEK,1533.5,ic50,ChEMBL,Vandetanib
ROCK2,21370.0,ic50,PubChem,Kinetin
ABCC4,133000.0,ic50,ChEMBL,Bexarotene
PPARG,3000.0,ic50,Guide to Pharmacology,Bexarotene
RARA,5003.0,ec50,ChEMBL,Bexarotene
RARB,5141.0,ec50,ChEMBL,Bexarotene
RARG,5324.0,ec50,ChEMBL,Bexarotene
RXRA,36.5,"ec50, ic50",ChEMBL,Bexarotene
RXRG,38.5,ec50,ChEMBL,Bexarotene
MAP2K1,12.0,ic50,"Guide to Pharmacology, US Patent",MEK162
MAP2K2,12.0,ic50,Guide to Pharmacology,MEK162
CFTR,2600.0,ec50,"Guide to Pharmacology, ChEMBL",VX-809
HDAC8,100000.0,ic50,Curated from the literature by BindingDB,Tamibarotene
RARA,45.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Tamibarotene
RARB,235.0,ec50,"Guide to Pharmacology, ChEMBL",Tamibarotene
RARG,591.0,ec50,"Guide to Pharmacology, ChEMBL",Tamibarotene
ABCC4,12100.0,ic50,ChEMBL,Zafirlukast
ADORA1,10000.0,ic50,ChEMBL,Zafirlukast
ADRA1A,10000.0,ic50,ChEMBL,Zafirlukast
ADRA2A,10000.0,ic50,ChEMBL,Zafirlukast
ADRB1,10000.0,ic50,ChEMBL,Zafirlukast
CHRM3,10000.0,ic50,ChEMBL,Zafirlukast
CYSLTR1,1.9,ic50,"Guide to Pharmacology, ChEMBL",Zafirlukast
DRD2,10000.0,ic50,ChEMBL,Zafirlukast
HRH1,10000.0,ic50,ChEMBL,Zafirlukast
HTR2A,10000.0,ic50,ChEMBL,Zafirlukast
NR1H4,3900.0,ec50,ChEMBL,Zafirlukast
OPRM1,10000.0,ic50,ChEMBL,Zafirlukast
PPARG,2440.0,ec50,"Guide to Pharmacology, ChEMBL",Zafirlukast
ABCC4,133000.0,ic50,ChEMBL,Riluzole
HTR1A,99000.0,ec50,PubChem,Riluzole
KCNK2,139400.0,ec50,ChEMBL,Riluzole
UGT1A1,170000.0,ic50,ChEMBL,Riluzole
ALK,10.0,ic50,Guide to Pharmacology,AZD3463
IGF1R,10.0,ic50,Guide to Pharmacology,AZD3463
ABCC4,133000.0,ic50,ChEMBL,Chlorzoxazone
KCNN4,100000.0,ec50,Guide to Pharmacology,Chlorzoxazone
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,Chlorzoxazone
CFTR,272.0,ec50,Guide to Pharmacology,VX-661
MLST8,190.0,ic50,ChEMBL,SAR245409
PIK3CD,43.0,ic50,ChEMBL,SAR245409
SEC13,190.0,ic50,ChEMBL,SAR245409
ABCC4,133000.0,ic50,ChEMBL,Zonisamide
CA1,947.5,ic50,"ChEMBL, US Patent",Zonisamide
ABCG2,176.0,ic50,ChEMBL,SN-38
UGT1A1,360000.0,ic50,ChEMBL,SN-38
ABCC4,133000.0,ic50,ChEMBL,Mifepristone
AR,8.55,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Mifepristone
ESR1,5000.0,ic50,ChEMBL,Mifepristone
ESR2,812.0,ic50,ChEMBL,Mifepristone
NR3C1,4.8,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Mifepristone
NR3C2,1155.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Mifepristone
PGR,0.3,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",Mifepristone
ABCC4,16600.0,ic50,ChEMBL,Cilostazol
CACNA1C,91200.0,ic50,ChEMBL,Cilostazol
PDE1B,1000000.0,ic50,ChEMBL,Cilostazol
PDE3A,190.0,ic50,"Guide to Pharmacology, ChEMBL",Cilostazol
PDE3B,380.0,ic50,Guide to Pharmacology,Cilostazol
ACHE,27380.0,ic50,ChEMBL,Methoxsalen
MAOA,85110.0,ic50,ChEMBL,Methoxsalen
DRD2,3.65,ec50,ChEMBL,Rotigotine
CACNA1C,7600.0,ic50,ChEMBL,Droperidol
SCN1A,740.0,ic50,ChEMBL,Droperidol
CSF1R,489.0,ic50,ChEMBL,Filgotinib
FLT3,338.0,ic50,ChEMBL,Filgotinib
FLT4,274.0,ic50,ChEMBL,Filgotinib
JAK2,167.34,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Filgotinib
JAK3,644.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Filgotinib
ABCG2,40.0,ic50,ChEMBL,Ponatinib
ABL1,1.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Ponatinib
CSF1R,8.6,ic50,ChEMBL,Ponatinib
DDR1,9.4,ic50,ChEMBL,Ponatinib
EGFR,1000.0,ic50,ChEMBL,Ponatinib
EPHA2,1.3,ic50,Curated from the literature by BindingDB,Ponatinib
FGFR1,1.6,ic50,ChEMBL,Ponatinib
FGFR2,1.65,ic50,ChEMBL,Ponatinib
FGFR3,13.7,ic50,ChEMBL,Ponatinib
FGFR4,8.0,ic50,ChEMBL,Ponatinib
FLT1,12.3,ic50,ChEMBL,Ponatinib
FLT3,6.65,ic50,ChEMBL,Ponatinib
FRK,1.3,ic50,ChEMBL,Ponatinib
GSK3B,12300.0,ic50,Curated from the literature by BindingDB,Ponatinib
HCK,0.11,ic50,ChEMBL,Ponatinib
IGF1R,1000.0,ic50,ChEMBL,Ponatinib
JAK2,169.0,ic50,ChEMBL,Ponatinib
KDR,2.9000000000000004,ic50,ChEMBL,Ponatinib
KIT,8.0,ic50,ChEMBL,Ponatinib
LCK,0.28,ic50,ChEMBL,Ponatinib
LYN,0.24,ic50,ChEMBL,Ponatinib
MAPK14,10.0,ic50,ChEMBL,Ponatinib
NTRK1,11.0,ic50,ChEMBL,Ponatinib
PDGFRB,1.2,ic50,ChEMBL,Ponatinib
RET,10.0,ic50,"Guide to Pharmacology, ChEMBL",Ponatinib
RIPK1,12.0,ic50,"Guide to Pharmacology, ChEMBL",Ponatinib
SRC,4.2,ic50,ChEMBL,Ponatinib
JAK2,5.0,ic50,ChEMBL,Peficitinb
JAK3,0.705,ic50,ChEMBL,Peficitinb
ABCC4,133000.0,ic50,ChEMBL,Tazarotene
RARA,63.0,ec50,"Guide to Pharmacology, ChEMBL",Tazarotene
RARB,0.8000000059604645,ec50,"Guide to Pharmacology, ChEMBL",Tazarotene
RARG,40.0,ec50,"Guide to Pharmacology, ChEMBL",Tazarotene
ABCC4,133000.0,ic50,ChEMBL,Desloratadine
FNTA,65000.0,ic50,ChEMBL,Desloratadine
HRH1,16000.0,ic50,"ChEMBL, US Patent",Desloratadine
FNTA,950.95,ic50,"Curated from the literature by BindingDB, ChEMBL",Lonafarnib
HRAS,1.899999976158142,ic50,Guide to Pharmacology,Lonafarnib
AURKA,255.0,ic50,ChEMBL,Reversine
AURKB,287.5,ic50,ChEMBL,Reversine
PLK1,5000.0,ic50,ChEMBL,Reversine
ABCC4,23700.0,ic50,ChEMBL,Tacrine
ACHE,171.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tacrine
BCHE,21.3,ic50,"Curated from the literature by BindingDB, ChEMBL",Tacrine
CHRM1,13000.0,ic50,ChEMBL,Tacrine
CHRNE,44.0,ic50,ChEMBL,Tacrine
GRIN1,44000.0,ic50,ChEMBL,Tacrine
GRIN2A,9100.0,ic50,ChEMBL,Tacrine
GSK3B,50500.0,ic50,ChEMBL,Tacrine
SLC6A2,11000.0,ic50,ChEMBL,Tacrine
ABCG2,5000.0,ic50,ChEMBL,Candesartan cilexetil
PPARG,4200.0,ec50,ChEMBL,Candesartan cilexetil
ABCC4,133000.0,ic50,ChEMBL,Loratadine
CACNA1C,11400.0,ic50,ChEMBL,Loratadine
HRH1,1500000.0,ic50,"ChEMBL, US Patent",Loratadine
NR1H4,3070.0,ic50,ChEMBL,Loratadine
PTAFR,92500.0,ic50,ChEMBL,Loratadine
CACNA1C,201.0,ic50,ChEMBL,Pimozide
KCNK2,1077.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB",Pimozide
OPRD1,3760.0,ic50,ChEMBL,Pimozide
OPRM1,372.0,ic50,ChEMBL,Pimozide
CTSB,11000.0,ic50,ChEMBL,Carfilzomib
PSMA3,9.3,ic50,ChEMBL,Carfilzomib
PSMA4,9.3,ic50,ChEMBL,Carfilzomib
PSMA5,9.3,ic50,ChEMBL,Carfilzomib
PSMA6,9.3,ic50,ChEMBL,Carfilzomib
PSMB1,2400.0,ic50,ChEMBL,Carfilzomib
PSMB2,1812.0,ic50,ChEMBL,Carfilzomib
PSMB5,7.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Carfilzomib
PSMB7,43.0,ic50,ChEMBL,Carfilzomib
PSMB8,27.0,ic50,ChEMBL,Carfilzomib
FNTA,0.8,ic50,ChEMBL,LB42708
ABCC4,133000.0,ic50,ChEMBL,Vildagliptin
DPP4,16.8,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Vildagliptin
BRD4,50000.0,ic50,US Patent,GSK461364
PLK1,100.0,ic50,ChEMBL,GSK461364
ABCC4,133000.0,ic50,ChEMBL,Tinidazole
ABCC4,133000.0,ic50,ChEMBL,Primidone
ABCC4,133000.0,ic50,ChEMBL,Pentoxifylline
ACHE,6600.0,ic50,ChEMBL,Pentoxifylline
BCHE,50000.0,ic50,ChEMBL,Pentoxifylline
PDE4A,168000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Pentoxifylline
PDE4B,90000.0,ic50,ChEMBL,Pentoxifylline
ABCC4,6400.0,ic50,ChEMBL,Diacerein
CASP3,7894.0,ec50,PubChem,Diacerein
HSP90AA1,9234.0,ic50,PubChem,Diacerein
NAAA,700.0,ic50,ChEMBL,Diacerein
TTR,5400.0,ic50,ChEMBL,Diacerein
ADRA1A,720.0,ec50,ChEMBL,Methoxamine
MAP2K1,10000.0,ic50,ChEMBL,Ulixertinib
MAPK1,31.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ulixertinib
MAPK3,25.150000005960464,ic50,"Guide to Pharmacology, US Patent",Ulixertinib
EGFR,180.0,ic50,Guide to Pharmacology,LY2228820
MAPK11,1.0,ic50,Guide to Pharmacology,LY2228820
MAPK14,5.5,ic50,Guide to Pharmacology,LY2228820
ADRB2,169.55,"ec50, ic50",Curated from the literature by BindingDB,Ractopamine
AR,26.0,ic50,ChEMBL,ODM-201
HDAC1,245.0,ic50,ChEMBL,LMK-235
HDAC2,881.0,ic50,ChEMBL,LMK-235
HDAC6,55.7,ic50,ChEMBL,LMK-235
HDAC8,1278.0,ic50,ChEMBL,LMK-235
AKR1B1,2390.0,ic50,ChEMBL,Tolmetin
CXCL8,90.0,ic50,ChEMBL,Tolmetin
ABL1,4.0,ic50,Guide to Pharmacology,Pexmetinib
FGFR1,28.0,ic50,Guide to Pharmacology,Pexmetinib
FLT1,47.0,ic50,Guide to Pharmacology,Pexmetinib
FLT4,42.0,ic50,Guide to Pharmacology,Pexmetinib
HCK,26.0,ic50,Guide to Pharmacology,Pexmetinib
LYN,25.0,ic50,Guide to Pharmacology,Pexmetinib
MAPK11,26.0,ic50,Guide to Pharmacology,Pexmetinib
MAPK14,19.5,ic50,"Guide to Pharmacology, ChEMBL",Pexmetinib
TEK,1.0,ic50,Guide to Pharmacology,Pexmetinib
ACVR1B,13.0,ic50,"Guide to Pharmacology, ChEMBL",EW-7197
KDR,97.0,ic50,ChEMBL,EW-7197
MAPK14,2565.0,ic50,ChEMBL,EW-7197
TGFBR1,11.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",EW-7197
FGFR1,9.199999809265137,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CH5183284
FGFR2,7.6,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CH5183284
FGFR3,22.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CH5183284
FGFR4,290.0,ic50,"Guide to Pharmacology, ChEMBL",CH5183284
KDR,2100.0,ic50,ChEMBL,CH5183284
PDGFRB,560.0,ic50,Guide to Pharmacology,CH5183284
SRC,5900.0,ic50,ChEMBL,CH5183284
PIK3C3,374.0,ic50,ChEMBL,GDC-0032
PIK3CA,14.0,"ec50, ic50",ChEMBL,GDC-0032
PIK3CD,0.7,ic50,ChEMBL,GDC-0032
ABCC4,133000.0,ic50,ChEMBL,Clopamide
ABCC4,133000.0,ic50,ChEMBL,Gatifloxacin
ABCC4,133000.0,ic50,ChEMBL,Oseltamivir
ABCC4,133000.0,ic50,ChEMBL,Disulfiram
AGTR1,6637.0,ic50,PubChem,Disulfiram
ALDH2,3400.0,ic50,ChEMBL,Disulfiram
CFTR,50000.0,ec50,PubChem,Disulfiram
FAAH,199639.025,ic50,"ChEMBL, US Patent",Disulfiram
TRPA1,3000.0,ec50,ChEMBL,Disulfiram
DDR1,105.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",DDR1-IN-1
MDM2,18.0,ic50,ChEMBL,RG-7112
CA1,12.0,ic50,"ChEMBL, US Patent",Ethoxzolamide
CA2,0.3,ic50,ChEMBL,Ethoxzolamide
CA9,0.99,ic50,ChEMBL,Ethoxzolamide
JAK2,5.85,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Baricitinib
JAK3,400.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Baricitinib
CSF1R,5.0,ic50,Guide to Pharmacology,Cerdulatinib
JAK2,6.0,ic50,"Guide to Pharmacology, ChEMBL",Cerdulatinib
JAK3,8.0,ic50,"Guide to Pharmacology, ChEMBL",Cerdulatinib
SYK,43.5,ic50,"Guide to Pharmacology, US Patent",Cerdulatinib
SCN1A,21200.0,ic50,ChEMBL,Pramoxine
ACHE,4.9,ic50,ChEMBL,Memantine
BCHE,10000.0,ic50,ChEMBL,Memantine
GRIN1,5500.0,ic50,ChEMBL,Memantine
GRIN2A,3330.0,ic50,ChEMBL,Memantine
SCN1A,2300.0,ic50,ChEMBL,Oxethazaine
CDK2,50000.0,ic50,"ChEMBL, US Patent",LEE011
CDK4,10.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",LEE011
CDK6,33.5,ic50,"ChEMBL, US Patent",LEE011
ABCC4,133000.0,ic50,ChEMBL,Imipramine
BRD4,828500.0,ic50,ChEMBL,Imipramine
CACNA1B,22000.0,ic50,ChEMBL,Imipramine
CACNA1C,8300.0,ic50,ChEMBL,Imipramine
DRD2,410.0,ic50,ChEMBL,Imipramine
HRH1,27.0,ic50,ChEMBL,Imipramine
SCN1A,3600.0,ic50,ChEMBL,Imipramine
SLC6A2,38.3,ic50,ChEMBL,Imipramine
SLC6A3,25600.0,ic50,ChEMBL,Imipramine
SLC6A4,5.1,ic50,ChEMBL,Imipramine
PSMA6,7800.0,ec50,Curated from the literature by BindingDB,Triflupromazine
CHRM3,3.2,ic50,US Patent,Atropine
ABL1,1000.0,ic50,ChEMBL,Entrectinib
AKT1,10000.0,ic50,ChEMBL,Entrectinib
ALK,13.5,ic50,"ChEMBL, US Patent",Entrectinib
AURKA,215.0,ic50,ChEMBL,Entrectinib
AURKB,669.0,ic50,"ChEMBL, US Patent",Entrectinib
CDK2,1000.0,ic50,ChEMBL,Entrectinib
CHEK1,10000.0,ic50,ChEMBL,Entrectinib
EGFR,10000.0,ic50,ChEMBL,Entrectinib
FGFR1,1000.0,ic50,ChEMBL,Entrectinib
FLT3,164.0,ic50,ChEMBL,Entrectinib
FLT4,1000.0,ic50,ChEMBL,Entrectinib
GSK3B,10000.0,ic50,ChEMBL,Entrectinib
IGF1R,263.0,ic50,"ChEMBL, US Patent",Entrectinib
IKBKB,10000.0,ic50,ChEMBL,Entrectinib
INSR,209.0,ic50,ChEMBL,Entrectinib
JAK2,40.0,ic50,ChEMBL,Entrectinib
JAK3,349.0,ic50,ChEMBL,Entrectinib
KDR,1000.0,ic50,ChEMBL,Entrectinib
KIT,1000.0,ic50,ChEMBL,Entrectinib
LCK,1000.0,ic50,ChEMBL,Entrectinib
MAPK1,10000.0,ic50,ChEMBL,Entrectinib
MAPK14,10000.0,ic50,ChEMBL,Entrectinib
MET,10000.0,ic50,ChEMBL,Entrectinib
NTRK1,2.2,ic50,"ChEMBL, US Patent",Entrectinib
NTRK2,2.0,ic50,"ChEMBL, US Patent",Entrectinib
NTRK3,3.0,ic50,"ChEMBL, US Patent",Entrectinib
PDGFRB,10000.0,ic50,ChEMBL,Entrectinib
PIM1,10000.0,ic50,ChEMBL,Entrectinib
PLK1,10000.0,ic50,ChEMBL,Entrectinib
PRKCB,1000.0,ic50,ChEMBL,Entrectinib
PTK6,195.0,ic50,ChEMBL,Entrectinib
RET,393.0,ic50,ChEMBL,Entrectinib
ROS1,6.0,ic50,ChEMBL,Entrectinib
SYK,1000.0,ic50,ChEMBL,Entrectinib
ZAP70,10000.0,ic50,ChEMBL,Entrectinib
ABCC4,133000.0,ic50,ChEMBL,Busulfan
IGF1R,10000.0,ic50,"Guide to Pharmacology, ChEMBL",PQ 401
MTOR,21.4,ic50,ChEMBL,GDC-0349
PIK3CA,4200.0,ic50,ChEMBL,GDC-0349
ABCC4,133000.0,ic50,ChEMBL,Hydroxyurea
ABCC4,133000.0,ic50,ChEMBL,Lornoxicam
ABCC4,133000.0,ic50,ChEMBL,Ranitidine
ATM,10000.0,ic50,ChEMBL,BYL719
ATR,9100.0,ic50,ChEMBL,BYL719
MTOR,3000.0,ic50,ChEMBL,BYL719
PIK3C3,9100.0,ic50,ChEMBL,BYL719
PIK3CA,7.25,ic50,"Guide to Pharmacology, ChEMBL",BYL719
PIK3CD,510.0,ic50,"Guide to Pharmacology, ChEMBL",BYL719
PIK3CG,194.5,ic50,"Guide to Pharmacology, ChEMBL",BYL719
PIK3R1,383.0,ic50,ChEMBL,BYL719
TP53,10000.0,ic50,ChEMBL,BYL719
FLT3,139.0,ic50,US Patent,PRT062607
JAK2,1750.0,ic50,ChEMBL,PRT062607
LCK,300.0,ic50,"ChEMBL, US Patent",PRT062607
LYN,218.5,ic50,"ChEMBL, US Patent",PRT062607
PRKCA,90.0,ic50,ChEMBL,PRT062607
SRC,244.0,ic50,US Patent,PRT062607
SYK,13.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",PRT062607
ZAP70,68.0,ic50,ChEMBL,PRT062607
ABL1,10000.0,ic50,ChEMBL,Palbociclib
CDK2,5000.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Palbociclib
CDK4,10.5,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Palbociclib
CDK6,16.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Palbociclib
CDK7,10000.0,ic50,ChEMBL,Palbociclib
CDK9,892.0,ic50,ChEMBL,Palbociclib
CSF1R,10000.0,ic50,ChEMBL,Palbociclib
FLT3,6740.0,ic50,ChEMBL,Palbociclib
JAK3,63.0,ic50,ChEMBL,Palbociclib
PIK3CD,10000.0,ic50,ChEMBL,Palbociclib
ACE,1.700000023841858,ic50,"Guide to Pharmacology, ChEMBL",Benazepril
CACNA1C,246700.0,ic50,ChEMBL,Raltegravir
KCND3,5011872.0,ic50,ChEMBL,Raltegravir
SCN5A,950560.5,ic50,ChEMBL,Raltegravir
UGT1A1,180000.0,ic50,ChEMBL,Raltegravir
ABCC4,133000.0,ic50,ChEMBL,Valaciclovir
ABCC4,133000.0,ic50,ChEMBL,Carbamazepine
SCN1A,100000.0,ic50,ChEMBL,Carbamazepine
SCN5A,46800.0,ic50,ChEMBL,Carbamazepine
ADRB1,178.0,"ec50, ic50",ChEMBL,Indacaterol
ADRB2,1.5,ec50,ChEMBL,Indacaterol
DRD2,17559.5,"ec50, ic50",ChEMBL,Indacaterol
DRD2,195.5,ec50,ChEMBL,Ropinirole
DRD3,14.75,ec50,ChEMBL,Ropinirole
ABCC4,133000.0,ic50,ChEMBL,Piracetam
TOP2A,40000.0,ic50,ChEMBL,Dexrazoxane
TOP2B,50000.0,ic50,ChEMBL,Dexrazoxane
ABCC4,133000.0,ic50,ChEMBL,Urapidil
HTR1B,12.0,ec50,ChEMBL,Eletriptan
HSP90AA1,38.0,ic50,ChEMBL,PF-04929113
HSP90AB1,37.0,ic50,ChEMBL,PF-04929113
ABCC4,133000.0,ic50,ChEMBL,Oxcarbazepine
ABCC4,133000.0,ic50,ChEMBL,Nevirapine
ABCC4,133000.0,ic50,ChEMBL,Tadalafil
CACNA1C,398107.0,ic50,ChEMBL,Tadalafil
PDE10A,14500.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tadalafil
PDE1B,30000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tadalafil
PDE3A,10000.0,ic50,ChEMBL,Tadalafil
PDE3B,50000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tadalafil
PDE4A,10000.0,ic50,ChEMBL,Tadalafil
PDE4B,10000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Tadalafil
PDE4D,19000.0,ic50,Curated from the literature by BindingDB,Tadalafil
PDE5A,4.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Tadalafil
SCN5A,142191.0,ic50,ChEMBL,Tadalafil
ABCC4,28500.0,ic50,ChEMBL,Olmesartan medoxomil
AKT1,5.6,ic50,"Guide to Pharmacology, ChEMBL, US Patent",AZD5363
AKT2,7.5,ic50,"Guide to Pharmacology, ChEMBL",AZD5363
AKT3,7.5,ic50,"Guide to Pharmacology, ChEMBL",AZD5363
ROCK1,470.0,ic50,ChEMBL,AZD5363
ROCK2,56.0,ic50,ChEMBL,AZD5363
AURKB,31.0,ic50,Guide to Pharmacology,BX-795
CDK2,430.0,ic50,Guide to Pharmacology,BX-795
CHEK1,510.0,ic50,Guide to Pharmacology,BX-795
GSK3B,620.0,ic50,Guide to Pharmacology,BX-795
IKBKE,41.0,ic50,"Guide to Pharmacology, ChEMBL",BX-795
KDR,1100.0,ic50,Guide to Pharmacology,BX-795
ABCC4,133000.0,ic50,ChEMBL,Metronidazole
CACNA1C,177900.0,ic50,ChEMBL,Metronidazole
CYP51A1,200000.0,ic50,ChEMBL,Metronidazole
ABCC4,133000.0,ic50,ChEMBL,Temozolomide
ABL1,100000.0,ic50,ChEMBL,Temozolomide
AXL,3.0,ic50,ChEMBL,BMS-794833
FLT3,3.0,ic50,ChEMBL,BMS-794833
KDR,15.0,ic50,ChEMBL,BMS-794833
MET,1.7,ic50,ChEMBL,BMS-794833
ABCC4,133000.0,ic50,ChEMBL,Emtricitabine
ABCC4,133000.0,ic50,ChEMBL,Cladribine
NISCH,3.5,ic50,ChEMBL,Moxonidine
ABCC4,27300.0,ic50,ChEMBL,Dasatinib
ABCG2,2000.0,ic50,ChEMBL,Dasatinib
ABL1,3.1,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Dasatinib
AKT1,50000.0,ic50,ChEMBL,Dasatinib
AURKA,2633.0,ic50,ChEMBL,Dasatinib
AURKB,6485.0,ic50,ChEMBL,Dasatinib
BTK,4.0,ic50,ChEMBL,Dasatinib
CACNA1C,251189.0,ic50,ChEMBL,Dasatinib
CDK2,5000.0,ic50,ChEMBL,Dasatinib
CSF1R,7.4,ic50,ChEMBL,Dasatinib
DDR1,4.8,ic50,"Curated from the literature by BindingDB, ChEMBL",Dasatinib
EGFR,322.0,ic50,ChEMBL,Dasatinib
EPHA2,137.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Dasatinib
ERBB2,710.0,ic50,ChEMBL,Dasatinib
FGFR1,880.0,ic50,ChEMBL,Dasatinib
FRK,10.0,ic50,US Patent,Dasatinib
HCK,10.0,ic50,US Patent,Dasatinib
IGF1R,50000.0,ic50,ChEMBL,Dasatinib
INSR,50000.0,ic50,ChEMBL,Dasatinib
ITK,228.0,ic50,ChEMBL,Dasatinib
KCND3,316228.0,ic50,ChEMBL,Dasatinib
KDR,2180.0,ic50,ChEMBL,Dasatinib
KIT,7.7,ic50,"ChEMBL, US Patent",Dasatinib
LCK,1.5,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Dasatinib
LYN,5.6,ic50,"ChEMBL, US Patent",Dasatinib
MAP2K1,1700.0,ic50,ChEMBL,Dasatinib
MAPK14,285.0,"ec50, ic50",ChEMBL,Dasatinib
MTOR,5500.0,ic50,"ChEMBL, US Patent",Dasatinib
PDGFRB,28.0,ic50,ChEMBL,Dasatinib
PRKCA,50000.0,ic50,ChEMBL,Dasatinib
PTK6,9.0,ic50,"ChEMBL, US Patent",Dasatinib
RAF1,164.0,ic50,ChEMBL,Dasatinib
RET,491.5,ic50,"ChEMBL, US Patent",Dasatinib
RPS6KA1,20000.0,ic50,ChEMBL,Dasatinib
SCN5A,249053.5,ic50,ChEMBL,Dasatinib
SRC,0.95,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Dasatinib
SYK,4820.0,ic50,ChEMBL,Dasatinib
ABCC4,133000.0,ic50,ChEMBL,Famciclovir
AKT1,13.0,ic50,ChEMBL,PF-04691502
MTOR,11.95,ic50,ChEMBL,PF-04691502
PIK3CA,4.074999999999999,ic50,"ChEMBL, US Patent",PF-04691502
PIK3CD,1.6,ic50,ChEMBL,PF-04691502
PIK3CG,1.9,ic50,ChEMBL,PF-04691502
HDAC1,1000.0,ic50,ChEMBL,BIIB021
HSP90AA1,38.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",BIIB021
HSP90AB1,30.0,"ec50, ic50","D3R, ChEMBL, Curated from the literature by BindingDB",BIIB021
RFC1,0.69,ic50,ChEMBL,Pralatrexate
ABCC4,133000.0,ic50,ChEMBL,Methotrexate
G6PD,114000.0,ic50,Curated from the literature by BindingDB,Methotrexate
GART,20000.0,ic50,ChEMBL,Methotrexate
PGD,142000.0,ic50,Curated from the literature by BindingDB,Methotrexate
RFC1,12.0,ic50,ChEMBL,Methotrexate
TYMS,29000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Methotrexate
ABCC4,133000.0,ic50,ChEMBL,Clofarabine
ADORA1,1000.0,ic50,ChEMBL,Roflumilast
ADORA2A,1000.0,ic50,ChEMBL,Roflumilast
PDE10A,200000.0,ic50,Curated from the literature by BindingDB,Roflumilast
PDE1B,200000.0,ic50,Curated from the literature by BindingDB,Roflumilast
PDE3A,100000.0,ic50,ChEMBL,Roflumilast
PDE3B,200000.0,ic50,Curated from the literature by BindingDB,Roflumilast
PDE4A,0.59,ic50,ChEMBL,Roflumilast
PDE4B,0.8200000000000001,ic50,"Curated from the literature by BindingDB, ChEMBL",Roflumilast
PDE4D,0.68,ic50,"Curated from the literature by BindingDB, ChEMBL",Roflumilast
PDE5A,17000.0,ic50,Curated from the literature by BindingDB,Roflumilast
ABCG2,2000.0,ic50,ChEMBL,Bosutinib
ABL1,1.1,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Bosutinib
ALK,5100.0,ic50,ChEMBL,Bosutinib
AXL,257.0,ic50,ChEMBL,Bosutinib
BTK,2.5,ic50,ChEMBL,Bosutinib
EGFR,53.0,ic50,ChEMBL,Bosutinib
EPHA2,2.0,ic50,Curated from the literature by BindingDB,Bosutinib
FRK,2.2,ic50,"Guide to Pharmacology, ChEMBL",Bosutinib
HCK,3.2,ic50,ChEMBL,Bosutinib
KIT,1476.5,ic50,ChEMBL,Bosutinib
LCK,1.3,ic50,ChEMBL,Bosutinib
LYN,8.0,ic50,"Guide to Pharmacology, ChEMBL",Bosutinib
MAP2K1,1.0,ic50,ChEMBL,Bosutinib
NTRK1,22.0,ic50,ChEMBL,Bosutinib
NTRK2,27.0,ic50,ChEMBL,Bosutinib
SRC,1.8,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Bosutinib
SYK,52.0,ic50,ChEMBL,Bosutinib
TEK,1191.0,ic50,ChEMBL,Bosutinib
PDE1B,310000.0,ic50,ChEMBL,Milrinone
PDE3A,795.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Milrinone
PDE3B,1000.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Milrinone
PDE4B,6000.0,ic50,ChEMBL,Milrinone
PDE5A,50370.0,ic50,"Guide to Pharmacology, ChEMBL",Milrinone
PTGS1,4700.0,ic50,ChEMBL,Milrinone
JAK2,5.0,ic50,"ChEMBL, US Patent",INCB018424 (S)
MLST8,1.0,ic50,ChEMBL,INK 128
MTOR,1.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",INK 128
PIK3CA,209.5,ic50,"Guide to Pharmacology, ChEMBL",INK 128
PIK3CD,215.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",INK 128
PIK3CG,210.5,ic50,"Guide to Pharmacology, ChEMBL, US Patent",INK 128
PIK3R1,550.0,ic50,US Patent,INK 128
SEC13,1.0,ic50,ChEMBL,INK 128
AKT1,3.0,ic50,"Curated from the literature by BindingDB, ChEMBL",CCT128930
AKT2,6.0,ic50,ChEMBL,CCT128930
GSK3B,1830.0,ic50,ChEMBL,CCT128930
ROCK2,1000.0,ic50,"ChEMBL, US Patent",CCT128930
RPS6KB1,120.0,ic50,ChEMBL,CCT128930
ABCC4,133000.0,ic50,ChEMBL,Azathioprine
CACNA1C,1421909.0,ic50,ChEMBL,Lamotrigine
SCN10A,97000.0,ic50,ChEMBL,Lamotrigine
SCN5A,62000.0,ic50,ChEMBL,Lamotrigine
BRD2,150.0,ic50,"Guide to Pharmacology, ChEMBL",I-BET-762
BRD3,160.0,ic50,"Guide to Pharmacology, ChEMBL",I-BET-762
BRD4,126.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",I-BET-762
DHODH,144000.0,ic50,ChEMBL,Cinchophen
BRAF,16000.0,ic50,ChEMBL,RepSox
CDK2,100000.0,ic50,ChEMBL,RepSox
ITK,16000.0,ic50,ChEMBL,RepSox
TGFBR1,20.0,ic50,ChEMBL,RepSox
GSK3B,300000.0,ec50,PubChem,Fludarabine phosphate
ABCC4,5150.0,ic50,ChEMBL,Dipyridamole
ABCG2,6400.0,ic50,ChEMBL,Dipyridamole
HSP90AA1,21068.2,ic50,PubChem,Dipyridamole
PDE1B,72500.0,ic50,ChEMBL,Dipyridamole
PDE3A,43000.0,ic50,ChEMBL,Dipyridamole
PDE4B,500.0,ic50,ChEMBL,Dipyridamole
PDE5A,520.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Dipyridamole
SLC29A1,144.8,ic50,Curated from the literature by BindingDB,Dipyridamole
ABCC4,133000.0,ic50,ChEMBL,Nelarabine
ABCC4,133000.0,ic50,ChEMBL,Ganciclovir
ABCC4,133000.0,ic50,ChEMBL,Telbivudine
CACNA1C,713900.0,ic50,ChEMBL,Telbivudine
SCN5A,3162278.0,ic50,ChEMBL,Telbivudine
ABCC4,133000.0,ic50,ChEMBL,FT-207
ABCC4,133000.0,ic50,ChEMBL,Methimazole
CYP51A1,200000.0,ic50,ChEMBL,Methimazole
ABCC4,133000.0,ic50,ChEMBL,Clozapine
ADRA1A,160.0,ic50,ChEMBL,Clozapine
CACNA1C,3600.0,ic50,ChEMBL,Clozapine
CHRM1,9.4,"ec50, ic50",ChEMBL,Clozapine
CHRM2,10000.0,ec50,ChEMBL,Clozapine
CHRM3,10000.0,ec50,ChEMBL,Clozapine
DRD2,206.0,ic50,"ChEMBL, US Patent",Clozapine
DRD3,450.0,ic50,ChEMBL,Clozapine
DRD4,55.0,ic50,ChEMBL,Clozapine
HTR1A,150.0,ic50,ChEMBL,Clozapine
HTR1B,2500.0,ic50,ChEMBL,Clozapine
HTR2A,12.0,ic50,ChEMBL,Clozapine
HTR2C,10.0,ic50,ChEMBL,Clozapine
HTR6,20.0,ic50,ChEMBL,Clozapine
HTR7,3.86,ic50,US Patent,Clozapine
SLC6A4,10000.0,ic50,ChEMBL,Clozapine
ABCC4,133000.0,ic50,ChEMBL,Famotidine
ABCG2,69100.0,ic50,ChEMBL,Atazanavir
UGT1A1,600.0,ic50,"ChEMBL, US Patent",Atazanavir
AKR1B1,500000.0,ic50,ChEMBL,Coumarin
MCL1,24380.0,ic50,ChEMBL,Coumarin
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,Coumarin
XPO1,25000.0,ic50,ChEMBL,Coumarin
AR,200.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",ARN-509
ABCC4,133000.0,ic50,ChEMBL,Brinzolamide
CA2,3.2,ic50,"Curated from the literature by BindingDB, ChEMBL",Brinzolamide
CA4,45.15,ic50,"Curated from the literature by BindingDB, ChEMBL",Brinzolamide
ADRB2,10000.0,ec50,Guide to Pharmacology,Mirabegron
ABCC4,133000.0,ic50,ChEMBL,Mesna
CA1,130000.0,ic50,ChEMBL,4-Aminosalicylate
CA2,750000.0,ic50,ChEMBL,4-Aminosalicylate
ESR2,10271.624366,ic50,PubChem,4-Aminosalicylate
ACHE,3013006.02,ic50,ChEMBL,Choline
ACHE,346000.0,ic50,ChEMBL,Salicylate
AKR1B1,1000000.0,ic50,ChEMBL,Salicylate
CA1,560000.0,ic50,ChEMBL,Salicylate
CA2,680000.0,ic50,ChEMBL,Salicylate
PTGS1,270000.0,ic50,ChEMBL,Salicylate
PTGS2,40000.0,ic50,ChEMBL,Salicylate
ABCC4,133000.0,ic50,ChEMBL,Allopurinol
XDH,3500.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Allopurinol
ABCC4,133000.0,ic50,ChEMBL,Clomipramine
CACNA1B,9000.0,ic50,ChEMBL,Clomipramine
PSMA6,12400.0,ec50,Curated from the literature by BindingDB,Clomipramine
SCN1A,10000.0,ic50,ChEMBL,Clomipramine
SLC6A2,65.0,ic50,ChEMBL,Clomipramine
SLC6A3,2777.0,ic50,ChEMBL,Clomipramine
SLC6A4,70.0,ic50,ChEMBL,Clomipramine
SCN1A,10000.0,ic50,ChEMBL,Biperiden
SCN1A,28000.0,ic50,ChEMBL,Dicyclomine
ABCC4,133000.0,ic50,ChEMBL,Amoxapine
CACNA1B,27000.0,ic50,ChEMBL,Amoxapine
ADRA1A,1980.0,ic50,ChEMBL,Vilazodone
ADRA2A,6000.0,ic50,ChEMBL,Vilazodone
DRD2,666.0,ic50,Guide to Pharmacology,Vilazodone
DRD3,71.0,ic50,Guide to Pharmacology,Vilazodone
HRH1,317.0,ic50,Guide to Pharmacology,Vilazodone
HTR1A,0.2,"ec50, ic50","Guide to Pharmacology, ChEMBL",Vilazodone
HTR1B,17500.0,"ec50, ic50",ChEMBL,Vilazodone
HTR1D,4000.0,ic50,ChEMBL,Vilazodone
HTR4,252.0,ic50,Guide to Pharmacology,Vilazodone
SLC6A2,158.0,ic50,ChEMBL,Vilazodone
SLC6A3,295.0,ic50,ChEMBL,Vilazodone
SLC6A4,0.4,ic50,ChEMBL,Vilazodone
BRD2,500.0,ic50,"Guide to Pharmacology, ChEMBL",I-BET151
BRD3,250.0,ic50,"Guide to Pharmacology, ChEMBL",I-BET151
BRD4,165.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",I-BET151
PDE4B,3981.07,ic50,ChEMBL,I-BET151
ABCC4,133000.0,ic50,ChEMBL,Epirubicin
ABCC4,133000.0,ic50,ChEMBL,Rizatriptan
HTR1A,320.0,ic50,ChEMBL,Rizatriptan
HTR1B,41.0,ic50,ChEMBL,Rizatriptan
HTR1D,9.7,"ec50, ic50",ChEMBL,Rizatriptan
HTR2A,7943.28,ic50,ChEMBL,Rizatriptan
HTR2C,8650.0,ic50,ChEMBL,Rizatriptan
HTR3A,10000.0,ic50,ChEMBL,Rizatriptan
TAAR1,3631.5,"ec50, ic50",PubChem,Betahistine
ABCC4,7430.0,ic50,ChEMBL,Amsacrine
TOP2A,5470.0,"ec50, ic50",ChEMBL,Amsacrine
TOP2B,6880.0,"ec50, ic50",ChEMBL,Amsacrine
PTAFR,50000.0,ic50,ChEMBL,Azatadine
HRH1,1.9,"ec50, ic50",ChEMBL,Pyrilamine
ABCC4,45800.0,ic50,ChEMBL,Quinidine
CACNA1C,13110.0,ic50,ChEMBL,Quinidine
SCN1A,3200.0,ic50,ChEMBL,Quinidine
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,Quinidine
ADRA1A,183.5,ec50,ChEMBL,Oxymetazoline
ADRA1B,15065.5,ec50,ChEMBL,Oxymetazoline
ADRA1D,15065.5,ec50,ChEMBL,Oxymetazoline
ADRA2A,3.3,ec50,ChEMBL,Oxymetazoline
HTR1A,248.0,ec50,PubChem,Oxymetazoline
HTR1D,137.0,ec50,ChEMBL,Oxymetazoline
ABCC4,133000.0,ic50,ChEMBL,Prochlorperazine
MCL1,3773.276395,ic50,PubChem,Prochlorperazine
NR1H4,45000.0,ec50,ChEMBL,Alpha-hydroxydeoxycholic acid
ABCC4,133000.0,ic50,ChEMBL,Bromopride
ABCG2,118000.0,ic50,ChEMBL,Chloroguanide
TAAR1,10000.0,ec50,ChEMBL,Chloroguanide
ABCC4,133000.0,ic50,ChEMBL,Ciprofloxacin
TOP2A,126800.0,"ec50, ic50",ChEMBL,Ciprofloxacin
TOP2B,754.0,ic50,ChEMBL,Ciprofloxacin
ACHE,890.0,ic50,ChEMBL,Clebopride
ABCC4,133000.0,ic50,ChEMBL,Clofibrate
PPARA,55000.0,ec50,ChEMBL,Clofibrate
PPARG,500000.0,ec50,ChEMBL,Clofibrate
ABCC4,133000.0,ic50,ChEMBL,Dapsone
MPO,420.0,ic50,ChEMBL,Dapsone
PRKCA,11000.0,ic50,ChEMBL,Dequalinium
ABCC4,133000.0,ic50,ChEMBL,Desipramine
CACNA1B,11000.0,ic50,ChEMBL,Desipramine
SCN1A,2400.0,ic50,ChEMBL,Desipramine
SCN5A,1520.0,ic50,ChEMBL,Desipramine
SLC6A2,3.3499999999999996,ic50,ChEMBL,Desipramine
SLC6A3,64950.0,ic50,ChEMBL,Desipramine
SLC6A4,108.0,ic50,ChEMBL,Desipramine
SCN1A,10000.0,ic50,ChEMBL,Dexpropranolol
ABCC4,133000.0,ic50,ChEMBL,Omeprazole
ABCG2,17600.0,ic50,ChEMBL,Omeprazole
ATP4A,501.0,ic50,ChEMBL,Omeprazole
MCL1,3144.812063,ic50,PubChem,Omeprazole
UGT1A1,56000.0,ic50,Curated from the literature by BindingDB,Omeprazole
CA1,3380.0,ic50,ChEMBL,Diflunisal (no structure)
CA2,2700.0,ic50,ChEMBL,Diflunisal (no structure)
TTR,6600.0,"ec50, ic50",ChEMBL,Diflunisal (no structure)
SCN1A,10000.0,ic50,ChEMBL,Doxepin
ACHE,780.0,ic50,ChEMBL,Edrophonium
BCHE,1370000.0,ic50,ChEMBL,Edrophonium
ALOX5,26000.0,ic50,ChEMBL,Eugenol (no structure)
AR,19000.0,ic50,ChEMBL,Eugenol (no structure)
PTGS1,11000.0,ic50,ChEMBL,Eugenol (no structure)
PTGS2,129000.0,ic50,ChEMBL,Eugenol (no structure)
TRPA1,168912.0,ec50,ChEMBL,Eugenol (no structure)
HTR1A,40000.0,ic50,PubChem,Fenbendazole
CASP3,1200.0,ic50,Curated from the literature by BindingDB,Fenbufen (no structure)
ABCC4,133000.0,ic50,ChEMBL,Fluorescein
ABCC4,133000.0,ic50,ChEMBL,Fluphenazine
KCNK2,4700.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB",Fluphenazine
SCN1A,3700.0,ic50,ChEMBL,Fluphenazine
TYMS,290000.0,ic50,ChEMBL,Folic acid
ESR1,2161.56,ic50,PubChem,Hexachlorophene
ESR2,98.273886,ic50,PubChem,Hexachlorophene
MCL1,14833.19604,ic50,PubChem,Hexachlorophene
MIF,6000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Hexachlorophene
ALOX5,3700.0,ic50,ChEMBL,Hexylresorcinol
TYR,47280.0,ic50,ChEMBL,Hexylresorcinol
ABCC4,83200.0,ic50,ChEMBL,Irbesartan
AGTR1,6.0,ic50,ChEMBL,Irbesartan
ABCC4,133000.0,ic50,ChEMBL,Mafenide
CA2,4000.0,ic50,ChEMBL,Mafenide
CA5A,27600.0,ic50,ChEMBL,Mafenide
ABCC4,15500.0,ic50,ChEMBL,Mebendazole
ABL1,5000.0,ic50,ChEMBL,Mebendazole
KDR,4300.0,ic50,ChEMBL,Mebendazole
SRC,10000.0,ic50,ChEMBL,Mebendazole
CHRNA1,1500.0,ic50,Guide to Pharmacology,Mecamylamine
CHRNA7,15600.0,ic50,Guide to Pharmacology,Mecamylamine
ABCC4,133000.0,ic50,ChEMBL,Melphalan
HTR1A,1765.75,ec50,"PubChem, ChEMBL",Metergoline
ABCC4,133000.0,ic50,ChEMBL,Metformin
DPP4,29000.0,ic50,ChEMBL,Metformin
ACHE,85000.0,ic50,ChEMBL,Minaprine
PRKACG,100000.0,ic50,ChEMBL,Minaprine
PRKCA,100000.0,ic50,ChEMBL,Minaprine
ESR1,24673.94,ic50,PubChem,Molsidomine
ABL1,100000.0,ic50,ChEMBL,Niclosamide
AKT1,59400.0,ic50,ChEMBL,Niclosamide
AURKA,54100.0,ic50,ChEMBL,Niclosamide
BRAF,100000.0,ic50,ChEMBL,Niclosamide
EGFR,10500.0,ic50,ChEMBL,Niclosamide
FGFR1,13100.0,ic50,ChEMBL,Niclosamide
FLT3,100000.0,ic50,ChEMBL,Niclosamide
GSK3B,77500.0,ic50,ChEMBL,Niclosamide
JAK2,55000.0,ic50,ChEMBL,Niclosamide
KDR,23100.0,ic50,ChEMBL,Niclosamide
KIT,27800.0,ic50,ChEMBL,Niclosamide
LYN,23800.0,ic50,ChEMBL,Niclosamide
MAPK1,100000.0,ic50,ChEMBL,Niclosamide
PDGFRB,100000.0,ic50,ChEMBL,Niclosamide
PRKCA,100000.0,ic50,ChEMBL,Niclosamide
SRC,10250.0,ic50,ChEMBL,Niclosamide
TEK,67800.0,ic50,ChEMBL,Niclosamide
AR,600.0,ic50,ChEMBL,Nilutamide
ABCC4,133000.0,ic50,ChEMBL,Norfloxacin
BRD4,980.0,ic50,ChEMBL,Norfloxacin
ABCC4,133000.0,ic50,ChEMBL,Norgestrel
PGR,1.0,ec50,ChEMBL,Norgestrel
ABCC4,23130.0,ic50,ChEMBL,Papaverine
ACHE,24330.0,ic50,ChEMBL,Papaverine
PDE10A,39.0,ic50,"Guide to Pharmacology, ChEMBL",Papaverine
PDE1B,15300.0,ic50,ChEMBL,Papaverine
PDE3A,917.0,ic50,"Guide to Pharmacology, ChEMBL",Papaverine
PDE3B,1030.0,ic50,"Guide to Pharmacology, ChEMBL",Papaverine
PDE4A,1600.0,ic50,ChEMBL,Papaverine
PDE4D,1400.0,ic50,ChEMBL,Papaverine
PDE5A,8800.0,ic50,ChEMBL,Papaverine
ABCG2,1000.0,ec50,ChEMBL,Pargyline
MAOA,4034.0,ic50,ChEMBL,Pargyline
MAOB,169.0,ic50,"ChEMBL, US Patent",Pargyline
ABCC4,133000.0,ic50,ChEMBL,Perphenazine
DRD2,0.3,ic50,ChEMBL,Perphenazine
ABCC4,12500.0,ic50,ChEMBL,Prazosin
ADRA1A,1.2,ic50,ChEMBL,Prazosin
ADRA1D,0.88,ic50,ChEMBL,Prazosin
SCN1A,10100.0,ic50,ChEMBL,Prazosin
ACHE,1445.0,ic50,ChEMBL,Propoxur
CACNA1B,14000.0,ic50,ChEMBL,Protryptyline
SCN1A,10000.0,ic50,ChEMBL,Protryptyline
SLC6A2,2.8,ic50,"Guide to Pharmacology, ChEMBL",Protryptyline
BCHE,3600.0,ic50,ChEMBL,Saccharin
CYP51A1,200000.0,ic50,ChEMBL,Sulfaphenazole
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,Sulfaphenazole
ALDH2,320.0,ic50,ChEMBL,Thiram
BBOX1,14000.0,ic50,ChEMBL,Thiram
FAAH,44668.36,ic50,ChEMBL,Thiram
JAK2,223.0,ic50,PubChem,Thiram
MDM2,180.0,ec50,PubChem,Thiram
ABCC4,133000.0,ic50,ChEMBL,Tiapride
ABCC4,133000.0,ic50,ChEMBL,Ticlopidine
ABCC4,133000.0,ic50,ChEMBL,Trazodone
DRD2,4485.0,ic50,ChEMBL,Trazodone
HTR1A,785.0,ec50,ChEMBL,Trazodone
HTR2A,243.0,ic50,ChEMBL,Trazodone
IDO1,498700.0,ic50,ChEMBL,Tryptophan
MPO,2250.0,ic50,ChEMBL,Tryptophan
XDH,60000.0,ic50,US Patent,Tryptophan
HNF4A,10866.0,ic50,PubChem,Carbetapentane
CA1,395000.0,ic50,Curated from the literature by BindingDB,Metamizole
CA2,356000.0,ic50,Curated from the literature by BindingDB,Metamizole
CACNA1C,398107.0,ic50,ChEMBL,Paliperidone
DRD2,8.29,ic50,ChEMBL,Paliperidone
HTR1A,10000.0,ec50,ChEMBL,Paliperidone
HTR2A,5.2,ic50,ChEMBL,Paliperidone
KCND3,63096.0,ic50,ChEMBL,Paliperidone
SCN5A,91804.0,ic50,ChEMBL,Paliperidone
ABCC4,133000.0,ic50,ChEMBL,Indinavir
ALOX5,160.0,ic50,ChEMBL,Nordihydroguaiaretic acid
ESR1,22193.67,ic50,PubChem,Nordihydroguaiaretic acid
G6PD,80000.0,ic50,PubChem,Nordihydroguaiaretic acid
HSP90AA1,16311.6,ic50,PubChem,Nordihydroguaiaretic acid
PTGS2,50000.0,ic50,ChEMBL,Nordihydroguaiaretic acid
TRPA1,35000.0,ec50,ChEMBL,Nordihydroguaiaretic acid
TTR,8500.0,ec50,ChEMBL,Nordihydroguaiaretic acid
ABCC4,133000.0,ic50,ChEMBL,Colchicine
F10,38.125,ic50,ChEMBL,Colchicine
HDAC1,50000.0,ic50,ChEMBL,Colchicine
HDAC2,50000.0,ic50,ChEMBL,Colchicine
HDAC3,50000.0,ic50,ChEMBL,Colchicine
PIM1,4300.0,ic50,ChEMBL,Colchicine
TUBB,3470.5,ic50,"Guide to Pharmacology, ChEMBL",Colchicine
ABCC4,133000.0,ic50,ChEMBL,Diatrizoic acid
MTOR,1.600000011920929,ic50,"Guide to Pharmacology, ChEMBL",Gedatolisib
PIK3CA,0.4000000029802322,ic50,"Guide to Pharmacology, ChEMBL",Gedatolisib
PIK3CD,8.0,ic50,ChEMBL,Gedatolisib
PIK3CG,8.5,ic50,ChEMBL,Gedatolisib
CACNA1C,30000.0,ic50,ChEMBL,Omarigliptin
DPP4,2.1,ic50,"ChEMBL, US Patent",Omarigliptin
SCN5A,30000.0,ic50,ChEMBL,Omarigliptin
PTGER2,4.0,"ec50, ic50",ChEMBL,Prostaglandin E2
PTGER3,2.5,"ec50, ic50",ChEMBL,Prostaglandin E2
PTGER4,3.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Prostaglandin E2
PTGFR,250.0,ec50,ChEMBL,Prostaglandin E2
ADRA2A,226.5,ec50,ChEMBL,Rilmenidine
ADRA2B,724.0,ec50,ChEMBL,Rilmenidine
ADRA2C,191.0,ec50,ChEMBL,Rilmenidine
MAPK11,98.0,ic50,"Guide to Pharmacology, ChEMBL",SCIO 469
MAPK14,10.0,ic50,"Guide to Pharmacology, ChEMBL",SCIO 469
MAPK13,7736.0,ic50,"ChEMBL, US Patent",AMG 548
MAPK14,35.0,"ec50, ic50",ChEMBL,AMG 548
ABL1,1048.0,ic50,ChEMBL,NVP-TAE 684
ALK,3.7,"ec50, ic50","ChEMBL, US Patent",NVP-TAE 684
CSF1R,50.0,ic50,ChEMBL,NVP-TAE 684
FGFR1,1108.0,"ec50, ic50",ChEMBL,NVP-TAE 684
FGFR3,1000.0,ec50,ChEMBL,NVP-TAE 684
FLT1,872.0,"ec50, ic50",ChEMBL,NVP-TAE 684
FLT3,500.0,"ec50, ic50",ChEMBL,NVP-TAE 684
IGF1R,0.35,ic50,ChEMBL,NVP-TAE 684
INSR,31.85,"ec50, ic50",ChEMBL,NVP-TAE 684
JAK2,1505.0,ic50,ChEMBL,NVP-TAE 684
KDR,1561.5,"ec50, ic50",ChEMBL,NVP-TAE 684
KIT,1000.0,ec50,ChEMBL,NVP-TAE 684
LCK,1000.0,ec50,ChEMBL,NVP-TAE 684
LYN,1308.0,ic50,ChEMBL,NVP-TAE 684
MET,1667.0,ic50,ChEMBL,NVP-TAE 684
NTRK2,212009.0,ic50,ChEMBL,NVP-TAE 684
NTRK3,1000.0,ec50,ChEMBL,NVP-TAE 684
PDGFRB,2110.0,"ec50, ic50",ChEMBL,NVP-TAE 684
RET,1192.5,"ec50, ic50",ChEMBL,NVP-TAE 684
ROS1,2.0,ic50,ChEMBL,NVP-TAE 684
SRC,1073.0,"ec50, ic50",ChEMBL,NVP-TAE 684
TEK,1167.0,"ec50, ic50",ChEMBL,NVP-TAE 684
ZAP70,1598.0,ic50,ChEMBL,NVP-TAE 684
PTGER4,2.9,ic50,ChEMBL,MK-2894
ABCG2,18700.0,ic50,ChEMBL,Delavirdine
BRAF,540.0,ic50,ChEMBL,CHEMBL410295
BTK,410.0,ic50,ChEMBL,CHEMBL410295
ITK,20000.0,ic50,ChEMBL,CHEMBL410295
JAK3,150.0,ic50,ChEMBL,CHEMBL410295
KDR,5100.0,ic50,ChEMBL,CHEMBL410295
KIT,560.0,ic50,ChEMBL,CHEMBL410295
LCK,803.5,ic50,ChEMBL,CHEMBL410295
LYN,21.0,ic50,ChEMBL,CHEMBL410295
MAPK14,10000.0,ic50,ChEMBL,CHEMBL410295
MAPK3,100000.0,ic50,ChEMBL,CHEMBL410295
MET,10000.0,ic50,ChEMBL,CHEMBL410295
SRC,120.0,ic50,ChEMBL,CHEMBL410295
SYK,200.0,ic50,ChEMBL,CHEMBL410295
TEK,750.0,ic50,ChEMBL,CHEMBL410295
ZAP70,1500.0,ic50,ChEMBL,CHEMBL410295
MAPK14,1160.0,ic50,"Guide to Pharmacology, ChEMBL",SKF-86002
ABL1,1000.0,ic50,ChEMBL,LOXO-101
NTRK1,5.75,ic50,"Guide to Pharmacology, ChEMBL, US Patent",LOXO-101
NTRK2,2.75,ic50,"ChEMBL, US Patent",LOXO-101
NTRK3,1.9,ic50,"ChEMBL, US Patent",LOXO-101
MLST8,2.0,ic50,ChEMBL,Torin 1
MTOR,0.29,ic50,"Guide to Pharmacology, ChEMBL",Torin 1
PIK3C3,533.0,ic50,ChEMBL,Torin 1
PIK3CA,1800.0,ec50,ChEMBL,Torin 1
PIK3CG,171.0,ic50,ChEMBL,Torin 1
PIK3R1,407.0,ic50,ChEMBL,Torin 1
SEC13,2.0,ic50,ChEMBL,Torin 1
KDR,670.0,ic50,Curated from the literature by BindingDB,AZM475271
SRC,7.5,ic50,"Curated from the literature by BindingDB, ChEMBL",AZM475271
PTPN1,62400.0,ic50,ChEMBL,Estramustine
TLR7,750.0,ec50,"Guide to Pharmacology, ChEMBL, US Patent",Resiquimod
TLR8,4500.0,ec50,"Guide to Pharmacology, ChEMBL, US Patent",Resiquimod
ABCC4,133000.0,ic50,ChEMBL,Sertindole
CACNA1C,7600.0,ic50,ChEMBL,Sertindole
KCNA5,2000.0,ic50,ChEMBL,Sertindole
BRAF,1895.0,ic50,Guide to Pharmacology,MLN 2480
ROCK1,13110.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",SLx-2119
ROCK2,100.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",SLx-2119
NR3C1,14.0,ic50,ChEMBL,Podophyllotoxin
ABCC4,133000.0,ic50,ChEMBL,Guanfacine
CHRM1,0.126,ic50,ChEMBL,Glycopyrrolate
CHRM2,0.3295,ic50,ChEMBL,Glycopyrrolate
CHRM3,0.251,ic50,ChEMBL,Glycopyrrolate
CHRM5,0.2,ic50,ChEMBL,Glycopyrrolate
PTGS2,5.0,ic50,ChEMBL,Parecoxib
IDH1,23.0,"ec50, ic50","ChEMBL, US Patent",Ivosidenib
BTK,1.0,ic50,ChEMBL,Olmutinib
EGFR,18.0,ic50,ChEMBL,Olmutinib
ERBB2,10.0,ic50,ChEMBL,Olmutinib
TBXA2R,770.0,ic50,ChEMBL,Laropiprant
AURKA,729.5,ic50,ChEMBL,GSK-1070916
AURKB,5.0,ic50,ChEMBL,GSK-1070916
FGFR1,76.0,ic50,ChEMBL,GSK-1070916
FLT1,42.0,ic50,ChEMBL,GSK-1070916
FLT4,74.0,ic50,ChEMBL,GSK-1070916
TEK,59.0,ic50,ChEMBL,GSK-1070916
TYMP,30.0,ic50,ChEMBL,Tipiracil
HTR1A,631.0,ec50,ChEMBL,Flibanserin
DPP4,324150.0,ic50,ChEMBL,Bestatin
HDAC1,100000.0,ic50,ChEMBL,Bestatin
MMP2,156000.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Bestatin
ABCC4,133000.0,ic50,ChEMBL,Imiquimod
TLR7,8750.0,ec50,"Guide to Pharmacology, ChEMBL",Imiquimod
TLR8,270000.0,ec50,ChEMBL,Imiquimod
CA1,619.0,ic50,"ChEMBL, US Patent",Dichlorphenamide
CA2,38.0,ic50,ChEMBL,Dichlorphenamide
CA4,380.0,ic50,ChEMBL,Dichlorphenamide
ABCC4,133000.0,ic50,ChEMBL,Neostigmine
ACHE,45.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Neostigmine
BCHE,8550.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Neostigmine
PTGS1,23750.0,ic50,ChEMBL,Loxoprofen
PTGS2,11800.0,ic50,ChEMBL,Loxoprofen
ABCC4,133000.0,ic50,ChEMBL,Ciclesonide
ABCC4,133000.0,ic50,ChEMBL,Aceclofenac
TTR,170000.0,ic50,ChEMBL,Aceclofenac
CYP19A1,53200.0,ic50,ChEMBL,Eicosapentaenoic Acid
F3,78000.0,ic50,ChEMBL,Eicosapentaenoic Acid
PPARA,1100.0,ic50,ChEMBL,Eicosapentaenoic Acid
PPARG,1600.0,ic50,ChEMBL,Eicosapentaenoic Acid
ADRA1A,0.32,"ec50, ic50",ChEMBL,Tamsulosin
ADRA1B,4.2,"ec50, ic50",ChEMBL,Tamsulosin
ADRA1D,0.7749999999999999,ic50,ChEMBL,Tamsulosin
ABCC4,2200.0,ic50,ChEMBL,Amlexanox
IKBKE,5114.5,ic50,ChEMBL,Amlexanox
PDE3A,299000.0,ic50,"Guide to Pharmacology, ChEMBL",Ibudilast
PDE4A,477.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Ibudilast
PDE4B,65.0,ic50,"Guide to Pharmacology, ChEMBL",Ibudilast
PDE4D,166.0,ic50,ChEMBL,Ibudilast
PDE5A,103000.0,ic50,"Guide to Pharmacology, ChEMBL",Ibudilast
CBR1,400.0,ic50,ChEMBL,Triclosan
TTR,53500.0,ic50,ChEMBL,Triclosan
ABCC4,133000.0,ic50,ChEMBL,Diazoxide
KCNJ11,113500.0,"ec50, ic50",ChEMBL,Diazoxide
ABCC4,133000.0,ic50,ChEMBL,Nortriptyline
CACNA1B,10000.0,ic50,ChEMBL,Nortriptyline
RET,3250.0,ic50,US Patent,Nortriptyline
SCN1A,10000.0,ic50,ChEMBL,Nortriptyline
CELA1,10000.0,ic50,ChEMBL,Boceprevir
CMA1,32.0,ic50,ChEMBL,Boceprevir
CTSB,4750.0,ic50,ChEMBL,Boceprevir
CTSL,760.0,ic50,ChEMBL,Boceprevir
PLG,100000.0,ic50,ChEMBL,Boceprevir
NR1H4,180.0,ec50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",INT-747
MTOR,165.0,ic50,"Guide to Pharmacology, ChEMBL",LY3023414
PIK3CA,6.099999952316284,ic50,"Guide to Pharmacology, ChEMBL",LY3023414
PIK3CD,24.0,ic50,"Guide to Pharmacology, ChEMBL",LY3023414
PIK3CG,30.899999618530273,ic50,"Guide to Pharmacology, ChEMBL",LY3023414
ABCG2,1500.0,ic50,ChEMBL,CH5424802
ALK,2.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",CH5424802
KDR,1400.0,ic50,ChEMBL,CH5424802
KIT,5000.0,ic50,ChEMBL,CH5424802
MET,5000.0,ic50,"Guide to Pharmacology, ChEMBL",CH5424802
RET,20.75,ic50,"ChEMBL, US Patent",CH5424802
MAPK14,25870.0,ic50,"ChEMBL, US Patent",LY-364947
TGFBR1,51.0,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",LY-364947
TGFBR2,400.0,ic50,ChEMBL,LY-364947
TLR7,30000.0,ec50,ChEMBL,Motolimod
TLR8,100.0,ec50,"Guide to Pharmacology, ChEMBL",Motolimod
DPP4,0.3700000047683716,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Teneligliptin
KIF11,12.0,ic50,ChEMBL,ARRY-520
XDH,150150.0,ic50,US Patent,Lesinurad
DRD2,10.0,ec50,ChEMBL,Brexpiprazole
BTK,11.0,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Acalabrutinib
EGFR,2756.5,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Acalabrutinib
ERBB2,1000.0,ic50,"Guide to Pharmacology, ChEMBL",Acalabrutinib
ITK,1000.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Acalabrutinib
JAK3,1000.0,ic50,"Guide to Pharmacology, ChEMBL",Acalabrutinib
LCK,1000.0,ec50,"Guide to Pharmacology, US Patent",Acalabrutinib
LYN,1000.0,"ec50, ic50","Guide to Pharmacology, US Patent",Acalabrutinib
SRC,1000.0,ec50,"Guide to Pharmacology, US Patent",Acalabrutinib
IDH1,4950.0,ic50,"ChEMBL, US Patent",Enasidenib
IDH2,319.0,ic50,"ChEMBL, US Patent",Enasidenib
ABCC4,133000.0,ic50,ChEMBL,Plerixafor
CXCR4,156.5,ic50,"Guide to Pharmacology, ChEMBL",Plerixafor
ABCC4,133000.0,ic50,ChEMBL,Amoxicillin Sodium
ALOX5,2250.0,ic50,ChEMBL,Curcumin
EGFR,8600.0,ic50,ChEMBL,Curcumin
F3,200.0,ic50,ChEMBL,Curcumin
HDAC1,115000.0,ic50,ChEMBL,Curcumin
HSD11B1,10242.0,ic50,ChEMBL,Curcumin
HTR4,10000.0,ec50,Curated from the literature by BindingDB,Curcumin
PRKCE,8810.0,ec50,ChEMBL,Curcumin
PTGS1,21945.0,ic50,ChEMBL,Curcumin
PTGS2,87780.0,ic50,"Curated from the literature by BindingDB, ChEMBL",Curcumin
TLR9,11814.0,ic50,PubChem,Curcumin
TOP2A,15000.0,ic50,ChEMBL,Curcumin
ABCC4,133000.0,ic50,ChEMBL,lovastatin
CFTR,50000.0,ec50,PubChem,lovastatin
CYP51A1,200000.0,ic50,ChEMBL,lovastatin
HDAC1,11911.0,ic50,"ChEMBL, US Patent",lovastatin
HDAC2,25933.0,ic50,"ChEMBL, US Patent",lovastatin
HDAC6,16285.0,ic50,"ChEMBL, US Patent",lovastatin
HMGCR,33.5,ic50,"Guide to Pharmacology, ChEMBL, US Patent",lovastatin
ICAM1,19700.0,ic50,ChEMBL,lovastatin
ABCC4,133000.0,ic50,ChEMBL,pravastatin (sodium salt)
HMGCR,30.0,ic50,"Guide to Pharmacology, ChEMBL",pravastatin (sodium salt)
SQLE,10000.0,ic50,ChEMBL,pravastatin (sodium salt)
ESR1,250000.0,ic50,US Patent,Resorcinol
ESR2,250000.0,ic50,US Patent,Resorcinol
TYR,3000000.0,ic50,ChEMBL,Resorcinol
ABCC4,133000.0,ic50,ChEMBL,Sitagliptin phosphate monohydrate
ACE,11000.0,ic50,ChEMBL,Sitagliptin phosphate monohydrate
CACNA1C,50073550.0,ic50,ChEMBL,Sitagliptin phosphate monohydrate
DPP4,19.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Sitagliptin phosphate monohydrate
KCND3,100000000.0,ic50,ChEMBL,Sitagliptin phosphate monohydrate
MME,100000.0,ic50,ChEMBL,Sitagliptin phosphate monohydrate
SCN5A,712642.5,ic50,ChEMBL,Sitagliptin phosphate monohydrate
CASP3,1400.0,ic50,Curated from the literature by BindingDB,indoprofen
GRIA2,35117.0,ec50,ChEMBL,L-Glutamic Acid
GRIA4,4898.0,ec50,ChEMBL,L-Glutamic Acid
GRIN2A,70.0,ic50,ChEMBL,L-Glutamic Acid
ABCC4,133000.0,ic50,ChEMBL,Ebastine
CHRM1,1100.0,ic50,ChEMBL,Ebastine
CHRM2,1000.0,ic50,ChEMBL,Ebastine
DRD2,61.0,ic50,ChEMBL,Ebastine
HTR1A,47.0,ic50,ChEMBL,Ebastine
ABCC4,133000.0,ic50,ChEMBL,Efavirenz
ABCG2,20600.0,ic50,ChEMBL,Efavirenz
ABCC4,133000.0,ic50,ChEMBL,Eplerenone
AR,18500.0,"ec50, ic50",ChEMBL,Eplerenone
ESR1,10000.0,ic50,ChEMBL,Eplerenone
ESR2,100000.0,ic50,ChEMBL,Eplerenone
NR3C1,18000.0,"ec50, ic50",ChEMBL,Eplerenone
NR3C2,240.0,"ec50, ic50",ChEMBL,Eplerenone
PGR,20000.0,"ec50, ic50",ChEMBL,Eplerenone
ABCC4,53000.0,ic50,ChEMBL,Etoricoxib
MAPK14,530.0,ic50,ChEMBL,Etoricoxib
PTGS1,100000.0,ic50,ChEMBL,Etoricoxib
PTGS2,554.0,ic50,"Guide to Pharmacology, ChEMBL",Etoricoxib
PPARA,24000.0,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB",Fenofibric acid
PPARG,50000.0,"ec50, ic50",ChEMBL,Fenofibric acid
PTGS1,950000.0,ic50,ChEMBL,Fenofibric acid
ABCC4,133000.0,ic50,ChEMBL,Mizoribine
GSK3B,300000.0,ec50,PubChem,Mizoribine
GSK3B,10000.0,ic50,ChEMBL,Niraparib (MK-4827) tosylate
PARP1,16.5,"ec50, ic50","Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",Niraparib (MK-4827) tosylate
PARP2,8.55,ic50,"Guide to Pharmacology, ChEMBL",Niraparib (MK-4827) tosylate
PARP3,296.0,ic50,ChEMBL,Niraparib (MK-4827) tosylate
GART,29.6,ic50,ChEMBL,Pemetrexed
RFC1,138.0,ic50,ChEMBL,Pemetrexed
TYMS,11000.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Pemetrexed
HTR2A,27.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",Pimavanserin
HTR2C,91.0,ic50,Curated from the literature by BindingDB,Pimavanserin
ROCK1,51.0,ic50,"Guide to Pharmacology, ChEMBL",Ripasudil (K-115) hydrochloride dihydrate
ROCK2,19.0,ic50,"Guide to Pharmacology, ChEMBL",Ripasudil (K-115) hydrochloride dihydrate
SLC6A1,112.5,ic50,"Guide to Pharmacology, ChEMBL",Tiagabine
MAP2K1,2.5500000000000003,ic50,"Guide to Pharmacology, ChEMBL",Cobimetinib
MAP2K2,199.0,ic50,Guide to Pharmacology,Cobimetinib
AURKA,80.0,ic50,ChEMBL,PKC 412
CDK2,32.5,ic50,US Patent,PKC 412
CSF1R,142.0,ic50,ChEMBL,PKC 412
FLT3,38.5,ic50,"Guide to Pharmacology, ChEMBL",PKC 412
GSK3B,4636.0,ic50,ChEMBL,PKC 412
KDR,250.0,ic50,ChEMBL,PKC 412
KIT,109.0,ic50,ChEMBL,PKC 412
IDO1,70000.0,ic50,ChEMBL,Dichlorophen
EGLN1,510000.0,ic50,ChEMBL,Butanedioic acid
XDH,92420.0,ic50,ChEMBL,6-Thioguanine
ACHE,100.0,ic50,ChEMBL,8-Hydroxyquinoline
BCHE,100.0,ic50,ChEMBL,8-Hydroxyquinoline
HDAC8,11100.0,ec50,ChEMBL,8-Hydroxyquinoline
HSP90AA1,50000.0,ic50,PubChem,8-Hydroxyquinoline
IDO1,750000.0,ic50,ChEMBL,8-Hydroxyquinoline
MMP2,130000.0,ic50,ChEMBL,8-Hydroxyquinoline
TGFBR1,12.0,ic50,ChEMBL,A 83-01
SLC6A2,71.0,ic50,Guide to Pharmacology,Zotepine
SLC6A4,7270.0,ic50,Guide to Pharmacology,Zotepine
AR,400.0,ic50,ChEMBL,Pamoic acid disodium salt
PTPN1,310000.0,ic50,ChEMBL,Pamoic acid disodium salt
P2RY12,23.5,ic50,ChEMBL,AZD 1283
ABCC4,133000.0,ic50,ChEMBL,Enoximone
PDE1B,1000000.0,ic50,ChEMBL,Enoximone
PDE3A,3800.0,ic50,"Guide to Pharmacology, ChEMBL",Enoximone
PDE4B,5000.0,ic50,ChEMBL,Enoximone
HTR1A,99000.0,ec50,PubChem,Dihydroergocristine mesylate
AGTR1,8.1,ic50,ChEMBL,Olmesartan
CYP11B1,15.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Metyrapone
CYP11B2,72.0,ic50,"ChEMBL, US Patent",Metyrapone
CYP17A1,10000.0,ic50,ChEMBL,Metyrapone
CYP19A1,2507.5,ic50,ChEMBL,Metyrapone
ABCC4,133000.0,ic50,ChEMBL,Tenofovir Disoproxil Fumarate
ABCC4,133000.0,ic50,ChEMBL,Nebivolol HCl
AKT1,3.2,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ipatasertib (GDC-0068)
AKT2,18.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ipatasertib (GDC-0068)
AKT3,8.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Ipatasertib (GDC-0068)
ABCC4,133000.0,ic50,ChEMBL,Pazufloxacin mesylate
ABCC4,133000.0,ic50,ChEMBL,Piribedil
ABCC4,8200.0,ic50,ChEMBL,4-Biphenylacetic acid
CASP3,14000.0,ic50,Curated from the literature by BindingDB,4-Biphenylacetic acid
ABCG2,180.0,ic50,ChEMBL,Topiroxostat
XDH,5.3,ic50,ChEMBL,Topiroxostat
ABCG2,11000.0,ic50,ChEMBL,Isavuconazole
CHRM3,10000.0,ic50,ChEMBL,Umeclidinium bromide
ABCC4,133000.0,ic50,ChEMBL,Benznidazole
AURKB,100000.0,ic50,ChEMBL,Benznidazole
DNMT1,7280.0,ic50,PubChem,Cephalothin
ABCC4,133000.0,ic50,ChEMBL,Saxagliptin hydrate
DPP4,3.2,ic50,ChEMBL,Saxagliptin hydrate
AR,4.5,"ec50, ic50","ChEMBL, Curated from the literature by BindingDB",Dihydrotestosterone(DHT)
MGAM,100000.0,ic50,ChEMBL,Dihydrotestosterone(DHT)
NR3C1,540.0,ic50,ChEMBL,Dihydrotestosterone(DHT)
NR3C2,360.0,ic50,ChEMBL,Dihydrotestosterone(DHT)
PGR,7750.0,"ec50, ic50",ChEMBL,Dihydrotestosterone(DHT)
SHBG,13.4,ic50,ChEMBL,Dihydrotestosterone(DHT)
AGTR1,4.5,ic50,ChEMBL,Fimasartan
PDE10A,97600000.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE1B,17900000.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE1C,71000000.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE3A,64000000.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE3B,58800000.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE4A,55.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE4B,110.0,ic50,ChEMBL,Crisaborole (AN2728)
PDE4D,272.5,ic50,ChEMBL,Crisaborole (AN2728)
PDE5A,56100000.0,ic50,ChEMBL,Crisaborole (AN2728)
ABCC4,133000.0,ic50,ChEMBL,Tilorone dihydrochloride
CFTR,40125.0,"ec50, ic50",PubChem,Tilorone dihydrochloride
CHRNA7,2500.0,ec50,ChEMBL,Tilorone dihydrochloride
CHRNB2,10000.0,ec50,ChEMBL,Tilorone dihydrochloride
KCNK2,2750000.0,ec50,Curated from the literature by BindingDB,4-Aminopyridine
DHODH,13000.0,ic50,ChEMBL,Clonixin
G6PD,56000.0,ic50,Curated from the literature by BindingDB,Thiocolchicoside
F10,134000.0,ic50,ChEMBL,Argatroban Monohydrate
F2,38.5,ic50,ChEMBL,Argatroban Monohydrate
PLG,800000.0,ic50,ChEMBL,Argatroban Monohydrate
ALK,7.25,ic50,"ChEMBL, US Patent",Lorlatinib?(PF-6463922)
FRK,53.0,ic50,ChEMBL,Lorlatinib?(PF-6463922)
NTRK1,24.0,ic50,ChEMBL,Lorlatinib?(PF-6463922)
NTRK3,46.0,ic50,ChEMBL,Lorlatinib?(PF-6463922)
ROS1,0.21,ic50,ChEMBL,Lorlatinib?(PF-6463922)
ALK,1.2,ic50,"Guide to Pharmacology, ChEMBL",Gilteritinib (ASP2215)
AXL,5.24,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Gilteritinib (ASP2215)
FLT3,0.3000000119209289,ic50,"Guide to Pharmacology, ChEMBL, US Patent",Gilteritinib (ASP2215)
NTRK1,1.100000023841858,ic50,Guide to Pharmacology,Gilteritinib (ASP2215)
RET,2.550000023841858,ic50,"Guide to Pharmacology, US Patent",Gilteritinib (ASP2215)
ROS1,1.7,ic50,"Guide to Pharmacology, US Patent",Gilteritinib (ASP2215)
MAPK14,14.0,ic50,ChEMBL,Pamapimod (R-1503
MTOR,70.0,ic50,Guide to Pharmacology,GDC-0084
PIK3CA,2.0,ic50,Guide to Pharmacology,GDC-0084
AKT1,5.0,ic50,"Guide to Pharmacology, ChEMBL",Miransertib (ARQ 092) HCl
AKT2,4.5,ic50,"Guide to Pharmacology, ChEMBL",Miransertib (ARQ 092) HCl
AKT3,12.95,ic50,"Guide to Pharmacology, ChEMBL",Miransertib (ARQ 092) HCl
FGFR1,1.5,ic50,"Guide to Pharmacology, ChEMBL",Erdafitinib (JNJ-42756493)
FGFR2,2.3949999809265137,ic50,"Guide to Pharmacology, ChEMBL",Erdafitinib (JNJ-42756493)
FGFR3,3.0,ic50,"Guide to Pharmacology, ChEMBL",Erdafitinib (JNJ-42756493)
FGFR4,5.659999942779541,ic50,"Guide to Pharmacology, ChEMBL",Erdafitinib (JNJ-42756493)
KDR,36.29999923706055,ic50,"Guide to Pharmacology, ChEMBL",Erdafitinib (JNJ-42756493)
RIPK1,1.6,ic50,"Guide to Pharmacology, ChEMBL",GSK2982772
SLC5A1,8444.0,ic50,"Guide to Pharmacology, ChEMBL",Tofogliflozin(CSG 452)
SLC5A2,2.900000047683716,ic50,"Guide to Pharmacology, ChEMBL",Tofogliflozin(CSG 452)
ITGB3,62000.0,ic50,ChEMBL,Tirofiban Hydrochloride
SLC5A1,1876.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Ipragliflozin (ASP1941)
SLC5A2,7.4,"ec50, ic50","Guide to Pharmacology, ChEMBL",Ipragliflozin (ASP1941)
TACR1,0.95,ic50,ChEMBL,Netupitant
AGTR1,12.0,ic50,ChEMBL,Losartan Carboxylic Acid
FLT1,33.0,ic50,Guide to Pharmacology,fruquintinib
FLT4,0.5,ic50,Guide to Pharmacology,fruquintinib
KDR,30.0,ic50,Guide to Pharmacology,fruquintinib
FGFR1,20.0,ic50,Guide to Pharmacology,anlotinib
FLT1,4.0,ic50,Guide to Pharmacology,anlotinib
FLT4,1.0,ic50,Guide to Pharmacology,anlotinib
KDR,45.0,ic50,Guide to Pharmacology,anlotinib
PTGS1,44000.0,ic50,ChEMBL,Flurizan
PTGS2,123000.0,ic50,ChEMBL,Flurizan
MC3R,1.5380414999999998,ec50,ChEMBL,Bremelanotide (Acetate)
MC5R,197.5,ic50,ChEMBL,Bremelanotide (Acetate)
CALCRL,0.14,ec50,ChEMBL,BMS-927711
PNP,3.5,ic50,ChEMBL,Forodesine (hydrochloride)
ABCC4,133000.0,ic50,ChEMBL,Dactolisib (BEZ235
ATM,7.0,ic50,ChEMBL,Dactolisib (BEZ235
ATR,21.0,ic50,Guide to Pharmacology,Dactolisib (BEZ235
HDAC6,2.0,ic50,ChEMBL,Dactolisib (BEZ235
JAK3,1000.0,ic50,ChEMBL,Dactolisib (BEZ235
MLST8,44.0,ic50,ChEMBL,Dactolisib (BEZ235
MTOR,9.8,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",Dactolisib (BEZ235
PIK3C3,450.0,ic50,ChEMBL,Dactolisib (BEZ235
PIK3CA,18.5,"ec50, ic50","Guide to Pharmacology, ChEMBL, US Patent",Dactolisib (BEZ235
PIK3CD,23.5,"ec50, ic50","Guide to Pharmacology, ChEMBL",Dactolisib (BEZ235
PIK3CG,33.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Dactolisib (BEZ235
PIK3R1,79.0,"ec50, ic50",ChEMBL,Dactolisib (BEZ235
SEC13,44.0,ic50,ChEMBL,Dactolisib (BEZ235
ADRB2,6900.0,ec50,Curated from the literature by BindingDB,Zilpaterol
OPRM1,78500.0,"ec50, ic50",Curated from the literature by BindingDB,Zilpaterol
F10,3.0,ic50,ChEMBL,Betrixaban
F2,10000.0,ic50,ChEMBL,Betrixaban
PLG,10000.0,ic50,ChEMBL,Betrixaban
BTK,40.95,ic50,ChEMBL,BTK IN-1
HRH2,24161.0,ec50,ChEMBL,Dexpramipexole (dihydrochloride)
BTK,3.1,ic50,ChEMBL,GDC-0853
HTR1F,87.92,ic50,ChEMBL,Lasmiditan (hydrochloride)
NR3C1,5.260000228881836,ic50,Guide to Pharmacology,fluocinonide
HSD11B1,630.0,ic50,ChEMBL,stetaderm
HSD11B2,400.0,ic50,ChEMBL,stetaderm
ABCC4,133000.0,ic50,ChEMBL,azithromycin
ABCC4,133000.0,ic50,ChEMBL,simvastatin
CFTR,50000.0,ec50,PubChem,simvastatin
HMGCR,11.650000190734865,ic50,"Guide to Pharmacology, ChEMBL",simvastatin
ATG4B,10400.0,ic50,PubChem,doxycycline
ABCC4,133000.0,ic50,ChEMBL,dicloxacillin
NR1H4,72500.0,ec50,ChEMBL,cholic-acid
NR1H4,11700.0,ec50,"Curated from the literature by BindingDB, ChEMBL, US Patent",chenodeoxycholic-acid
NR1H4,75000.0,ec50,ChEMBL,ursodiol
NR3C1,298700.0,ec50,ChEMBL,ursodiol
DRD2,100.0,ic50,ChEMBL,raclopride
GAA,100.0,ic50,ChEMBL,miglustat
MGAM,5550.0,ic50,ChEMBL,miglustat
SI,500.0,ic50,ChEMBL,miglustat
ABCC4,133000.0,ic50,ChEMBL,pancuronium
NR3C2,2.94,ec50,US Patent,hydrocortisone-butyrate
CA1,28380.0,ic50,Curated from the literature by BindingDB,sulfapyridine
CA2,276.0,ic50,Curated from the literature by BindingDB,sulfapyridine
MPO,5000.0,ic50,ChEMBL,lomefloxacin
ADORA1,105000.0,ic50,ChEMBL,theobromine
ADORA2A,250000.0,ic50,ChEMBL,theobromine
ADORA3,100000.0,ic50,ChEMBL,theobromine
ABCC4,133000.0,ic50,ChEMBL,loteprednol
ABCC4,133000.0,ic50,ChEMBL,cefaclor
ABCC4,133000.0,ic50,ChEMBL,ofloxacin
TOP2A,157950.0,"ec50, ic50",ChEMBL,ofloxacin
TOP2B,2760.0,ic50,ChEMBL,ofloxacin
ADRB1,1.8,ec50,ChEMBL,propranolol
SCN1A,13000.0,ic50,ChEMBL,propranolol
GRIN1,30000.0,ic50,US Patent,dimemorfan
SIGMAR1,527.0,ic50,US Patent,dimemorfan
EGLN1,10000000.0,ic50,ChEMBL,malic-acid
CXCL8,50.0,ic50,ChEMBL,ibuprofen
AKR1C3,32700.0,ic50,ChEMBL,ibuprofen-(s)
PTGS1,789.5,ic50,ChEMBL,ibuprofen-(s)
PTGS2,1595.0,ic50,ChEMBL,ibuprofen-(s)
ALK,2.9,ic50,ChEMBL,brigatinib
EGFR,21.0,ic50,"Guide to Pharmacology, ChEMBL, US Patent",brigatinib
FLT3,2.1,ic50,ChEMBL,brigatinib
IGF1R,24.9,ic50,"Guide to Pharmacology, ChEMBL",brigatinib
INSR,196.0,ic50,"Guide to Pharmacology, ChEMBL",brigatinib
MET,70.0,ic50,US Patent,brigatinib
ROS1,1.9,ic50,ChEMBL,brigatinib
ABCC4,133000.0,ic50,ChEMBL,iohexol
ABCC4,7100.0,ic50,ChEMBL,telithromycin
G6PD,2280000.0,ic50,Curated from the literature by BindingDB,paricalcitol
CELA1,30.0,ic50,"Guide to Pharmacology, ChEMBL",telaprevir
CMA1,26.0,ic50,ChEMBL,telaprevir
CTSB,2300.0,ic50,ChEMBL,telaprevir
CTSL,3500.0,ic50,ChEMBL,telaprevir
PLG,8700.0,ic50,ChEMBL,telaprevir
PRSS1,10000.0,ic50,ChEMBL,telaprevir
CACNA1C,17.0,ic50,ChEMBL,gallopamil
SCN1A,3600.0,ic50,ChEMBL,gallopamil
HTR7,16.0,ic50,ChEMBL,lurasidone
ABCC4,133000.0,ic50,ChEMBL,fludarabine-phosphate
SLC5A1,890.5,"ec50, ic50","Guide to Pharmacology, ChEMBL, Curated from the literature by BindingDB, US Patent",dapagliflozin
SLC5A2,2.4,"ec50, ic50","Guide to Pharmacology, ChEMBL, Curated from the literature by BindingDB, US Patent",dapagliflozin
ADRB1,5.9,ic50,ChEMBL,alprenolol
ADRB2,1.5122179999999998,ic50,ChEMBL,alprenolol
AKR1C3,526.0,ic50,ChEMBL,meclofenamic-acid
ALOX5,5640.0,ic50,Curated from the literature by BindingDB,meclofenamic-acid
PTGS1,135.0,ic50,"Guide to Pharmacology, ChEMBL",meclofenamic-acid
PTGS2,45.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",meclofenamic-acid
TTR,25252.0,ic50,"ChEMBL, US Patent",meclofenamic-acid
ACHE,2473.0,ic50,ChEMBL,metacresol
TAAR1,4729.0,ec50,ChEMBL,synephrine
MIF,98100.0,ic50,ChEMBL,metaraminol
AOC3,19.950000381469728,ic50,"Guide to Pharmacology, ChEMBL",phenelzine
IDO1,14000.0,ic50,ChEMBL,phenelzine
MAOA,238.0,ic50,ChEMBL,phenelzine
MAOB,143.0,ic50,ChEMBL,phenelzine
ACHE,996000.0,ic50,ChEMBL,pralidoxime-chloride
ACHE,878000.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL",pralidoxime
AR,1000.0,ic50,ChEMBL,salicylamide
SRC,2000000.0,ic50,ChEMBL,fosfosal
CA1,59.0,ic50,ChEMBL,methazolamide
CA2,14.0,"ec50, ic50","Curated from the literature by BindingDB, ChEMBL",methazolamide
CA4,205.0,ic50,Curated from the literature by BindingDB,methazolamide
CA9,0.25,ic50,ChEMBL,methazolamide
ABCC4,133000.0,ic50,ChEMBL,amrinone
PDE1B,650000.0,ic50,ChEMBL,amrinone
PDE3A,40500.0,ic50,"Guide to Pharmacology, ChEMBL",amrinone
PDE3B,31200.0,ic50,Guide to Pharmacology,amrinone
PDE4B,113500.0,ic50,ChEMBL,amrinone
XDH,60000.0,ic50,US Patent,L-methionine
UGT1A1,300000.0,ic50,Curated from the literature by BindingDB,clomethiazole
ACE,7244360.0,ic50,ChEMBL,bucillamine
KIF11,63000.0,ic50,ChEMBL,SCMC-Lys
TAAR1,3777.0,"ec50, ic50",PubChem,hydroxyamphetamine
ADRB1,47.0,ec50,ChEMBL,isoprenaline
ADRB2,20.0,"ec50, ic50","ChEMBL, US Patent",isoprenaline
F2R,47.0,ic50,ChEMBL,vorapaxar
ABCC4,2700.0,ic50,ChEMBL,pranlukast
CYSLTR1,2.55,ic50,"Guide to Pharmacology, ChEMBL",pranlukast
NR1H4,15000.0,ec50,ChEMBL,pranlukast
ACHE,0.7,ic50,ChEMBL,ambenonium
BCHE,7000.0,ic50,ChEMBL,ambenonium
CACNA1C,2150.0,ic50,ChEMBL,barnidipine
PTPN1,1300.0,ic50,ChEMBL,evans-blue
TPH1,64.0,ic50,ChEMBL,telotristat
CCKBR,1.9,"ec50, ic50",ChEMBL,pentagastrin
KCNK2,2000.0,ec50,Curated from the literature by BindingDB,flupentixol
ABCC4,133000.0,ic50,ChEMBL,ezetimibe
NPC1L1,370.0,ic50,ChEMBL,ezetimibe
ABCC4,133000.0,ic50,ChEMBL,cabergoline
HTR2B,13.0,ec50,ChEMBL,cabergoline
PDE5A,100.0,ic50,US Patent,mirodenafil
ABCC4,133000.0,ic50,ChEMBL,dutasteride
SRD5A1,4.0,ic50,ChEMBL,dutasteride
SRD5A2,0.1,ic50,ChEMBL,dutasteride
PTGDR2,195.0,ic50,ChEMBL,ramatroban
TBXA2R,9.6,ic50,ChEMBL,ramatroban
PDE3A,10700.0,ic50,ChEMBL,vesnarinone
PDE3B,13870.0,ic50,ChEMBL,vesnarinone
ABCC4,133000.0,ic50,ChEMBL,rivaroxaban
F10,3.395,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",rivaroxaban
ABCC4,133000.0,ic50,ChEMBL,mupirocin
KCNK2,232.0,ec50,Curated from the literature by BindingDB,fluspirilene
ABCC4,36800.0,ic50,ChEMBL,valrubicin
ABCC4,20000.0,ic50,ChEMBL,dilazep
SCN1A,600.0,ic50,ChEMBL,dilazep
SLC29A1,18.0,ic50,ChEMBL,dilazep
AURKB,9140.0,ic50,Curated from the literature by BindingDB,diosmin
IKBKB,3890.0,ic50,ChEMBL,diosmin
ABCC4,133000.0,ic50,ChEMBL,alvimopan
CACNA1C,5012.0,ic50,ChEMBL,alvimopan
OPRM1,3.1,ic50,ChEMBL,alvimopan
SCN5A,251189.0,ic50,ChEMBL,alvimopan
ABCC4,133000.0,ic50,ChEMBL,escitalopram
SLC6A4,10.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",escitalopram
HRH1,2454.71,ic50,ChEMBL,promazine
SCN1A,5400.0,ic50,ChEMBL,promazine
TTR,3090.0,ic50,"ChEMBL, US Patent",tafamidis-meglumine
ACHE,40.0,ic50,"Curated from the literature by BindingDB, ChEMBL",physostigmine
BCHE,40.0,ic50,"Curated from the literature by BindingDB, ChEMBL",physostigmine
SCN1A,3400.0,ic50,ChEMBL,dimethisoquin
PDE1B,275000.0,ic50,ChEMBL,Ro-20-1724
PDE3A,300000.0,ic50,ChEMBL,Ro-20-1724
PDE4A,3300.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",Ro-20-1724
PDE4B,4800.0,ic50,"Guide to Pharmacology, ChEMBL",Ro-20-1724
PDE4D,631.0,ic50,Guide to Pharmacology,Ro-20-1724
ABCC4,133000.0,ic50,ChEMBL,hydroflumethiazide
DRD1,1000.0,ic50,ChEMBL,cariprazine
DRD2,1.35,"ec50, ic50",ChEMBL,cariprazine
DRD3,5.8,ec50,ChEMBL,cariprazine
ABCC4,133000.0,ic50,ChEMBL,voglibose
GAA,2835.0,ic50,ChEMBL,voglibose
MGAM,1300.0,ic50,ChEMBL,voglibose
PTGS1,2000.0,ic50,ChEMBL,flurbiprofen-(S)-(+)
PTGS2,910.0,ic50,"Guide to Pharmacology, ChEMBL",flurbiprofen-(S)-(+)
CASP3,810.0,ic50,Curated from the literature by BindingDB,tiaprofenic-acid
ABCC4,133000.0,ic50,ChEMBL,silver-sulfadiazine
AURKA,21000.0,ic50,ChEMBL,silver-sulfadiazine
CA1,26190.0,ic50,Curated from the literature by BindingDB,silver-sulfadiazine
CA2,341.0,ic50,Curated from the literature by BindingDB,silver-sulfadiazine
HTR1A,40000.0,ic50,PubChem,oxibendazole
MIF,6810.0,ic50,ChEMBL,iguratimod
ABCC4,133000.0,ic50,ChEMBL,abiraterone
CYP11B1,1608.0,ic50,"Curated from the literature by BindingDB, ChEMBL",abiraterone
CYP11B2,1750.0,ic50,"Curated from the literature by BindingDB, ChEMBL",abiraterone
CYP17A1,48.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",abiraterone
CYP19A1,20000.0,ic50,ChEMBL,abiraterone
ABCG2,230.0,ic50,ChEMBL,atovaquone
DHODH,2700.0,ic50,ChEMBL,atovaquone
ABCC4,133000.0,ic50,ChEMBL,indoramin
ABCC4,133000.0,ic50,ChEMBL,pergolide
PSMA6,11900.0,ec50,Curated from the literature by BindingDB,metixene
MIF,64000.0,ic50,ChEMBL,ISO-1
MMP2,53600.0,ic50,"Guide to Pharmacology, ChEMBL",tiludronate
ABCC4,133000.0,ic50,ChEMBL,stepronin
CYP11B1,9.85,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",fadrozole
CYP11B2,1.0,ic50,"Curated from the literature by BindingDB, ChEMBL, US Patent",fadrozole
CYP17A1,5000.0,ic50,ChEMBL,fadrozole
CYP19A1,30.0,ic50,"Guide to Pharmacology, Curated from the literature by BindingDB, ChEMBL, US Patent",fadrozole
ABCC4,3000.0,ic50,ChEMBL,dehydroepiandrosterone-sulfate
ABCC4,7100.0,ic50,ChEMBL,dinoprost
PTGER2,55000.0,ic50,ChEMBL,dinoprost
PTGER3,322.0,"ec50, ic50",ChEMBL,dinoprost
PTGER4,2550.0,"ec50, ic50","Guide to Pharmacology, ChEMBL",dinoprost
PTGFR,7.0,"ec50, ic50",ChEMBL,dinoprost
TBXA2R,1400.0,"ec50, ic50",ChEMBL,dinoprost
APEX1,80.0,ic50,ChEMBL,hycanthone
ACHE,1404500.0,ic50,ChEMBL,obidoxime
DHODH,8000.0,ic50,ChEMBL,flunixin-meglumin
AR,267.0,ic50,"ChEMBL, US Patent",bicalutamide
ACE,0.4,ic50,ChEMBL,zofenopril-calcium
CA2,30.0,ic50,ChEMBL,dorzolamide
PTGS2,100000.0,ic50,ChEMBL,carprofen
PTGS1,100000.0,ic50,ChEMBL,ketorolac
PTGS2,100000.0,ic50,ChEMBL,ketorolac
ABCC4,133000.0,ic50,ChEMBL,etacrynic-acid
AKT1,9600.0,ic50,"Guide to Pharmacology, ChEMBL",miltefosine
AURKB,100000.0,ic50,ChEMBL,miltefosine
ABCC4,133000.0,ic50,ChEMBL,eszopiclone
MAOA,8700.0,ic50,ChEMBL,tedizolid
MAOB,5700.0,ic50,ChEMBL,tedizolid
ADRA1A,1.2,ic50,ChEMBL,bunazosin
PTGS1,36000.0,ic50,ChEMBL,deracoxib
PTGS2,50.06,ic50,ChEMBL,deracoxib
ALOX5,70.0,ec50,ChEMBL,tepoxalin
PTGS2,2850.0,ic50,ChEMBL,tepoxalin
ABCC4,133000.0,ic50,ChEMBL,gestodene
PTGS1,62500.0,ic50,ChEMBL,firocoxib
PTGS2,140.0,ic50,ChEMBL,firocoxib
MAOA,1640.0,ic50,ChEMBL,toloxatone
